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Multiple myeloma (MM) is an essentially incurable malignancy associated with 
profound cellular and soluble immune deficiencies. Despite recent progresses in the 
treatment of MM, the prognosis remains frequently poor due to the difficulty in targeting 
MM progenitor cells, which are responsible for disease relapse. Immunotherapy, and in 
particular the employment of Natural Killer (NK) cells, offers the potential to target and 
eliminate MM cells within the bone marrow stromal sanctuaries, where they appear to be 
better protected against conventional therapeutic interventions. However, these 
strategies have so far provided limited clinical benefit, possibly reflecting the various 
escape mechanisms employed by MM cells to avoid immune recognition.  
The work presented in this thesis aims to further elucidate the mechanisms 
underlying MM-induced inhibition of NK cells and to investigate the therapeutic potential 
of immunomodulatory strategies to reverse this inhibition.  
Initially, the effect of co-culturing MM cell lines and healthy donor (HD) peripheral 
blood mononuclear cells (PBMCs) on NK cell phenotype and function was analysed. The 
results demonstrate that MM cell lines are able to impair NK cell cytolytic activity. This 
inhibition, which correlates with the downregulation of activating receptors such as 
NKG2D, NKp30, and DNAM-1, was shown to be the product of direct and contact-
dependent interactions between MM and NK cells, without the need for other peripheral 
blood components. Importantly, the analysis of NK cells isolated from MM patients show 
that they display the same suppressed phenotype and activity as healthy donor NK cells 
co-cultured in the presence of MM cells lines, thereby suggesting that the detected 
suppression of NK cell activation by MM cells is a function of MM cells rather than any 
inherent defect in NK cells isolated from MM patients. 
3 
In the light of this immunosuppressive effect, MM cells genetically-modified with a 
self-inactivating lentiviral vector encoding CD80 (B7.1) and IL-2 were tested for their 
ability to enhance and recover NK cell functional competence. Our results show that the 
in vitro co-culture of healthy donor or MM patient PBMCs with CD80/IL-2-modified MM 
cells is able to expand NK and T cell numbers, and to induce a significant increase in the 
fraction of NK cells expressing activating receptors such as NKp44, NKG2D, NKp30, and 
CD69, when compared to unmodified MM cells. More importantly for potential 
therapeutic applications, stimulated NK cells from healthy donors show increased 
cytolytic activity. These data suggest that the stimulation of PBMCs with 
CD80/IL-2-modified MM cells may be able to overcome the immune suppressive 
functions of unmodified MM cells and to stimulate NK and T cell mediated responses. 
Therefore, vaccination with CD80/IL-2-modified MM cells may represent a 
potential strategy for NK cell recovery and stimulation and, possibly, for the induction of a 
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ITAM  Immuno-receptor Tyrosine-Based Activation Motif 
ITIM  Immuno-receptor Tyrosine-Based Inhibition Motif 
IU  Infective Units 
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KIR  Killer Immunoglobulin-like Receptor 
LFA-1  Lymphocyte Function Associated Antigen-1 
LNs  Lymph nodes 
LTR  Long Terminal Repeat 
LV  Lentivirus 
mAbs  Monoclonal Antibodies 
MAIT  Mucosal-Associated Invariant T (cells) 
MFI  Mean Fluorescence Intensity 
MGUS  Monoclonal Gammopathy of Undetermined Significance 
MICA/B Major histocompatibility complex class I-related chains A/B 
MHC  Major Histocompatibility Complex 
MM  Multiple Myeloma 
MMP  Matrix Metalloproteases 
NCR  Natural Cytotoxicity Receptor 
NF-kB  Nuclear Factor-kappa B 
NK cell  Natural Killer Cell 
NKT  Natural Killer T Cell 
NKR  NK cell receptor 
PBMCs Peripheral Blood Mononuclear Cells 
PD-1  Programmed Cell Death-1 
PD-1L  Programmed Cell Death-1 Ligand 
PEI  Polyethylenimine 
PCR  Polymerase Chain Reaction 
PMP  Para Magnetic Particle 
RIC  Reduced-Intensity Conditioning 
RNA  Ribonucleic Acid 
RPMI1640 Roswell Park Memorial Institute medium 1640 
STAT  Signal Transducers and Activators of Transcription 
TAA  Tumour-Associated Antigen 
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TCR  T Cell Receptor 
TGF  Transforming Growth Factor  
TNF  Tumour necrosis factor 
TLRs  Toll-Like Receptors 
Th  T helper 
Treg  T Regulatory cells (regulatory T cells) 
VEGF  Vascular Endothelial Growth Factor 
VSV-G  Vesicular Stomatitis Virus G glycoprotein 
WHO  World Health Organisation 
WPRE  Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element 

























1.1 Multiple Myeloma 
1.1.1 Introduction and pathogenesis 
Multiple myeloma (MM) is a clonal B cell disorder in which malignant plasma cells 
expand and accumulate in the bone marrow leading to cytopenia, bone resorption, and 
production of the characteristic monoclonal protein (Fonseca et al. 2009).  
It commonly presents with bone pain, tiredness, lethargy and renal impairment (Palumbo 
and Anderson 2011). It accounts for approximately 1% of neoplastic diseases and 13% 
of haematological cancers (Palumbo and Anderson 2011).  
MM is a disease of the elderly, with the median age at diagnosis of approximately 
73 years, and appears to occur more and more frequently in younger individuals 
(Phekoo et al. 2004). Although the majority of cases present de novo with evidences of 
advancing disease, it is now recognised that myeloma is preceded by a period of 
asymptomatic monoclonal gammopathy of undetermined significance (MGUS) phase in 
virtually all patients (Bird et al. 2011), with a cumulative risk of overall progression of 
1-2% per annum (Kyle and Rajkumar 2007). Whilst survival has significantly improved in 
the last 15 years, myeloma remains the paradigm of an incurable disease. 
As a tumour of antibody-producing plasma B cells, it is instructive to understand 
how B cells develop, in order to appreciate how myeloma initiates and progresses 
(Figure 1-1). B cells are a class of lymphocytes involved in the humoral branch of the 
adaptive immune response. Their main role is the secretion of proteins called antibodies 
(see 1.2.1) in the body fluids.  
23 
The initiation of the myeloma tumour cell results from the physiological gene 
rearrangement process necessary to generate antibody diversity within B cells which, 
combining with genetic changes, including translocations, copy number abnormalities, 
mutation, hyper-methylation, and micro-DNA abnormalities, leads to the immortalisation 
of a myeloma-propagating cell (Gonzalez et al. 2007).  
 
Figure 1-1 Myeloma initiation in the context of B cell development (Morgan et al. 2012) 
 
Subsequently, the malignant plasma cell migrates from the germinal centre to the bone 
marrow, where it continues to evolve and proliferate. At this stage, the interactions and 
establishment of a positive feedback loop with the supportive bone marrow 
microenvironment is crucial for the survival and resistance of myeloma to various 
treatments (Mitsiades et al. 2006; Hideshima et al. 2007). The consequent disruption of 
the bone marrow microenvironment affects the homeostasis of the normal plasma cell 
niche leading to the development of immune suppression. Therefore, it seems that the 
price of generating a wide antibody repertoire, which is necessary for an effective 
immune system, is a background rate of B cell tumours and myeloma, particularly later in 
life. This could explain why clonal expansion of plasma cells in the form of MGUS is 




1.1.2 Diagnosis and standard treatment 
The diagnosis of myeloma is based on the presence of at least 10% clonal bone 
marrow plasma cells, lytic bone lesions and the presence of monoclonal proteins in the 
serum or urine (Palumbo and Anderson 2011). The recommended tests for diagnosis 
include physical examination, routine laboratory testing, bone marrow examination and 
skeletal imaging. Myeloma patients bearing chromosomal abnormalities such as the 
translocations t(11;14), t(4;14), t(14;16), t(6;14), t(14;20), hyperdiploidy, and deletion of 
17p, have normally a less favourable outcome compared to those showing a normal 
karyotype (Table 1-1) (Palumbo and Anderson 2011).  







Whilst manifesting clinically as clonal proliferation of plasma cells, the 
International Myeloma Working Group reports that multiple myeloma is, actually, a 
heterogeneous disease in terms of prognosis, with some patients dying within a few 
weeks of diagnosis, whereas others live for longer than 10 years (Fonseca et al. 2009). 
The reason for this heterogeneity is the result of interactions between host factors, such 
as performance status, comorbidities and age, as well as features intrinsic to the disease 
biology, such as genetic features of the tumour cells and interactions with the tumour 
and bone marrow microenvironment. 
 Treatment strategies include induction regimens, which aim to induce high rates 
of complete response, followed by maintenance treatment, which aims to delay tumour 
re-growth. Host factors, in particular age and co-existing conditions, normally influence 
the choice of the induction regimen because of the relative risk of toxicity from different 
anti-myeloma agents. Current data support the initiation of induction therapy with 
Category Characteristics Frequency 
Low-risk Absence of intermediate-risk or 
high risk factors  
75% 
Intermediate-risk t(4;14) and absence of 17p 
deletion or high-risk gene-
expression-profiling signature 
10% 





thalidomide (Thalidomid), lenalidomide (Revlimid) or bortezomib (Velcade) in conjunction 
with autologous haematopoietic stem-cell transplantation for patients under the age of 
65 years who do not have substantial heart, lung, renal or liver dysfunction. Reduced 
intensity conditioning regimens are instead considered for older patients or those with 
co-existing conditions (Figure 1-2) (Palumbo and Anderson 2011).  
 
Figure 1-2 Treatment approaches in MM  
a)Treatment approaches for newly diagnosed transplant candidates b) Treatment approaches for 
newly diagnosed elderly, non-transplant candidates. Abbreviations: ASCT, autologous stem cell 
transplantation; VCD, velcade–cyclophosphamide–dexamethasone; VMP, velcade–melphalan–
prednisone; VRd, velcade–lenalidomide–dexamethasone (Rajkumar 2011). 
 
The treatment of multiple myeloma has changed and evolved dramatically in the 
past decade thanks to the discovery of the central role of the bone marrow 
microenvironment in myeloma pathogenesis (Caligaris-Cappio et al. 1992). This has 
been the major contributor to the development of new active agents and drug 
combinations (Podar et al. 2009; Palumbo and Anderson 2011). However, the fact that 
only a fraction of cases shows responses to single agents suggests that the molecular 
subtype of the disease may influence the response to specific therapies.  
Recent studies have highlighted how molecular events that characterise plasma cell 
transformation are acquired through a branching non-linear pathway rather than in a 
linear fashion (Morgan et al. 2012). The resulting intra-clonal diversity within the MM cell 
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population has important implications as specific treatments may allow for the selection 
and expansion of resistant sub-clones, particularly in the bone marrow niches. 
Whilst new targeted strategies and drug agents have been demonstrated to 
prolong progression free survival, benefits in terms of overall survival are still not clear 
and multiple myeloma remains an incurable disease. New therapeutic approaches are 
therefore needed and, in this context, serological and cellular approaches that use a 
different mechanism of action compared to current therapeutic strategies, have the 
potential to target drug-resistant myeloma sub-clones in bone marrow niches. However, 
as immune function remains depressed following high-dose therapy for many months, 
ex-vivo or in-vivo immunomodulatory strategies to enhance host immunity against 




















1.2 The immune system and Natural Killer (NK) cells 
The human immune system can be divided into a cellular and a soluble molecular 
arm. With respect to the tremendous knowledge of the immune system that has been 
developed and broadened over the years, this thesis will not aim to discuss all its 
components but will cover aspects that relate to this study and, specifically, to the role of 
NK cells in the control of MM.  
1.2.1 Soluble immunity: cytokines, chemokines and antibodies 
Cytokines are polypeptides involved in the regulation of cellular activation, differentiation, 
proliferation, and survival (Murphy 2011). They act by inducing intracellular activation 
signals through specific cell surface receptors, which are selectively expressed by 
different subsets of immune cells.  
 The cytokines that play a major role in the immune response can be categorised 
as pro-inflammatory cytokines and inhibitory cytokines.  
Examples of pro-inflammatory cytokines are the interleukins (ILs), the tumour necrosis 
factors (TNFs) and the interferons (IFNs).  
IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 are type I cytokines belonging to the common 
cytokine receptor -chain family, which all share the same IL-2R subdomain (Murphy 
2011). Amongst them, of particular importance is IL-2, which was identified for its 
fundamental role in enhancing NK and T cell proliferation and activity (Cooper et al. 
2001; Boyman and Sprent 2012). Due to its ability to trigger tumour cell lysis by immune 
cells (Lotze et al. 1981; North et al. 2007) this cytokine was administered to patients 
affected by various malignancies (Rosenberg et al. 1985; Lotze and Rosenberg 1986; 
Rosenberg et al. 1987), with a number of complete and partial remissions being reported 
(Harrison and Cook 2005).  
IL-12, IL-15 and IL-18 are, instead, important players in the cross-talk between NK and 
dendritic cells (DCs) that initiates the adaptive immune response (Walzer et al. 2005) 
IFN-γ belongs to the type II interferon group. It is primarily released from activated DCs, 
NK and T cells (Ye et al. 1995) and is involved in T cell priming (Das et al. 2001).  
In contrast to the immune stimulatory cytokines, IL-10 and tumour growth factor (TGF)-β 
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mediate the inhibition of immune responses and modulate the expression of immune 
receptors (Pratt et al. 2007). 
 Chemokines are a family of small cytokines that control chemotaxis, a process 
through which resting and activated cells migrate towards specific sites in the body. This 
represents a critical step, as the convergence of different players of the immune system 
is required to allow the exchange of signals necessary for the initiation of the immune 
response. Chemokines exert their biological effects via G protein-linked transmembrane 
receptors that are selectively expressed by subsets of immune cells (Watson 2002). 
Within these, CCL19 and CCL21 are particularly important as they recruit 
CCR7-expressing immune cells to lymph nodes, whereas the chemokine ligand 
CX3CL1, which is primarily expressed by activated endothelial cells, promotes strong 
adhesion of leukocytes to activated endothelial cells (Bazan et al. 1997; Imai et al. 1997). 
Antibodies are large proteins produced by B cells. They have the ability to 
recognise and bind a unique part of a target, called antigen, allowing its neutralisation or 
its attack by the immune system. This occurs either by activating Fc receptors expressed 
on Natural Killer (NK) cells or macrophages and leading to antibody-dependent cell-
mediated cytotoxicity (ADCC), or by activating the complement cascade, resulting in 
complement-dependent cytototoxicity (CDCC) (Murphy 2011). 
1.2.2 Cellular immunity 
The immune system is composed of many different cell types that have distinct 
functions and distribution pathways in the body. Immune cells arise from haematopoietic 
stem cells (HSCs) in the liver, thymus and the yolk sac during foetal life, and in the bone 
marrow after birth (Dzierzak 1999). They are continuously renewed and enter the 
circulation where they stay or are induced to migrate to specific tissue sites.  
The cellular immune system can be divided into the innate and adaptive arm.  
The innate system includes granulocytes, monocytes, macrophages, dendritic cells 
(DCs), Natural Killer T (NKT) cells, mucosal-associated invariant T (MAIT) cells, and 
innate lymphoid cells (ILCs) such as NK cells. These cells have the ability to recognise 
foreign antigens, without the need for prior sensitisation, through germline-encoded 
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receptors.  Once activated, DCs and NK cells develop a crosstalk network of cytokines 
and chemokines, which then help in shaping the subsequent onset of the adaptive 
responses (Walzer et al. 2005). In fact, activated DCs that have recognised and engulfed 
pathogens, migrate to the draining lymph nodes where they present digested epitopes of 
the pathogen to T cells, initiating the adaptive immune response.  
Specific T cell subsets, upon recognition of the presented epitopes, proliferate and 
migrate to the site of infection where they kill the infected cells. This process also 
generates epitope-specific memory T cells that can protect the host upon re-infection. 
The inflammatory reaction is terminated by the activation of biochemical programmes 
with lipid mediators, which enable inflamed tissues to return to homeostasis (Murphy 
2011).  
This process is controlled by regulatory T cells (Treg), which have the ability to suppress 
the action of immune cells by secreting inhibitory cytokines (like IL-10 and TGF-β). Tregs 
can also induce apoptosis or exert direct cytotoxicity on the immune cells (Vignali et al. 
2008).  
 In the following sections the main features and characteristics of NK cells, in 
relation to DCs and T cell activation, will be discussed. 
1.2.2.1 Natural Killer (NK) cells 
NK cells were serendipitously identified in the early 70s as a disturbing 
background observed while investigating specific cytotoxic effects of lymphocytes 
against tumour cell lines. In 1975, they were defined as lymphocytes capable of killing 
tumour cells in the absence of specific immunisation (Herberman et al. 1975). Their 
presence in non-human mammals and in other vertebrates suggests their evolutionary 
selection and importance in higher eukaryotes (Vivier et al. 2011).  
In addition to their direct involvement in the killing of virally-infected and tumour 
cells, the ability of NK cells to localise to the sites of infection, as well in the major 
lymphoid organs, installs them in the centre of a complex immunological cross-talk and 
highlights their important regulatory role in the onset of the adaptive immune response 
(Brilot et al. 2008) (Fig. 1-3). 
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Figure 1-3 The biological function of NK cells (Vivier et al. 2008). 
 
1.2.2.1.1 Human NK cell subsets 
Human NK cells account for about 10 to 15% of all peripheral blood lymphocytes 
and are normally defined phenotypically by their expression of CD56 and lack of 
expression of CD3. With the advent of monoclonal antibodies (Abs), two distinct 
populations of human NK cells were identified, according to their cell-surface density of 
CD56 and CD16 (Fig. 1-4) (Cooper et al. 2001). 
 
Figure 1-4 Human NK cell subsets (Cooper et al. 2001) 
Flow cytometric analysis of CD56-PE (A) and CD56-PE/CD16-FITC expression before (B) and 
after (C) FACS purification of a representative donor. 
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The CD56 antigen is an isoform of the human neural cell adhesion molecule. Its function 
in NK cells is still unknown, although early studies suggested that this molecule might 
mediate interactions between NK cells and target cells (Nitta et al. 1989). 
CD16 is a low-affinity FcγRIII receptor present on the surface of some NK cells. It has 
been shown to bind to antibody-coated targets and to direct antibody-dependent cellular 
cytotoxicity (ADCC) (Leibson 1997).  
The majority (about 90%) of human NK cells in the peripheral blood exhibit 
low-density expression of CD56 (CD56dim) and express high levels of CD16, whereas the 
remaining 10% is CD56brightCD16dim or CD56brightCD16negative (Cooper et al. 2001). 
CD56dim NK cells 
 Early studies on resting CD56dim NK cells have revealed that these cells are more 
cytotoxic than CD56bright NK cells, although after activation with IL-2 or IL-12 in vitro, or 
following low dose therapy with IL-2, CD56bright and CD56dim cells have similar levels of 
cytotoxicity (Robertson et al. 1992). Consistent with differences in their resting cytotoxic 
potential, CD56dim NK cells store higher levels of cytotoxic granules compared to 
CD56bright cells, although they present similar levels of expression of perforin. 
CD56dim NK cells also seem to be the major subset responsible for ADCC. This particular 
function, in fact, requires the engagement and activation of CD16 FcγR by 
antibody-coated targets and therefore, CD56dim NK cells, displaying higher levels of 
expression of CD16, exhibit greater levels of ADCC compared with the CD56bright subset 
(Cooper et al. 2001). 
CD56bright NK cells 
 Freshly isolated CD56bright human NK cells have been defined as the primary 
source of NK cell-derived immunoregulatory cytokines, including IFN-γ, tumour necrosis 
factor β (TNF-β, lymphotoxin), IL-10, IL-13 and granulocyte–macrophage colony-
stimulating factor (GM-CSF) (Cooper et al. 2001). This subset appears to be more 
responsive to IL-2, due to its constitutive expression of the high-affinity heterotrimeric 
IL-2 receptor (IL-2Rαβγ). They also seem to be readily responsive to chemotactic signals 
as they express CCR7, the CXC-chemokine receptor 3 (CXCR3) and the adhesion 
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molecule L-selectin (CD62L). Consequently, this subset has the potential to traffic to 
secondary lymphoid organs (Campbell et al. 2001b).  
These results, taken together with the ability of the CD56bright NK-cell to respond to IL-2 
produced by T cells and DCs (Baume et al. 1992), postulate a role for this subject in the 
activation of a cytokine feedback loop between the innate and adaptive immunity within 
secondary lymphoid organs. 
1.2.2.1.2 NK cell activation and regulation 
NK cells use preformed lytic granules to facilitate the rapid killing of target cells. 
Therefore, the cytotoxic potential of NK cells requires a well-regulated mechanism of 
control. 
The “missing self hypothesis” was proposed by Ljunggren and Kärre (Ljunggren 
and Karre 1986; Ljunggren and Karre 1990) to explain the ability of NK cells to spare 
normal tissues, whilst killing transformed cells. This hypothesis postulates that 
NK cell-mediated surveillance depends on the expression of sufficient levels of “self” 
molecules, which protect target cells from NK cell-mediated lysis. This phenomenon is 
regulated by the expression of MHC class I–specific inhibitory receptors that functionally 
dominate over the triggering potential induced by activating receptors. The functions of 
NK cells, including their cytolytic activity, are therefore regulated by the balance of 
interactions between a complex array of inhibitory and activating receptors and ligands 
(Biassoni 2009) (Figure 1-5).  
Any condition altering the strength of the inhibitory receptors/MHC class-I-induced 
signalling results in direct killing of the infected or transformed cell, as well as in the 




Figure 1-5 The dynamic regulation of NK cell effector functions (Vivier et al. 2011). 
 
 The study of NK cell-mediated tumour killing provided new insights into the 
process of NK cell activation. In fact, it has been demonstrated that presence or absence 
of NK cell ligands on tumour cells alone is inadequate for triggering lysis by resting 
NK cells, which requires some additional form of stimulation. This priming signal may be 
nonspecific (e.g. IL-2 or IFN-γ) or can be provided by a tumour cell, while the triggering 
signal should be specific to prevent auto-reactivity (North et al. 2007). This led to the 
hypothesis that NK-sensitive tumour cells provide both priming and triggering signals. In 
contrast, NK-resistant tumours evade NK-mediated lysis through the lack of priming 
and/or triggering ligands for NK cells (Bryceson et al. 2011). 
NK cells, like T and B cells, have the potential for autoreactivity. This is because 
the array of receptors that individual NK cells come to express during development is 
largely random and the MHC ligands recognised by these receptors are inherited 
independently of the genes encoding for the receptors (Parham 2005). To avoid this risk, 
an “education system” exists whereby the potentially autoreactive NK cells acquire a 
state of hypo-responsiveness to stimulation (Fig. 1-6). This is achieved through the 
induction of an anergic state, as happens in autoreactive T cells and B cells, or through 
the failure of these NK cells to undergo terminal functional maturation.  
Several findings also suggested that the responsiveness of mature NK cells is not fixed 
but may adapt to a changing environment in vivo (Vivier et al. 2011). Thus, persistent 
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stimulation without inhibition results in NK cell hypo-responsiveness, whereas persistent 
stimulation coupled with commensurate inhibition results in NK cell responsiveness.  
 Immunological memory is a hallmark of adaptive immunity and is characterised 
by the long-term persistence of memory cells that rapidly undergo clonal expansion and 
present enhanced effector functions in response to secondary challenge (Vivier et al. 
2011). Cooper and colleagues (Cooper et al. 2009) recently showed that, once activated, 
mature NK cells might acquire stable and heritable properties that influence their 
behaviour during subsequent infections. In vivo models showed, in fact, that activated 
NK cells, after transfer into naïve hosts, return to a quiescent state whilst retaining an 
intrinsic capacity to respond more robustly after reactivation with cytokines or via 
engagement of activating NK receptors (Cooper et al. 2009). 
1.2.2.1.3 Human Natural Killer Receptors (NCR) 
NK cell activation is regulated by the integration and amplification of multiple 
signalling pathways, which depend on a number of surface receptors that bind specific 
ligands expressed by target cells (Fig. 1-6). Transmission of the signal requires the 
co-aggregation with other activating/inhibitory receptors at the immuno-synapse 
interface. This allows NK cells to focus their inhibitory/activating signals to a limited cell 
surface area while maintaining their potential surveillance and cytolytic capacity in 
different membrane areas (Biassoni 2009). 
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Figure 1-6 NK cell receptors (Vivier et al. 2011). 
 
The Killer-Cell Immunoglobulin-like Receptors (KIR) 
 The KIRs recognise HLA class-I molecules through their extracellular domain. 
These molecules are normally expressed on most healthy cells in the body, but may be 
lost upon viral or malignant transformation and during tumour evolution (Beersma et al. 
1993; Hill et al. 1994; Seliger 2008).  
Individuals differ in the number and type of KIRs expressed. The variegated 
expression pattern of KIRs on NK cells may also be explained by the fact that specific 
KIR gene products are expressed randomly in distinct subsets of NK cells (Valiante et al. 
1997; Andersson et al. 2009). Two major and divergent KIR haplotypes have been 
identified amongst the human population, which are composed of combinations of both 
activating and inhibitory KIRs.  
Inhibitory and activating KIRs share the same structural features of their 
extracellular domain (2D or 3D, reflecting the number of Ig-like domains), but have 
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different cytoplasmic tails with either a long (L) or a short (S) tail, mediating inhibition and 
activation, respectively (Bashirova et al. 2006).  
Most functionally mature NK cells express at least one inhibitory receptor specific 
for a self HLA class-I ligand. In humans, CD94/NKG2A represents the main HLA class-I-
specific KIR, as it recognises HLA-A, HLA-B, and HLA-C alleles and HLA-E molecules 
(Moretta and Moretta 2004; Lanier 2005). Under normal conditions, inhibition signals 
dominate over activation signals in NK cells (Long 2008). However in some situations, 
the activation signals may override the inhibitory signals as demonstrated for NKG2D-
mediated killing of some MHC class I expressing tumour cell lines in mice (Diefenbach et 
al. 2000; Cerwenka et al. 2001). 
 Receptors with a short tail are, instead, characterised by activating function 
(KIR2DS, KIR3DS) and their transmembrane portion displays the immune-receptor 
tyrosine-based activation motif (ITAM), which is responsible for the triggering function of 
these receptor (Biassoni 2009).  
Receptors mediating Natural Cytolysis 
The major family of NK cell receptors responsible for the induction of 
NK-mediated killing is formed by the natural cytotoxicity receptors (NCRs) or natural 
killer receptors (NKR) NKp46 (NCR1), NKp30 (NCR3), and NKp44, which belong to the 
Ig-like superfamily, and the NKG2D (KLRK1) lectin-like receptor (Biassoni 2008).  
Studies conducted to date have demonstrated that, unlike their inhibitory counterparts, 
these receptors are organised into multichain complexes where the ligand-binding and 
signal-transducing subunits are separate polypeptides (Yokoyama et al. 2004). In this 
way, their activation results in the engagement of multiple downstream triggering 
pathways, whose functional cross-talk and integration determine the degree of cell 
activation.  
The role of these receptors in NK cell-mediated target killing has been widely 
demonstrated in solid tumours (Balsamo et al. 2009; Garcia-Iglesias et al. 2009; Pietra et 
al. 2012) and haematological malignancies (Sanchez et al. 2011), including MM (El-
Sherbiny et al. 2007; von Lilienfeld-Toal et al. 2010). The presence and importance of 
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these receptors was demonstrated with the aid of anti-NCR monoclonal antibodies and 
thanks to the identification of NCR-ligands on tumour cells (Pessino et al. 1998; Vitale et 
al. 1998; Pende et al. 1999; Sivori et al. 1999). 
NKp46 (NCR1, CD335)  
NKp46 is expressed on the surface of either resting or activated NK cells and is 
thought to be the major receptor responsible for the efficient NK cell-mediated killing of 
different cancer cell lines (Elboim et al. 2010). It is involved, together with NKp44, in the 
response against influenza virus and in the recognition of tumour cells, such as MM (El-
Sherbiny et al. 2007), which express the membrane-associated heparan sulfate 
proteoglycans (Bloushtain et al. 2004). NKp46 also helps modulate the adaptive immune 
response by synergising with NKp30 and DNAM-1 to activate the killing of immature DCs 
(Wai et al. 2011).  
NKp44 (NCR2, CD336)  
NKp44 is the only receptor expressed by activated NK and γδ T cells, but not by 
resting NK cells (Cantoni et al. 1999). NKp44 uses a different activating downstream 
pathway from that used by NKp46. This may explain why activated NK cells display a 
higher cytolytic potential; in fact, by expressing an additional triggering receptor, the 
combined signals activated by the engagement of NKp44 and NKp46 may lead to a 
stronger activation (Biassoni 2009). A possible role for NKp44 in tumour 
immune-surveillance has been postulated following studies showing its downregulation 
in the presence of tumour cells such as melanoma (Pietra et al. 2012). 
NKp30 (NCR3, CD337)  
NKp30 is expressed on both resting and activated NK cells. Its role is more 
complex than initially thought, since it has been involved not only in the response to 
tumour cells (El-Sherbiny et al. 2007; Pietra et al. 2012) and pathogens, but also in the 
modulation and editing of the intensity and quality of the adaptive immune responses. 
NKp30 has been shown to participate in the cross-talk between NK cells and DCs, 
particularly in NK-cell mediated killing (Ferlazzo et al. 2002; Vitale et al. 2005; Pietra et 
al. 2012) and maturation of immature DCs. The mechanism controlling the dual roles of 
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NKp30 is not clear, although the ratio of NK cells to DCs is thought to be an important 
factor (Wai et al. 2011) 
NKG2D (CD314, KLRK1)  
NKG2D is constitutively expressed on the surface of all human NK cells, and γ/δ 
and CD8+ T lymphocytes (Biassoni 2009). Human NKG2D has been shown to bind 
different ligands, which are expressed on the cell surface in response to cellular 
stresses. In particular, NKG2D interacts with the stress-inducible MHC class I–related 
molecules MICA and MICB and is involved in the rejection of both virally infected and 
tumour cells (Raulet 2003; Eagle and Trowsdale 2007; Guerra et al. 2008). In addition, 
Poggi’s data indicate that NKG2D may be involved in autoimmunity (Poggi and Zocchi 
2007). 
NKG2D also binds to surface structures encoded by the homologous genes of 
the murine retinoic acid–inducible molecules encoded in the Raet1 gene cluster. A splice 
variant of the Raet1G gene, which encodes a soluble ligand form, may compete with and 
disrupt the NKG2D/ligand interaction and affect the killing of tumour cells, unveiling an 
additional escape mechanism for tumour cells from the immune system (Burgess et al. 
2008). Additionally, other soluble (Pietra et al. 2012) and non-soluble (von Lilienfeld-Toal 
et al. 2010) factors have been shown to play a role in tumour-mediated downregulation 
of NKG2D.  
Activating co-receptor molecules 
 Additional surface receptors are involved in triggering NK cell-mediated cytolytic 
activity. Some of these molecules are not exclusively expressed by NK cells and they 
mainly operate as co-receptors or mediate NK cell-to-target cells adhesion (Biassoni 
2009). The most important ones include NKp80 (KLRF1), signalling lymphocytic 
activation molecule or SLAM (2B4, NTB-A, and CS1) receptors, CD16, CD28 and 
DNAM-1 (CD226).  
 DNAM-1 is particularly relevant, as it has been implicated in cell adhesion and in 
triggering of T and NK cell–mediated cytolysis. Its function is dependent on the physical 
association with lymphocyte-associated antigen-1 (LFA-1; CD18/CD11a) (Shibuya et al. 
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1999). Two ligands for DNAM-1 have been identified: CD155 (PVR) and CD112 (Nectin-
2) (Bottino et al. 2003). The former appears to have a predominant role in inducing 
DNAM-1 activation. There are some indications that DNAM-1 may also cooperate 
synergistically with other NCRs and, in particular, NKG2D to trigger NK cell mediated 
cytotoxicity (Bryceson et al. 2006). This combination seems to be important in the 
protection from tumour development (Iguchi-Manaka et al. 2008). Furthermore, DNAM-1 
has been found to be an additional pathway used by NK cells in the cross-talk with DCs 
as these latter cells express DNAM-1 ligands (Iguchi-Manaka et al. 2008). 
 Another important activating receptor is CD16 (FcγRIIIa), which is expressed by 
the majority of human peripheral blood NK cells, as well as by activated monocytes and 
T cells. Its binding to the constant region (Fc) of IgG results in phosphorylation of 
tyrosine residues in the CD3ζ and FcεRIγ ITAM sequences, which then initiate the 
activating signalling cascade that leads to antibody-dependent cytotoxicity (ADCC) 
(Biassoni 2009). 
 The 2B4 (CD244) receptor is expressed on the majority of human NK cells. It 
binds to CD48, which is commonly expressed by most hematopoietic cells (Korinek et al. 
1991). Interactions between 2B4 and its ligand results in the induction of proximal 
activating signals but the magnitude of the signal is not sufficient to induce effective NK 
cell activation alone (Bryceson et al. 2006). 
 CD28 is a member of the immunoglobulin superfamily and is constitutively 
expressed on T cells (Schmidt-Weber et al. 2002). Its binding to CD80 and CD86, which 
are found on antigen presenting cells, provides a potent co-stimulatory signal which, in 
synergy with the T-cell receptor (TCR) signal, promotes T cell activation and survival 
(Manickasingham et al. 1998). Although its expression and importance on murine NK 
cells has been established (Geldhof et al. 1995; Chambers et al. 1996), its role in human 
NK cell activation remains controversial (Galea-Lauri et al. 1999; Wilson et al. 1999).  
Firstly, the detection of CD28 on the surface of NK cells is still the object of debate. 
Galea-Lauri and colleagues (Galea-Lauri et al. 1999) have demonstrated that, despite 
the presence of steady-state levels of CD28 mRNA in NK cells, the detection of this 
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molecule on their surface strongly varies according to the antibody clone used and also 
between NK cell lines and individuals. This result could be potentially due to post-
translational modification or the generation of splice variants of CD28 (Galea-Lauri et al. 
1999), which could mask epitopes recognised by a particular antibody clone. 
Alternatively, the existence of an unknown receptor on NK cells able to interact with 
CD80 has also been hypothesised (Wilson et al. 1999).  
Another issue that needs to be addressed is the role of this receptor in NK cell activation 
in humans, as some studies have demonstrated that CD80 stimulation does not always 
lead to NK cell activation (Galea-Lauri et al. 1999; Wilson et al. 1999; Luque et al. 2000). 
Further experiments are needed to demonstrate whether this is the result of the lack of 
appropriate expression of adhesion and/or co-stimulatory molecules, which may operate 
in parallel with CD80 to trigger NK cell activation. Additionally, although previous works 
have shown direct activation of NK cells by CD80-expressing tumour cells (Galea-Lauri 
et al. 1999; Wilson et al. 1999; Hardwick et al. 2010), including myeloma (Geldhof et al. 
1995; Yeh et al. 1995), further studies should to investigate the ability of NK cells to 
recognise these molecules and to exclude the possible contribution of T cells (Goodier 
and Londei 2004) to this phenomenon. 
Regulation of NCR expression 
 Recent studies have demonstrated that NCR expression is dynamic and can be 
altered by several mechanisms such as cytokines, soluble ligands or through direct 
contact with targets expressing ligands for NCRs. It is known, in fact, that IL-2 increases 
the expression of NKG2D (de Rham et al. 2007), and stimulates NK cells to express 
NKp44 (Cantoni et al. 1999), whereas TGF-β is able to down-regulate NKG2D and IL-21 
affects both NKG2D and NKp44 expression (Castriconi et al. 2003; Burgess et al. 2006; 
de Rham et al. 2007; Ghio et al. 2009).  
NCR expression may also be modulated by interactions with their cognate 
ligands, as exemplified by trogocytosis, where NCRs, such as NKG2D and DNAM-1, 
were shown to be literally ripped from the NK cell surface or internalised after 
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receptor-ligand interaction (Groh et al. 2002; Mota et al. 2004; Coudert et al. 2005; 
Oppenheim et al. 2005; Roda-Navarro et al. 2006).  
1.2.2.1.4 The cross-talk between NK cells and dendritic cells (DCs) in the initiation 
of the immune response 
Recent findings have highlighted the role of NK cells as an evolutionary “bridge” between 
innate and adaptive immunity. Indeed NK cells, as the centre of a complex crosstalk 
between DCs and T cells, can influence the outcome of both “specific” adaptive-like 
responses, as well as “non- specific” innate-like responses (Brilot et al. 2008). 
 DCs are a sparsely distributed migratory groups of bone-marrow-derived 
leukocytes, which were initially identified due to their particular morphology and 
functional specialisation for antigen uptake, transport, processing and presentation to 
T cells (Walzer et al. 2005). At the ‘immature’ stage of development, DCs continuously 
sample the antigenic environment in peripheral tissues and migrate at a slow rate to 
lymph nodes. Under these steady-state conditions, DCs express low levels of MHC and 
co-stimulatory molecules, and their interaction with naive T cells leads to T-cell 
tolerance. By contrast, the encounter with microbial products or tissue damage in the 
periphery initiates DCs maturation and their rapid migration to lymph nodes. This 
activation program is, in part, due to the engagement of a complex set of receptors, such 
as the toll-like receptors (TLRs), which are able to recognise molecules or molecular 
patterns shared by various classes of microbes. Mature DCs start expressing high levels 
of MHC and co-stimulatory molecules, such as CD80 and CD86, which allow the 
activation of naive T cells and secrete an array of cytokines known to enhance NK cell 
cytotoxic function and IFN-γ production (Walzer et al. 2005).  
However, this system is more complex than previously thought as DC activation 
leads to bi-directional and complex interactions among DCs, NK, and T cells, which are 
responsible for tuning the outcome of the overall immune response. 
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NK maturation induced by DC 
DCs are able to produce a wide range of cytokines that trigger NK cell activation 
processes such as IFN-γ production, cytotoxicity, and proliferation.  
IL-12 is produced by many DC subsets in response to various stimuli, and is known to 
synergise with IL-18 to induce IFN-γ secretion and NK-cell cytotoxicity (Ferlazzo et al. 
2004).  
IL-15 is produced by mouse PBMCs propagated in the presence of GM-CSF and IL-4, 
and its secretion and trans-presentation on IL-15Rα by DCs promotes in vitro NK cell 
cytotoxicity and IFN-γ secretion (Lucas et al. 2007). Ferlazzo and colleagues (Ferlazzo 
et al. 2004) recently found that in humans, IL-15 production by monocyte-derived DCs or 
spleen DCs induces NK cell proliferation.  
IFN-α and β also appear to be essential for the in vitro induction of NK cell cytotoxicity by 
various types of DCs (Walzer et al. 2005) (Figure 1-8). 
As pointed out by one of the first studies on NK cells–DCs crosstalk (Fernandez 
et al. 1999), NK cell activation by DCs also requires direct cell-to-cell contact. This can 
be explained by the importance of the interaction of membrane-bound receptor–ligand 
pairs (Figure 1-7) and by the necessity for local delivery of cytokines at high 
concentration at the interface between DCs and NK cells. 
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Figure 1-7 Interactions between NK cells and DCs in the periphery (Cooper et al. 2004). 
Abbreviations: LN, lymph node; NKR: natural killer receptor; iDC: immature DC; mDC, mature DC 
 
DC maturation induced by NK cells 
NK cells are able to induce DC maturation either directly or in synergy with 
suboptimal levels of danger signals. This process appears to be dependent on TNF-α 
and IFN-γ secretion, and cell-to-cell contact is critical for optimal DC activation and 
subsequent induction of T cell responses. This process is particularly important in 
conditions where inflammation is poor (e.g, cancer), but where NK cell activation could 
occur through direct recognition of target cells (Walzer et al. 2005).  
NK cells also exert a very important role in regulating DC homeostasis, and 
thereby the balance between tolerance and immunity, by killing immature DCs while 
sparing mature DCs. In vitro studies showed that signals delivered by NKp30, DNAM-1 
and CD40 are critical for the lysis of immature DCs (Vivier and Biron 2002), whereas 
resistance to NK lysis is achieved by the up-regulation of MHC class I molecules during 
DC maturation, in particular HLA-E (Della Chiesa et al. 2003) (Figure 1-7). 
44 
Accumulating evidence suggests that the site of NK cell–DC interaction may also 
influence the outcome of the immune response. In lymph nodes, NK cells may contribute 
to DC activation and skew T cell differentiation, whereas NK cell–DC interactions in 
inflamed non-lymphoid tissues could promote NK effector functions or trigger DC 
maturation, as discussed in the following section (Walzer et al. 2005). 
Role of NK–DC interactions in T and NK cell responses 
 In humans, CD56bright NK cells are present in large numbers in lymph nodes where 
they have been shown to co-localise with DCs in the T cell areas (Bajenoff et al. 2006). 
This finding, together with the role of NK cells in DC maturation and activation, 
postulates a function for NK cells in the priming of T cell responses and in the 
polarisation of T cell responses through the secretion of high levels of cytokines in 
response to DC activation (Martin-Fontecha et al. 2004; Walzer et al. 2005) (see Figure 
1-8). However, it is still not clear whether the cytokinesproduced by NK cells are directly 
affecting naïve T cells or are necessary for T cell priming by DCs, or both. Nevertheless, 
there is a suggestion that NK cell recruitment in lymph nodes might be important to 
license DCs to prime Th1 T cell responses by providing an early source of IFN-γ (Walzer 
et al. 2005).  
 Additionally, van den Broeke and colleagues (van den Broeke et al. 2003) have 
shown NK cell activation by DCs-activated CD4+ T cells. This phenomenon has also 
been confirmed in the context of MM, where immunomodulatory drugs (IMiDs) have 




Figure 1-8 Interaction between NK cells, DCs and T cells in the lymph node (LN) (Cooper et al. 
2004) 
Abbreviations: LN, lymph node; T8: CD8 T cells; T4: CD4 T cells; mDC, mature DC 
 
Role of NK–DC crosstalk in anti-tumour responses 
NK cell activation by tumour cells has been shown to promote the initiation of 
cognate and protective T cell responses against tumours (Fernandez et al. 1999). The 
crosstalk between NK cells and DCs has, in fact, developed as a sophisticated switch to 
turn on innate and adaptive immune responses against most pathological conditions. In 
the case of a tumour that does not cause inflammation but does express ligands for 
activating NK cell receptors, NK cells would be the first cells to be activated and to 
subsequently provide help for DC maturation and the downstream activation of T 
lymphocytes (Degli-Esposti and Smyth 2005) (Fig. 1-9). 
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Figure 1-9 Role of DC cross-talk in the immune response against tumours (Degli-Esposti and 
Smyth 2005) 
  
Interestingly, while freshly-isolated NK cells can recognise and kill tumour targets 
without the need for additional activation, NK cells can produce IFN-γ and induce the 
maturation of DC only when receiving an additional co-stimulatory signal. This second 
signal for the induction of NK cell “helper” activity can be provided by type-1 interferons, 
such as IFN-α and IFN-β, or by IL-2 produced by activated CD4+ T cells (Kalinski et al. 
2005).  
This more-stringent requirement for two-signals for the activation of NK cell “helper” 
functions, as opposed to their cytolytic “effector” function, may explain the poor 
effectiveness of immune responses against cancer. In fact, during early phases of 
tumour growth, NK cells are able to eliminate the transformed cells but, due to the lack of 
a second signal, they cannot perform their “helper role” and fail to support the 
development of type-1 tumour-specific immunity, resulting in the failure of tumour 
surveillance (Kalinski et al. 2005).  
Therefore, the initiation of a proper immune response is dependent on the recognition of 




1.3 Immunodeficiencies in multiple myeloma (MM) 
 Several studies have highlighted the importance of the immune system in the 
disease progression of MM, particularly in the transformation from MGUS.  
In fact, while displaying a genetic expression profile remarkably similar to MM, MGUS 
patients demonstrate a better ability to mount a vigorous T cell response when 
challenged with autologous plasma cells, compared to T cells from MM patients (Kyle 
and Rajkumar 2003). This phenomenon is likely to be the consequence, amongst many 
others, of the poorer expression of co-stimulatory molecules such as CD80 and HLA-DR 
(Perez-Andres et al. 2005), and activating molecules like NKG2D (Girlanda et al. 2005) 
by plasma cells from MM patients.  
 These observations provide strong evidences as to the importance of the host 
immune system in controlling disease progression, and have prompted the investigation 
the mechanisms underlying MM-induced immunodeficiency in order to identify potential 
strategies to enhance the autologous immune response to MM (Pratt et al. 2007). 
Results from these studies have helped to identify two principal mechanisms through 
which MM inhibits the immune system: a cytokine-mediated and a cellular mediated 




Figure 1-10 Interaction between MM cells and the immune system.  
Abbreviations: VEGF, vascular endothelial growth factor; IL6, interleukin 6; IDO, indoleamine 2,3-
dioxygenase; β 2M, β 2 microglobulin; TGFβ, transforming growth factorβ; IL10, interleukin-10; 
TNFα, tumour necrosis factor α; SDF-1α, stromal-derived factor 1α; IGF, insulin growth factor; 
HGF, hepatocyte growth factor; MMP, matrix metalloproteases; TLR, toll-like receptors (Pratt et 
al. 2007). 
 
1.3.1 Cytokine-mediated immunosuppression 
 When considering the cytokine-mediated mechanisms involved in MM-induced 
immunosuppression, it is interesting to note that many of the molecules involved have a 
dual mechanism of action. In fact, they support tumour cell survival and drug resistance 
through the establishment of interactions with the bone marrow stroma, while promoting 
immune suppression. A number of immunologically active compounds have been 
identified, particularly within the bone marrow microenvironment.  
IL-6 and L-10 are multifunctional cytokines, which play an important role in the biology of 
many tumours. In MM, they are involved in the inhibition of cancer cell apoptosis, 
stimulation of angiogenesis, and drug resistance (Pratt et al. 2007). In addition to these 
activities, they have also been linked to DC functional defects in MM patients (Brown et 
al. 2001), with IL-6 additionally promoting a humoral-mediated T helper cell type-2 
response over a cellular mediated T helper cell type-1 response (Diehl and Rincon 
2002).  
Myeloma cells also produce high levels of Transforming Growth Factor beta 
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(TGF-which suppresses B and T cells through the inhibition of IL-2 autocrine 
pathways (Pratt et al. 2007), while stimulating the proliferation of T regulatory cells (Treg) 
(Braga et al. 2012).  
The Vascular Endothelial Growth Factor (VEGF) has a fundamental role in promoting 
growth, survival and migration of myeloma plasma cells. Additionally, it was also shown 
to inhibit DC maturation and to elicit the production of IL-6 (Pratt et al. 2007).  
The production of the glycoprotein Muc-1 has been shown to skew the differentiation of 
DCs into cells with a regulatory phenotype (Monti et al. 2004; Rughetti et al. 2005) whilst 
acting as a chemo-attractant for immature DCs (Carlos et al. 2005).  
The high secretion of cyclooxygenase-2 (Cox-2) and prostanoids is considered a poor 
prognostic marker in MM. This is due to the fact that these molecules are responsible for 
tumour cell proliferation and survival, but also for negatively influencing anti-tumour 
immunity. This function is achieved through the induction of myeloid-derived suppressor 
cells, which inhibit T cell responses, NK cells and macrophage functions while expanding 
Treg numbers (Obermajer et al. 2012).  
The activation of the immune response against MM is also suppressed through the 
release of matrix metalloproteinases (MMPs). These molecules, originally thought to be 
involved only in tumour invasion, have been also shown to have immunomodulatory 
properties as they prevent NK and T cell activation by shredding activating receptors 
from their cell surface and by inducing the release of immunomodulatory compounds 
(Gialeli et al. 2011). 
1.3.2 Cellular-mediated immunosuppression 
 A second mechanism responsible for immune suppression is achieved through 
the expression of immunomodulatory receptors or ligands on the surface of MM and 
immune cells.  
Fas Ligand (FasL) can normally be found on activated T cells, where its cross-link with 
Fas receptor induces apoptosis of the target cells. However, T and NK cells from MM 
patients have been shown to express significantly higher levels of Fas receptor, while 
MM cells present high levels of FasL and are therefore able to induce T cell and NK cell 
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apoptosis (Villunger et al. 1997; Poggi et al. 2005; Pratt et al. 2007).  
In MM the presence of an imbalance of the Programmed Cell Death 1 (PD-1)/PD-L1 
axis, which plays a key role in modulating the balance between tolerance and immune 
activation, has also been observed. Specifically, MM cells up-regulate the expression of 
PD-L1 in the presence of IFN- (Liu et al. 2007) while T (Rosenblatt et al. 2011) and NK 
cells (Benson et al. 2010) from MM patients present high levels of its ligand PD-1 and 
are therefore susceptible to PD-L1-induced cell apoptosis.  
The expression of HLA-G on myeloma cells has been proposed to be relevant to tumour 
escape by directly conferring resistance to NK cell-mediated killing, and by affecting 
other immune effector cells such as T lymphocytes and DCs (Maki et al. 2008). 
Additionally, MM cells have also developed a poor capacity to present antigens to the 
immune system. Their expression of HLA-DR and MHC class I (Pratt et al. 2007) as well 
as that of co-stimulatory molecules such as CD80 and CD40 (Yi et al. 1997) are often 
down-regulated. 
1.3.3 Cellular immune defects in MM 
 The suppressive microenvironment created by MM leads to several cellular 
immune defects.  
The cytokine milieu produced by tumour cells, including MM, blocks DC differentiation 
and attracts immature DCs. As a consequence, the majority of peripheral blood DCs 
from MM patients present an immature phenotype and, when stimulated, fails to up-
regulate the expression of the co-stimulatory molecule CD80 (Brown et al. 2001).   
This phenomenon also has an impact on T cells which, in MM patients, present a 
skewed CD4 to CD8 ratio (Pratt et al. 2007) and reduced cell numbers, possibly owing to 
the concurrent effects of IL-6, IL10, TGF-, FAS-L and PD-L1 (Raitakari et al. 2003).  
It has been shown that several types of tumours activate Treg in order to down-regulate 
the immune response (Joshua et al. 2008). However, although the MM cytokine 
microenvironment has the capacity to support the expansion of Treg and there is 
evidence demonstrating direct induction of Treg cells by both fresh myeloma cells and 
cell lines in vitro (Feyler et al. 2012; Feyler et al. 2013), there is still significant 
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disagreement in the literature concerning in vivo Treg numbers and function in myeloma 
patients (Braga et al. 2012). This discrepancy is probably due to differences in assay and 
purification techniques (Joshua et al. 2008) and, therefore, will require further 
investigations.  
NK cells have an important role in the lysis of tumour cells, including MM plasma cells 
(Carbone et al. 2005; Harrison and Cook 2005). However, during the transition between 
MGUS and MM, malignant plasma cell sub-clones with low expression of immuno-
stimulatory molecules, such as NKG2D, and increased levels of inhibitory receptors, 
such as HLA-G, MICA, PD-L1 and FASL, emerge (Raitakari et al. 2003; Carbone et al. 
2005; Maki et al. 2008). These plasma cells have the potential to induce NK cell 
apoptosis and to cause the loss of inflammatory functions.  
 In view of this suppressive environment produced by MM cells and their 
microenvironment, several strategies to enhance autologous responses to MM have 

















1.4 Immunotherapy for MM 
 Immunotherapy holds promise for treating several types of cancers, including 
haematological tumours as, by using different mechanisms of action, it has the potential 
to target the chemotherapy-resistant disease. These strategies are more likely to be 
effective in the setting of minimal residual disease following chemotherapy or 
haematopoietic stem cell transplantation (HSCT) as either consolidation or maintenance. 
The unique potential of immunotherapy for the treatment of MM is supported by the 
higher rate of molecular remission and lower rate of relapse and disease progression 
that are observed when comparing patients treated with allogeneic HSCT or donor 
lymphocyte infusion and those treated with autologous HSCT (Harrison and Cook 2005). 
Results reported by the European Group for Blood and Bone Marrow Transplantation, 
derived from 229 MM patients who received allogeneic HSCT with RIC regimens from 33 
clinical centres (Crawley et al. 2005), suggest that the establishment of an allogeneic T 
cell response, demonstrated by the presence of chronic graft versus host disease 
(GVHD), is associated with better overall-survival and progression-free survival (Rutella 
and Locatelli 2012). Anti-tumour immunotherapy has therefore the potential to provide a 
powerful intervention to maintain long-lasting control of minimal residual disease or to 
even eradicate disseminated tumour cells.  
Some immune therapeutic strategies have achieved clinical success and have been 
approved for clinical use for non-Hodgkin’s lymphoma and prostate cancer (Zhang et al. 
2012). Nevertheless, an immunotherapy protocol with unequivocal clinical benefit is yet 
to be established in MM (Zhang et al. 2012). 
 Despite the success of HSCT in other haematological malignancies, the use of 
allografting in the context of MM is limited by the high treatment-related morbidity and 
mortality (Harrison and Cook 2005). Several strategies have been tested to overcome 
this problem, such as the use of a T cell depleted graft followed by donor leukocyte 
infusion (DLI) (Alyea et al. 2001), the use of reduced-intensity conditioning regimens 
(Rosenblatt and Avigan 2008), and the administration of high dose autologous stem cell 
transplants in conjunction with high-dose melphalan therapy, followed by a 
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non-myeloablative reduced-intensity allogeneic transplant from HLA-identical sibling 
(Maloney et al. 2003).  
Nevertheless, separating the graft versus myeloma effect (GVM) from the graft versus 
host disease remains a challenge. Orsini and colleagues demonstrated that GVHD and 
the GVM effects are mediated by distinct T cell populations that emerge at different times 
following DLI (Orsini et al. 2000). Using spectrotyping analysis and functional 
characterisation of the T cell receptor repertoire following donor leukocyte infusion, this 
group showed that one of the GVM clones was able to specifically recognise CD138+ 
MM cells but not CD138- bone marrow cells in an HLA class-I-dependent manner. 
Therefore, on the basis of these results, future studies should aim to segregate the GVM 
effect from the GVHD effect through the identification and targeting of unique MM 
antigens by immune effector cells.  
 However, the establishment and growth of myeloma cells, despite the existence 
of T cells specific for tumour-associated antigens (TAA) in cancer patients, suggests that 
the presence of their targets is not sufficient to elicit a protective immune response. This 
might be due to a lack of tumour-reactive effector cells in the immune repertoire, or to the 
inability to expand and activate these cells effectively, due to the presence of a tumour-
immune suppressive microenvironment. Following these considerations, the 
development of effective immunotherapies for myeloma should rely on the identification 
of appropriate tumour targets, the augmentation of antigen-presenting and effector cell 
functions, and the reversal of the tumour-mediated immunosuppressive state (Rosenblatt 
and Avigan 2008).  
Within the last few years, a number of immunologically active compounds have 
been investigated in vitro and in vivo to test their ability to recover or increase the 






1.4.1 Humoral immunotherapy 
1.4.1.1 Thalidomide and immunomodulatory drugs (IMiDs) 
After its infamous banning in 1960s, thalidomide was rehabilitated for the 
treatment of multiple myeloma thanks to its anti-inflammatory, anti-angiogenic and 
immunomodulatory properties (Quach et al. 2010). Subsequently, analogues were 
synthesised with the aim of optimising thalidomide clinical effect while reducing toxicity. 
The two leading IMiDs compounds, lenalidomide (CC5-013, or IMiD3 or Revlimid) and 
pomalidomide (CC-4047 or IMiD1 or Actimid), are derived by adding an amino group to 
the fourth carbon of the phthaloyl ring of thalidomide (Quach et al. 2010).  
Preclinical studies have unveiled multiple mechanisms of action for these 
compounds. Besides their ability to suppress plasma cell proliferation and disrupt 
MM-tumour microenvironment interaction, one of the most interesting and studied 
functions of IMiDs is the activation of the immune response (Quach et al. 2010). In vitro 
studies have, in fact, shown that IMiDs increase both the adaptive and innate immune 
responses by inducing the proliferation of partially activated T cells and the enhanced 
production of Th1 cytokines, such as IL-2 and IFN- when compared to control 
conditions (Davies et al. 2001).  
The molecular mechanism of T cells co-stimulation involves enhanced transcriptional 
activity of activated protein 1 (AP-1), a key driver for IL-2 production, which is then able 
to induce NK cell activation against MM cells (Davies et al. 2001). Additionally, LeBlanc 
and colleagues showed an increase in the tyrosine phosphorylation of CD28 on T cells 
(LeBlanc et al. 2004), which has the potential to lead to T cell activation.  
This co-stimulatory effect of IMiDs has also been confirmed in an in vivo mouse 
model where IMiDs administered in the context of a tumour cell vaccination enhanced 






1.4.1.2 Monoclonal antibodies 
Monoclonal antibodies are antibody molecules specific for a particular antigen 
that have been generated by a clonally expanded cell (Murphy 2011). The potential 
advantage of the use of monoclonal antibodies (mAbs) in MM therapy relies on their 
specificity for tumour-exclusive targets and their ability to recruit and activate cytotoxic 
effector mechanisms of the innate immune system (Danylesko et al. 2012). A variant of 
this strategy is the use of mAbs as targeted carriers of cytotoxic agents (Harrison and 
Cook 2005; Weiner et al. 2010). 
Potentially valuable targets, which include molecules exclusively expressed on 
MM cells and involved in key tumour survival and migration (such as CD40, CD138, 
CD162, IL-6, VEGF) and immunomodulatory mechanisms (such as IL-6, VEGF, PD-
1/PD-L1, CD200) have been evaluated over the past years. However, when employed 
as mono-therapy, these strategies have failed to produce impressive clinical responses. 
Nevertheless, results from preclinical in vitro and in vivo studies have recently suggested 
a potential synergistic effect when this approach is combined with traditional therapies 
(dexamethasone), immune modulators (thalidomide, lenalidomide), and other novel 
therapies such as bortezomib. Additionally, mAbs have shown the ability to overcome 
resistance to these conventional therapies (Danylesko et al. 2012). 
An example of this phenomenon is provided by CT-011, a novel humanised IgG1 
antibody against PD-1, which modulates immune response through disruption of the 
PD-1/PD-L1 axis. A phase 1 clinical trial of patients with advanced malignancies, 
including MM, showed that CT-011 administration as a single intravenous dose is safe, 
well tolerated, and is able to expand T cell subsets, with evidence of response in 33% of 
patients. Additionally, it increased migration of NK cells towards MM targets and 
enhanced the formation of immune synapses between patient-derived NK cells and 
PD-L1-bearing primary autologous MM cells (Berger et al. 2008). CT-011 also increases 
IFN- secretion and NK cytotoxicity against primary MM cells. Worthy of note, 
lenalidomide was shown to down-regulate PD-L1 expression on CD38+CD138+ primary 
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tumour cells, suggesting the employment of a combined immunotherapy with CT-001 
and lenalidomide in MM (Rutella and Locatelli 2012).  
These observations support the development of multi-agent therapies incorporating 
specific mAbs on the basis of clinical trial results and, possibly, on the identification of 
patient-specific MM disease factors (Danylesko et al. 2012). 
1.4.2 Cellular immunotherapy 
1.4.2.1 NK cells 
NK cells play a major role in the development of the adaptive immune response 
thanks to their functional modulation of DCs (see paragraph 1.2.2.1.4). Resting NK cells, 
activated in the presence of IL-2 and IFN-, are able to induce maturation of DCs in MM 
patients. These mDCs are characterised by enhanced production of IL-12p70 and are 
able to generate strong functional cytotoxic T lymphocytes (CTLs) against MM cells in 
vitro (Nguyen-Pham et al. 2012). 
NK cells from MM patients have the potential to kill autologous MM cells and MM 
cell lines (Frohn et al. 2002). Adoptive transfer of activated NK cells to myeloma-bearing 
mice resulted in prolonged survival (Rosenblatt and Avigan 2008).  
On this basis, a protocol to expand NK cells from MM patients ex vivo, in a good 
manufacturing practice compliant fashion, was optimised. After 20 days of culture, the 
number of NK cells was expanded and they were shown to kill autologous MM cells 
while cytotoxicity against normal cells was not observed (Alici et al. 2008). 
Recently, it has also been shown that autologous NK cells from MM patients expanded 
ex vivo with IL-2 displayed significant cytotoxicity against primary autologous plasma 
cells. Furthermore, tumour-activated NK cells from MM patients were demonstrated to 
induce substantial lysis of myeloma cell lines, as well as autologous and allogeneic 
freshly isolated bone marrow malignant plasma cells (Katodritou et al. 2011). 
Modulation of inhibitory and activating NK cell receptor ligands on tumour cells 
represents an additional promising therapeutic approach against MM. Proteasome 
inhibitors that target inhibitory KIR ligands on MM cells may contribute to the activation of 
cytolytic effector NK cells in vivo (Danylesko et al. 2012).  
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Depletion of Treg was also tested using cyclophosphamide in a mouse model. 
This strategy was successful in selectively depleting Treg while recovering NK cell and 
DC numbers and functions of (Sharabi and Ghera 2010).  
1.4.2.2 T cells 
Campbell and colleagues demonstrated that the ex vivo activation of T cells, 
using anti-CD3 monoclonal antibody in the presence of exogenous IL-15, was able to 
overcome MM-induced inhibition of T cells (Campbell et al. 2001a). However, these cells 
then became cytokine-dependent and failed to respond to antigens presented by DCs in 
the absence of IL-2 and IL-15.  
Another problem for T cell-based therapies is the fact that the T cell repertoire in 
MM patients is severely skewed towards a type-2 T cell response. Autologous T cells 
activated with anti-CD3 and anti-CD28 beads and infused intra-venously after stem cell 
infusion succeeded in correcting the skewing of V TCR repertoire and the lymphocyte 
count following bone marrow transplantation (Brown et al. 1997).  
An additional interesting strategy could rely on the depletion of the suppressive Treg, 
which has been shown in vitro and in vivo to alter the Treg to T-effector cell ratio in 
favour of an anti-tumour response (Feyler et al. 2013). 
1.4.2.3 DC-loaded with myeloma-associated antigens 
DC-based vaccines have become an attractive tool for cancer immunotherapy 
and have been tested for the treatment of various malignancies such as melanoma, 
renal cell carcinoma, prostate cancer, and colorectal carcinoma (Nguyen-Pham et al. 
2012). The potential of this strategy in the context of MM is supported by the 
identification of TAA-specific T cells in MM patients (see Table 1-2). These results 
suggest that T cells might be able to kill MM cells selectively, if a clonal population of T 
cells is activated and expanded effectively by a potent TAA.  
The ideal TAA needs to be specific to the targeted tumour cell and, at the same 
time shared by a large proportion of patients. Additionally, it should be indispensable to 
tumour survival, in order to avoid escape through mutation or deletion, and be able to 
elicit a strong humoral and cellular immune response. 
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However, as the MM microenvironment interferes with DC functions, protocols for 
the generation of MM-specific DCs should involve the ex vivo culture of circulating blood 
precursors, which should then educated and matured in the presence of tumour antigens 
and inflammatory cytokines prior to administration to patients.  
1.4.2.3.1 Idiotype (Id) proteins 
In the context of MM, the antigen that appears to meet most of these 
requirements is the idiotype protein, which represents the variable segment of the 
monoclonal immunoglobulin generated by the plasma cell clone.  
Early in vitro studies using this molecule showed the induction of both antibody and 
Id-specific CD4+ and CD8+ T cells, which were able to kill autologous primary myeloma 
cells in vitro (Wen et al. 2001b). However, despite these promising results and the 
induction of Id-specific CTLs in vivo in some patients (Danylesko et al. 2012; Nguyen-
Pham et al. 2012), there has been no real evidence of clinical efficacy for this strategy 
(Harrison and Cook 2005).  
Several clinical trials have subsequently attempted to improve the 
immunogenicity of this vaccination protocol through a combination with subcutaneous 
administration of cytokines. GM-CSF was tested alone or in combination with IL-12 (Rice 
and Hart 2002; Harrison and Cook 2005), and was able to elicit idiotype-specific T cells 
response and to significantly prolong time to disease progression. In one study, following 
autologous stem cell transplantation, MM patients were vaccinated with autologous 
idiotype protein conjugated with keyhole limpet haemocyanin (KLH), in conjunction with 
GM-CSF. Although humoral responses were observed and idiotype-specific delayed type 
hypersensitivity (DTH) skin tests were positive in 85% of the patients, residual disease 
was not eliminated (Coscia et al. 2004).  
An alternative approach tested the immunomodulatory ability of T cells 
genetically-modified to express a TCR for the idiotype protein. Although these cells 
specifically killed primary MM cells in vitro, their in vivo efficacy was much more limited 
(Rosenblatt and Avigan 2008; Danylesko et al. 2012).  
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In view of the limited number of clinical responses observed and with the aim of 
overcoming the functional deficiencies of DCs in MM patients, the addition of ex vivo 
generated DCs to idiotype-based vaccination strategies has been evaluated. The clinical 
application of this strategy was reported to be safe and to be able to induce both cellular 
and humoral immune responses and decrease in monoclonal protein (Reichardt et al. 
1999).  
However, the clinical outcome of these strategies is still overall disappointing, 
possibly because of the weak expression of idiotype proteins, which, in the context of the 
immunosuppressive tumour microenvironment (Rosenblatt and Avigan 2008) fails to 
stimulate idiotype-specific Th1 responses that are strong enough to control the growth of 
myeloma cells in vivo (Danylesko et al. 2012). Additionally, MM cells have been shown 
to induce tolerance to the idiotype protein in vivo (Rosenblatt and Avigan 2008). These 
considerations prompted the study and identification of alternative antigens. 
1.4.2.3.2 Tumour-associated antigens 
Tumour-associated antigens (TAAs) have been identified and tested in many 
solid and haematological tumours. On the basis of the discovery of MM-specific T cells, 
many potential TAAs have been investigated, including polymorphic epithelial mucin 
(MUC1), human telomerase reverse transcriptase (hTERT), PRAME, HM1.24, SP17, 
WT-1, Dickkopf-1 and members of cancer germ-like family (MAGE and NY-ESO-1) 
(Nguyen-Pham et al. 2012).  
This last family has been intensively studied in the context of myeloma and other 
tumours, given its limited expression in testis and placenta and, consequently its low risk 
of inducing autoimmunity secondary to immunotherapeutic strategies.  
A summary of the principal TAAs that have been tested so far in the context of MM and 
the immune responses they were able to generate is reported in Table 1-2. 
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Table 1-2 Principal TAAs emlpoyed in MM-immunotherapy and stimulatory potential, adapted, expanded and integrated from (Zhang et al. 2012) 
Antigen Function Expression in MM Expression in normal 
tissue 
Humoral response in MM CD8+ T cell response in MM Clinical trials in MM 
MUC1 Multiple functions 
including surface barrier, 
and signal transduction  




Ubiquitous on the 
luminal surface of most 
simple epithelial cells  
Natural antibodies to MUC1 have 
been detected in patients  
Recognised by CTL in an MHC-unrestricted manner (Danylesko et 
al. 2012). MUC1 peptide-pulsed DCs or plasma cell RNA-loaded 
DCs (Nguyen-Pham et al. 2012) are able to generate CTLs specific 
for MUC1 expressing cell lines (Zhang et al. 2012) 
Immunotherapy trial targeting MUC-1 
peptide with GM-CSF (Danylesko et 
al. 2012; Zhang et al. 2012) 
WT-1 Transcription factor Frequent but low levels of 
expression 
Placenta N/A Rise in WT-1-tetramer positive cells after 12 weeks of weekly 
intradermal injections of WT-1 peptide 
Myeloma cells can be recognised and lysed by WT-1-specific CTLs 
(Danylesko et al. 2012) 
Decline in serum paraprotein and 
percentage of marrow plasma cells 
observed in one patients following 
weekly intradermal injections of WT-1 
peptide vaccine (Rosenblatt and 





70-80% Testis, placenta Specific antibodies against 
MAGE-C1 were detected in 50% 
of AML patients with MAGE-C1 
expressing MM cells. 
IgG antibodies detected in 10 out 
of 66 patients (9 out of 10 had 
undergone allogeneic HSCT) 
(Rutella and Locatelli 2012) 
CD8
+
 T cell reactions against MAGE-C1 detected in MM patients. 
HLA-A2-restricted epitopes have been identified for MAGE-C1 and 
specific CD8
+
 T cells were able to recognise MAGE-C1 expressing 
MM cells (Zhang et al. 2012) 
CD4
+
 T cell reactions against MAGE reported but not in all MM 
patients. 
Immunotherapy trial targeting MAGE-
A3 peptide with GM-CSF (Danylesko 





Expressed in bone 
marrow of patients with 
MM but not in normal 
BM. Correlates with 
advanced disease 
Testis, placenta Spontaneous humoral response 
detected in patients with 
advanced disease. 
Antibody responses against NY-




 T cell response to NY-ESO-1 identified in 
patients with advanced disease (Nguyen-Pham et al. 2012). NY-
ESO-1-specific CTLs from MM patients expanded by autologous 
DCs pulsed with NY-ESO-1-derived peptide, showed to kill primary 
MM cells, normal cells pulsed with a NY-ESO-1 peptide but not 
normal cells pulsed with an irrelevant peptide (Rosenblatt and 
Avigan 2008; Nguyen-Pham et al. 2012; Zhang et al. 2012) 
Immunotherapy trial targeting NY-
ESO-1 peptide with GM-CSF 
(Rosenblatt and Avigan 2008; 
Danylesko et al. 2012; Zhang et al. 
2012) 
Ropporin Unknown 44% Testis Specific antibodies detected in 
the serum of ropporin positive 
patients (Zhang et al. 2012) 
Specific CTLs were generated by incubation with autologous DCs 
loaded with ropporin and showed cytolytic effect against autologous 
MM cells (Zhang et al. 2012) 
N/A 
RHAMM Receptor for hyaluronic 
acid mediated motility 
100%  Testis, placenta, 
thymus  
N/A Rise in circulating cells binding to the RHAMM tetramer following 
vaccination with an immunogeneic peptide derived from RHAMM 
(Rosenblatt and Avigan 2008); 
Two phase I/II peptide vaccination 
trials including 7 MM patients with 3 
showing clinical response (table) and 6 
an increase in RHAMM-specific CD8
+
 
T cells (Danylesko et al. 2012) 
DKK1 Inhibitor of osteoblast 
differentiation 
Almost all patients Placenta, prostate and 
testis  
Two anti-DKK1 neutralising 
antibodies have been tested as 
therapeutic agents in mice 
bearing human primary MM 
(Zhang et al. 2012) 
DKK1-specific CTLs were detected in MM patients although at a 
low frequency and stimulation by autologous DCs loaded with 
DKK1 peptids generated specific T cells which were able to lyse 
DKK1-expressing primary cells in an HLA-A2 restricted manner 
(Zhang et al. 2012); (Nguyen-Pham et al. 2012) 
N/A 
HM1.24 Cell signalling 100% Terminally 
differentiated T cells 
but its expression in 
normal tissue needs to 
be further investigated. 
A humanised anti-HM1.24 
monoclonal antibody has been 
developed and has exhibited anti-
myeloma effect by inducing 
ADCC in vivo in a mouse model 
(Zhang et al. 2012) 
HM1.24-specifi CTLs can be induced in vitro in healthy volunteers 
and MM patients (Danylesko et al. 2012) by HM1.24-loaded DCs. 
Several HLA I-restricted epitopes within HM1.24 have been 
identified and proved to be of potent immunogenicity (Zhang et al. 
2012)  
N/A 
hTERT Human telomerase 
reverse transcriptase 
85% (Vonderheide et al. 
2001) 




N/A Stimulation of CTLs by DCs loaded with hTERT-derived 
nonapeptide was capable of triggering anti-tumour CTL responses 
and kill hTERT
+
 tumour cells (Rosenblatt and Avigan 2008; 
Nguyen-Pham et al. 2012) 
Vaccine-primed T-cells early after 
transplant in conjunction with post-
transplant boosters (pneumococcal-
conjugated vaccine) is being evaluated  
Sp17 Cell-to-cell adhesion and 
migration (Wen et al. 
2001a) 
26% (Lim et al. 2001) Testis N/A Sp17-specific HLA class restricted CTLs were successfully 
generated by Dcs loaded with recombinant Sp17 protein. These 
CTLs were able to kill autologous tumour cells expressing Sp17 






Nevertheless, none of these strategies resulted in a significant clinical response. 
These disappointing results may be explained by the fact that this approach shares the 
same limitations previously discussed in the context of idiotype vaccines (see 1.4.2.3.1).  
Several studies, which are employing bivalent or multivalent antigens and a wide range 
of immune adjuvants, such as NY-ESO-1 or MAGE-A3 peptides with GM-CSF or MUC1 
peptide with GM-CSF, are still ongoing and their results should cast a new light on the 
potential and efficacy of this strategy (Zhang et al. 2012).  
However, it is also worth noting that as most of MM immunogenic antigens are 
expressed on mature MM cells, this approach might spare tumour stem cells, which 
retain the capacity to self-renew, proliferate and lead to disease relapse (Harrison and 
Cook 2005). 
1.4.2.4 Whole MM cells 
1.4.2.4.1 DC loaded/fused with MM cells 
Recent studies on tumour immunotherapy have revealed that the success of this 
strategy is limited by two main mechanisms: the selection of an edited tumour for loss of 
susceptibility to immune rejection, and a tumour edited immune system, already depleted 
of its most potent effector cells by chronic stimulation-mediated exhaustion and clonal 
deletion (Chan et al. 2006). 
A possible alternative approach to improve the anti-tumour response and limit the 
risk of immunological escape may rely on the use of a broad panel of tumour antigens 
derived from whole tumour cells. This would allow the presentation of multiple epitopes 
on DCs, which would then have the potential to generate a polyclonal T cell response 
against known and unknown patient-specific TAAs. This strategy could also avoid the 
exhaustion and clonal deletion of TAA-specific T cells caused by the chronic immune 
stimulation provided by the tumour. In contrast, some of the weaker antigens, which may 
have failed to spontaneously induce an effective immunological response, could activate 
a reserve of unstimulated cells in the presence of the appropriate adjuvants and helper 
functions (Chan et al. 2006). 
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This strategy has been tested using different tumour preparations such as MM 
lysates, myeloma apoptotic bodies, DC transfected with myeloid-derived RNA and DC-
myeloma hybrids (Nguyen-Pham et al. 2012).  
DCs loaded with MM lysates were able to generate highly cytotoxic CTLs able to kill 
autologous tumour cells (Wen et al. 2002). Apoptotic bodies were interestingly shown to 
be more effective than cell lysates at inducing CTLs against autologous myeloma cells, 
possibly owing to the up-regulation of antigen presenting molecules (Nguyen-Pham et al. 
2012).  
DC/tumour fusions have the unique advantage to present a broad array of 
patients’ specific and potentially unidentified antigens in the context of the antigen-
presenting machinery of the DC fusion partner. After promising in vitro results the 
therapeutic potential of this strategy was evaluated in a clinical trial and shown to be well 
tolerated and to induce cellular and humoral immune responses. In particular, 17 out of 
18 patients vaccinated with autologous DCs/tumour cell hybrids in combination with 
GM-CSF successfully responded to vaccination and 11 out of 15 evaluable patients 
showed an expansion of MM-reactive CD4+ and CD8+ cells (Rosenblatt and Avigan 
2008).  
The generation of a balanced CD4 and CD8-mediated response is crucial for the 
development of memory effector cells and the establishment of long-term anti-tumour 
immunity. Therefore, considering that cancer vaccines may increase the presence of 
regulatory T cells, one strategy to improve responses to vaccination involves the 
combination of active vaccination with adoptive transfer of CD3/CD28-expanded T cells. 
Furthermore, CD25+ regulatory T cells can also be depleted by specific monoclonal 
antibodies like denileukin difitox (Danylesko et al. 2012). 
However, while it was possible to detect the induction of antigen-specific immune 
responses following virtually all these vaccination strategies, none of them was actually 
able to induce tumour regression. Recent studies have highlighted limitations of these 
strategies and, have consequently suggested new ideas for improving the efficacy of 
DC-based vaccination strategies (Table 1-3). 
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Table 1-3 Different anti-tumour vaccine strategies and related advantages and disadvantages. 
Adapted from (Harrison and Cook 2005) 
 
As MM patients present dysfunctional DCs due to the inhibitory effects of the MM 
microenvironment, several strategies have attempted to restore and enhance DC 
activation. The incorporation of Th1 polarising cytokines, such as IL-1, TNF-, IL-6 and 
prostaglandin, in the vaccination protocol was successful in recovering and inducing the 
expression of co-stimulatory molecules and chemokine receptors. However, it also 
promoted Th2 polarisation, secretion of IL-10 and activation of Treg (Nguyen-Pham et al. 
2012).  
An alternative strategy relies on the inhibition of pathways involved in 
MM-induced impairment of DCs such as JAK2/STAT3 pathway, p38 activation, 
MEK/ERK pathway, MAK pathway and IL-6. This last strategy successfully rescued the 
abnormal phenotype and function of MM patient monocyte-derived DCs (Wang et al. 
2006). More recently, this protocol has been further developed by Nguyen-Pham; by 
pre-treating MM cells with a combination of JAK2/STAT3 inhibitors and bortezomib they 
were, in fact, able to generate potent myeloma-specific CTLs (Nguyen-Pham et al. 
2012).  
An additional approach for the improvement of vaccination efficacy relies on the 
activation of DC migration to primary lymphoid organs, which can be potentiated by the 
synergistic effects of IFNs and TLR agonists. These molecules are in fact able to induce 
Antigen Advantages Disadvantages 
Tumour-associated 
proteins 
Possibility to monitor the immune 
response to these antigen through the use 
of tetramers; ubiquitous antigens  
Relies on the ability of a single 
antigen to be adequately processed 
and elicit a strong immune response. 
Tumour lysates Easy to prepare (freeze/thaw heat or 
sonication); produces a wide number of 
antigens available for processing by 
antigen presenting cells 
Patient-specific; may expose antigen 
presenting cells to inhibitory 
molecules from the tumour; efficacy 




All tumour antigens available Patient-specific; how to convert 
tumour cells into efficient APC; 
efficacy difficult to monitor.  
Tumour cells/DCs 
fusion 
All tumour antigens available Fusion process can be toxic to DCs; 
efficacy difficult to monitor. 
Transfection of 
DCs with tumour 
DNA/RNA 
Possibility to monitor the immune 
response to these antigen through the use 
of tetramers; ubiquitous antigens 
Relies on high efficiency and low 
toxicity of the transfection process; 
relies on the ability of a single 
antigen to be adequately processed 
and elicit a strong immune response. 
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the up-regulation of CD38, CD74 and CCR7 on DCs, which are required for DC 
mobilisation to lymph nodes (Nguyen-Pham et al. 2011).  
Finally, following the promising results obtained in the context of idiotype 
vaccination, the use of lenalidomide was tested in conjunction with DC/myeloma hybrid 
cell vaccination. This resulted in the induction of Th1 immune responses and in the 
suppression of PD-1 expressing cells and Treg cells, supporting the potential of the 
combination of these strategies (Luptakova et al. 2013).  
Combination approaches using DC-based vaccines to reduce tumour cells and 
immunomodulatory agents to overcome tumour microenvironment might therefore be 
helpful to improve the disease status. 
Given the points discussed above, Nguyen-Pham and colleagues suggested that 
patients might benefit from vaccination strategies as illustrated in 
Figure 1-12 (Nguyen-Pham et al. 2012). 
 
Figure 1-11 Suggested DC-based vaccine strategies for patients with MM (Nguyen-Pham et al. 
2012). 
 
However, since MM patients have generally insufficient numbers of myeloma 
cells in the bone marrow at the time of diagnosis or during the progression of the disease 
to provide with enough material for these therapeutic approaches and, considering the 
enormous cost and limitations of personalised therapies, allogeneic myeloma cell lines 
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are currently being investigated as a source of universal tumour antigens (Nguyen-Pham 
et al. 2012).  
 Nevertheless, despite the promising results and the encouraging advances 
reported, MM-DC fusion vaccination strategies still present disadvantages that need to 
be taken into consideration when evaluating their feasibility and optimising their clinical 
efficacy. 
First of all, Harrison and Cook (Harrison and Cook 2005) highlighted the fact that the 
fusion process might be toxic to DCs. This issue, when considered in the context of the 
poor cell numbers and viability of MM patients’ DCs after in vitro culture and the cost of 
the protocol, may represent a limit to the application of this strategy.  
Another potential concern is the fact that the tumour fusion partner may inhibit 
the expression of co-stimulatory molecules on DCs or the maturation of the hybrid cell as 
an efficient antigen-presenting cell, as noted in vivo in patients with malignancy.  This 
hypothesis is not supported by the results presented by Vasir and colleagues (Vasir et al. 
2005) as they described that fusion of immature patient-derived DCs with autologous 
myeloma cells resulted in the marked up-regulation of expression of co-stimulatory and 
maturation markers. This was also associated with an increased expression of IL-12 and 
of the chemokine receptor CCR7, which directs migration towards the draining lymph 
nodes (Vasir et al. 2005). DC/myeloma fusions also stimulated T cell-mediated lysis of 
myeloma targets (Vasir et al. 2005). Further studies are needed to confirm these 
findings. 
1.4.2.4.2 Whole cancer cell vaccines 
A possible alternative to DC-based vaccines relies on the use of whole cancer 
tumour cells. However, this idea poses a great challenge: can tumours and, specifically, 
MM cells be converted to efficient antigen-presenting cells?  
Vaccination with irradiated tumour cells has been studied in various animal 
models since the late 1970s. Hanna’s group was the first to test irradiated hepatocellular 
carcinoma cells as a vaccine in a guinea pig model. This preparation was administered 
in conjunction with the general immune adjuvant Bacillus Calmette-Guérin (BCG) in an 
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attempt to boost the immunostimulatory ability of the tumour cells (Hanna and Peters 
1978). This study was successful in generating protective immunity against a 
subsequent challenge with syngeneic non-irradiated tumour cells (Hanna and Peters 
1978). These results also highlighted the importance of using intact tumour cells, 
suggesting either the direct involvement of the tumour cells themselves in antigen 
presentation or the importance of prolonged expression and release of TAA to allow the 
activation of immune effector cells at a site distant from the natural tumour 
microenvironment (de Gruijl et al. 2008). 
Following these promising results, several clinical trials were conducted in the context of 
colorectal cancer and melanoma. The data collected showed a significant increase in 
overall and disease-free survival for vaccinated patients and delayed type 
hypersensitivity (DTH) reactions to autologous tumour cells, suggesting the induction of 
tumour-specific immunity (de Gruijl et al. 2008). Additionally, these observations strongly 
support the importance of administration of immunostimulating adjuvants in the 
effectiveness of booster vaccination. However, although BCG was proven to be a 
successful immune adjuvant, the observed ulcers at vaccination sites prompted the 
evaluation of alternative adjuvants for cancer vaccination.  
The identification of hypomethylated CpG sequences derived from bacterial DNA 
as the immunoactivating component of BCG (Sandler et al. 2003) led to the design of a 
Phase II trial in which patients with advanced renal cell cancer were vaccinated with an 
autologous whole tumour cell vaccine mixed with a combination of CpG (type-B, PF-
3512676), IFN, and GM-CSF. This study showed a 20% clinical response rate in 
association with a strong anti-tumour DTH skin reactivity and demonstrated the 
equivalence of this adjuvant combination to BCG in terms of immune activation, without 
inducing ulcer formations (Haanen et al. 2006).  
Following these encouraging results, scientists have been looking for alternative, 
targeted and controlled ways to achieve a cellular and humoral immune response 
following whole cancer cell vaccination.  
 It is important to highlight that the efficacy of the whole cancer cell vaccines 
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depends on two important events: the activation and maturation of antigen presenting 
cells, such as DCs, upon encounter with the vaccine, and the appropriate presentation of 
vaccine-derived TAAs to specific cytotoxic T cells. This consideration was the basis for 
the co-administration of immunostimulatory adjuvants along with tumour cells, at the site 
of vaccination. However, in order to maximise the efficacy of this strategy, whole cancer 
cells can be engineered to express and produce immunostimulatory molecules. The 
presence and release of high levels of immunomodulating cytokines in proximity with the 
tumour cells has, in fact, the potential of resulting in the effective stimulation of DCs, NK 
and cytotoxic T cells (Chan et al. 2006).  
Based on these considerations and on the encouraging results obtained from preclinical 
studies, tumour cells transduced with GM-CSF (GVAX), have been tested clinically in a 
number of malignancies, including MM (Harrison and Cook 2005), and were shown to 
induce tumour-specific immunity and durable anti-tumour responses against melanoma, 
pancreatic and prostate cancer (de Gruijl et al. 2008).  
 While GVAX mono-therapy has shown moderate clinical efficacy, this may be 
improved by targeting checkpoints required for T cell activation. In 2000, Allison’s group 
published a study where GM-CSF-secreting vaccine was administered in combination 
with a CTLA-4-blocking antibody. CTLA-4 regulates an inhibitory checkpoint for T cell 
activation and its blockage results in improved anti-tumour immunity and protection from 
tumour outgrowth in in vivo mouse models. These encouraging data have led to the 
initiation of a Phase I clinical study for prostate cancer (de Gruijl et al. 2008).  
 As T cell activation depends on the balance of activating and inhibitory signals, a 
possible alternative strategy to counteract tumour-mediated immune suppression and 
induce an effective cellular response might be to provide additional activating signals 
rather than neutralising the inhibitory ones. In order to increase their antigen-presenting 
ability, tumour cells may, in fact, be genetically modified to express the co-stimulatory 
molecule CD80. This receptor, which is often poorly expressed by tumour cells, has the 
fundamental role of providing the co-stimulatory signal necessary to induce T cell 
proliferation and activation following antigen presentation (Chan et al. 2006). Numerous 
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studies have demonstrated the effectiveness of increased expression of CD80 in 





























Table 1-4 Summary of studies investigating CD80-expressing cancer vaccines. 
Tumour Transgene Experiments in 
vitro/in vivo 
Results Reference 
ALL, AML, CLL CD80 and GMCSF In vitro T-cell proliferation in an autologous 
mixed lymphocyte reaction 
(Stripecke et al. 2000) 
AML CD80 In vitro Stimulate allogeneic CD4 and CD8 
T cells 
(Hirst et al. 1997) 
 CD80 In vitro  Generation of leukaemia reactive 
CD4+ T-cell lines and clones. 
(Mutis et al. 1998) 
 CD80 and GM-CSF In vitro T cell expansion and activation (Stripecke et al. 1998; 
Stripecke et al. 1999; 
Koya et al. 2002) 
 CD80, GM-CSF and 
CD154 
In vivo T cell expansion and activation (Vereecque et al. 
2000) 
 CD80 and IL-2 
producing stromal cells 
In vivo In vitro anti-leukaemic response (Hicks et al. 2003) 
 CD80 and IL-2 In vitro and in 
vivo 
T and NK cell expansion and 
activation 
(Chan et al. 2005a; 
Chan et al. 2006; 
Ingram et al. 2009) 
Breast cancer CD80 In vitro, in vivo 
(Phase I/II) 
Stimulation of CD8+ T cells, IFN- 
release 
(Guckel et al. 1995) 
 CD80 and IL12 In vitro Propagation of T cells for adoptive 
transfers. 
(Guckel et al. 1999) 
 CD80 and HL with 
exogenous GM-CSF or 
BCG 
In vivo (Phase 
I) 
Safety and feasibility. Vaccine-
induced immune responses in a 
minority of patients 
(Dols et al. 2003) 
Cervical 
carcinoma 
CD80, IL7 and IL2 In vitro Stimulation of cytotoxic T 
lymphocytes 
(Kaufmann et al. 
2000) 
Melanoma CD80, CD86, IL-12 
(systemic) 
In vitro T cell proliferation (Rudy et al. 1997) 
 CD80 and CD86 In vitro Lymphocytes proliferation with 
transcription of IL-10, IL-2 and IFN-
. Blocking of IL-10 augments these 
effects. 
(Dummer et al. 1998) 




IL-2, IFN- In vivo Expansion and activation of naïve 
PBL in vitro. Is more effective in 
preventing tumour growth compared 
to systemic administration of IL-2. 
(Belldegrun et al. 
1993) 
 IL-2 In vitro Propagation of renal cancer cell-
specific tumour infiltrating 
lymphocytes (TILs) 
(Mulders et al. 1998) 
 CD80 and systemic      
IL-2 
In vivo (phase I) Safety and acceptable toxicity; 
immunological and clinical response 
in some patients 
(Antonia et al. 2002) 
 CD80  In vitro (HD) CD8+ T cell proliferation which 
were able to specifically lyse tumour 
cells 
(Schendel et al. 2000) 
 GM-CSF In vivo (Phase 
I) 
Positive DTH skin tests following 
autologous vaccination in all 
patients. Enhanced anti-tumour 
cellular and humoral responses. 
(Tani et al. 2004) 
 CD80 and IL-2 and     
IL-7 
In vitro Generation of CTL and proliferation 
of autologous effector memory T 
cells. 
(Frankenberger et al. 
2005) 
 CD80 and IL-2 In vivo (Phase 
1) 
Safety and feasibility. Vaccine-
induced responses against multiple 
TAAs in the majority of study 
participants. 
(Buchner et al. 2010) 
 CD80, IL-7 In vivo Vaccination feasible and safe; no 
indication of T cell activation 
(Westermann et al. 
2011) 
Myeloma CD80 In vivo Rejection of CD80-expressing 
tumours 
(Wendtner et al. 1997) 
 CD80 In vitro Allogeneic CD8+ T cell activation (Tarte et al. 1999) 
 CD80 and IL-12 In vitro Enhanced lympho-proliferation (Wen et al. 2001a) 
 CD80 and CD154 In vitro Enhanced proliferation and anti-
tumour-specific response by CD8+ T 
cells 
(Cignetti et al. 2005) 
 CD80, p53 and GM-
CSF 
In vitro Autologous CD8+ T cell expansion 
and activation 
(Ren et al. 2006) 
 CD80 and 4-1BB ligand In vitro Activation and expansion of MM-
specific T cells 
(Lu et al. 2007) 
Prostate cancer IL-2 and IFN- In vivo (Phase 
II/III) 
Safe, well tolerated; prolongation of 
prostate specific antigen doubling 
time (PSA-DT) 
(Brill et al. 2009) 
Mouse sarcoma CD80 and IL-2 In vivo Prolonged survival (Bubenik et al. 1997) 
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 Dunussi-Joannopoulos and colleagues have shown that despite the presence of 
activated anti-tumour CD8+ T cells, CD80-based vaccines are able to eliminate only a 
relatively small tumour burden (Dunussi-Joannopoulos et al. 1998). Variables influencing 
this outcome may include the immunogenicity of the tumour, the tumour 
microenvironment surrounding the tumour and the type and amount of cytokine secreted. 
Therefore, in this respect, several groups have investigated whether transduction of 
tumour cells with additional molecules could enhance immunogenicity and vaccine 
efficacy. The results demonstrated that the combined expression of CD80 and 
stimulatory cytokines such as IL-2, IL-7 and GM-CSF, convert tumour cells into potent 
stimulators of both allogeneic and autologous T cells (reviewed in Table 1-4).  
In the context of MM, following results by Wendtner (Wendtner et al. 1997) and 
Tarte (Tarte et al. 1999), which highlighted the potential of CD80 gene transfer in 
activating MM cell lysis by allogeneic T cells in vitro, a number of groups have addressed 
the potential of different cytokines to increase the CD80-mediated stimulation. Wen and 
colleagues showed enhanced allogeneic lympho-proliferation in response to co-culture of 
PBMCs with CD80/IL-12 modified U266 cells (Wen et al. 2001a). Cignetti’s and Ren’s 
groups, similarly, demonstrated that the lentiviral and retroviral transduction of primary 
MM cells was achievable and that the genetic transfer of CD80-CD40L or CD80-p53-
GM-CSF turned MM cells into efficient antigen presenting cells, able to activate 
autologous cytotoxic CD8+ T cells (Cignetti et al. 2005; Ren et al. 2006). Finally, in 2007, 
it was shown that a T cell repertoire recognising myeloma tumour antigens persisted in 
the peripheral blood of MM patients, and that it could be activated and amplified by 
autologous tumour cells transduced with CD80 and 4-1BB ligand (Lu et al. 2007).  
Due to the controversial role of CD80 in NK cell activation, (Geldhof et al. 1995; 
Galea-Lauri et al. 1999; Wilson et al. 1999; Luque et al. 2000; Terrazzano et al. 2002) 
none of these studies evaluated the effect of these strategies on NK cell expansion and 
activation. However Ingram and colleagues demonstrated NK cell expansion and 
activation following co-culture of PBMCs with IL-2/CD80 expressing acute myeloid 
leukaemia (AML) cells (Ingram et al. 2009).  
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Genetic modification of tumour cells 
 Gene therapy has achieved some important successes in treating severe inherited 
and acquired diseases (Naldini 2009). However, until recently, the application of this 
strategy has been limited by the safety concerns related to these procedures and the 
poor transduction efficiencies obtained using the available vectors.  
Although many other agents such as calcium-phosphate, lipids and electric current are 
adequately used for gene transfer, viral vectors are endowed with a sophisticated 
machinery that facilitates efficient cell entry, transport and expression of their genome in 
the nucleus of target cells (Dropulic 2011).  
 Retroviruses were chosen for their ability to stably transduce cells by integrating 
their DNA into the cells genome (Dropulic 2011). A member of the Retroviridae family, 
lentiviral vectors, was selected and optimised on the basis of its efficiency in transducing 
both dividing and non-dividing cells, such as haematopoietic cells, its capacity for 
encoding large transgenes (up to 8kb) and its low potential for genotoxicity due to 
insertional mutagenesis (Hu et al. 2011).   
 Lentiviral vectors have been constructed from several types of lentiviruses, but the 
most commonly used is the human immuno-deficiency virus (HIV). These lentiviruses 
are composed of 2 copies of RNA, a nuclear capsid, a capsid, a membrane associated 
matrix, envelope proteins and transmembrane proteins and enzymes such as integrase, 
protease, reverse transcriptase, and accessory proteins (TAT, VIF, VPR, NEF and VPU). 
The HIV-based lentiviral vectors that are in use today have undergone improvements, 
which have mainly focused on increasing their safety and improving their tropism and 
transgene expression (Dropulic 2011).  
 Firstly, these vectors were proven to be safe due to the fact that most of the viral 
genes are removed from the viral genome. The necessary genes are provided in trans 
by transfecting the vector producing cells (helper cell) with plasmids encoding for viral 
proteins. This means that multiple recombination events are required in order to form a 
replication competent virus.  
Additionally, the viral RNA carries a mutation in the 3’ end. When the viral RNA is 
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transcribed into DNA inside the host cell, as part of the virus replication, it looses 
sequences at the 5’ end and 3’ end, which correspond to the promoter sequence and the 
Poly A signal. During the subsequent reverse transcription process that occurs to 
regenerate the viral RNA, the sequences on the 3’ end are copied and placed on the 5’ 
end through “jumps”. As a consequence, the deletion present on the U3 segment of the 
original copy of the viral RNA is copied onto the 5’ end of the final RNA, inactivating its 
promoter and, therefore, impairing the ability to form replicant competent lentiviruses. 
 HIV-1 based lentiviral vectors have also been optimised to be able to transduce a 
variety of dividing and non-dividing cells. This property is conferred by the presence of 
the VPR accessory viral protein and the use of Vesicular Stomatitis Virus G (VSV-G) 
glycoprotein, which enables the transduction of a wide range of cell types (Chan et al. 
2005b).  
 Furthermore, several elements have been added to the transgene sequence in 
order to increase transgene expression. Incorporation of the HIV central polypurine tract 
(cppt) and termination sequence (cts) has been demonstrated to be important for the 
nuclear import pathway and for the transfer of viral DNA across the host cell nuclear 
membrane (Zennou et al. 2000; Follenzi et al. 2002). In addition, insertion of the 
woodchuck hepatitis virus posttranscriptional regulatory element in the 3’ untranslated 
region of the lentiviral vector significantly increases the expression of the transgene as a 
result of improved intracellular messenger RNA stability (Zufferey et al. 1998). Finally, 
the incorporation of the Woodchuck Hepatitis Virus Post-transcriptional Regulatory 
Element (WPRE) along with lineage-specific U3 promoter sequences such as that of the 
spleen focus-forming virus, ensures the promotion of high levels of transgene expression 
(Barry et al. 2000; Yam et al. 2002). 
 Another issue that has been addressed is the development of strategies to 
efficiently concentrate lentiviral vectors. As large quantities of vectors might be needed to 
achieve the desirable transgene expression, the use of concentrated virus is important to 
avoid its dilution in the culture media, which can negatively affect the transduction 
efficiency, and to remove the inhibitory factors produced by helper cells (Chan et al. 
73 
2005b). VSV-G-pseudotyped vectors have been extensively used because of the 
remarkable stability of VSV-G envelope protein, which allows vector concentration by 
ultracentrifugation (Strang et al. 2004). However, due to VSV-G toxicity at high 
concentrations (Sakuma et al. 2010), alternative methods of vector pseudotyping and 
concentration have been developed in recent years.  
An interesting one takes advantage of the fact that, when the virus exits from the 
producer cell (budding), proteins present on the membrane of the virus-producing cells 
are introduced on the surface of the lentiviral vector (Chan et al. 2005b; Nesbeth et al. 
2006). On this basis, Darling and his group (Chan et al. 2005b) have been able to 
produce biotinilated viruses, which were then captured and concentrated using 
streptavidin magnesphere paramagnetic particles (PMP). The large increases in titers 
observed when using this protocol suggested the promotion of additional vector-target 
cell interactions in addition to the removal of inhibitory factors (Chan et al. 2005b). 
 A final issue that has been investigated is the efficient transduction of target cells 
with more than one gene. A well-established strategy is the use of internal ribosome 
entry sites (IRES). However, the instability of vectors when more than one IRES is used, 
restricts the suitability of IRES vectors to express multiple genes (Gaken et al. 2000). To 
facilitate the efficient co-transduction of both CD80 and IL-2, Gaken and colleagues 
developed a ‘‘fusagene’’ approach. This strategy consists of the expression of multiple 
gene products as a fusion protein from a single cistron (Gaken et al. 2000). The fusion 
protein contains recognition sequences for the ubiquitous endoprotease furin, which is 
located primarily in the Golgi. Furin cleavage results in the generation of biologically 
active constituents from the fusion protein. Thus soluble IL-2 is released extra-cellularly 
whilst transmembrane CD80 remains anchored at the cell surface. This strategy also 
avoids the problems associated with transduction of target cells with two single gene 
vectors, or promoter interference arising when using two separate promoters (Gaken et 




1.4.3 Considerations and future directions 
Despite the incredible potential illustrated in this chapter, immunotherapy for MM 
has yet to prove its clinical efficacy. There are many reasons underlying the failure in 
translating extremely promising in vitro results into effective therapies. 
First of all, in vivo studies have been conducted as very small clinical trials, 
thereby limiting the possibility of obtaining statistically significant results. Furthermore, 
most of these studies have focused on patients with refractory disease, while these 
immunotherapeutic approaches are likely to be more effective in patients with low tumour 
burden (Harrison and Cook 2005). 
Some strategies have not been taken to the clinic because of poor 
immunostimulatory activity in vitro. While it is understandable to focus on the best 
immunoactivating strategies, especially considering the suppressive activity of the 
tumour microenvironment, Harrison and Cook (Harrison and Cook 2005) rightly observed 
that there is no proof that a cancer vaccine has to stimulate a large number of T cells in 
order to initiate tumour rejection. T cell responses to tumour antigens may be of a low 
level and negative results obtained with most ex vivo assays may not exclude the 
beneficial effect of tumour-specific T cells in vivo (Chan et al. 2006). 
Nevertheless, given the complexity of myeloma cell-microenvironment 
interactions, combination therapies might be required to increase cytotoxicity and 
overcome drug resistance. As suggested by Harrison and Cook (Harrison and Cook 
2005) a good strategy may rely on the combination of chemotherapy and IMiDs to lower 
the disease burden, DC/whole cancer cell-based vaccine to prime the immune system 
with pre-stimulation of T cells to correct tumour-induced anergy, followed up by low dose 
sub-cutaneous IL-2 and/or IMiDs, to maintain the activation of the immune system.  
Such protocols should include close immunological monitoring of patients to 
evaluate and confirm the safety of this strategy and to examine the effect of each 
component, individually and in combination, on T and NK cell expansion and activation 
and on Treg activation. 
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1.4.4 Aims of the thesis 
The studies reported in Chapter 1 outline the presence of abnormalities in the 
immune system of MM patients. However, although the phenotype and aberrations of T 
cells in MM patients have been extensively studied, little is still known about NK cells. In 
addition, the immunotherapeutic approaches intended to enhance immunogenicity have 
so far targeted T cells, with only modest efficacy in vivo, highlighting the need for a 
different approach.  
On these bases, I wanted to test the hypotheses that MM cells have the ability to 
inhibit NK cells and that this inhibition can be abrogated via the stimulation with a 
genetically modified whole cancer cell vaccine. Specifically, my aim was to delineate and 
explain the mechanisms underlying NK cell abnormalities and to define whether this 
inhibition is contact or non-contact dependent and whether it is specifically directed at 
NK cells.  
Secondly, I wanted to optimise a protocol to genetically modify MM cells to express 
CD80 and IL-2. These genetically-modified cells were then used, alone or in combination 
with immunomodulatory drugs (IMiDs), to stimulate healthy donor and MM patient 





















2.1 Cell culture 
2.1.1 Preparation of media and solutions 
Cell lines were cultured, according to the supplier specifications, in complete 
medium obtained by adding 10 mL of a 100x stock solution of penicillin/streptomycin 
(10000 IU of penicillin and 10000 g/mL streptomycin; Sigma, UK) and foetal bovine 
serum (FBS) (10% or 20% volume/volume; Life Technologies, UK) to either 1 L of 
Dulbecco’s Modified Eagle Medium (DMEM) or RPMI1640 (Sigma, UK). 
Recombinant human IL-2, IFN- and IL-6 were purchased from Peprotech (USA). 
The vials were centrifuged at 2000 x g for 30 seconds and the lyophilised cytokines were 
reconstituted to a concentration of 10 mg/mL using 100 mM Acetic Acid (Sigma, UK) and 
deionised water (Sigma, UK) respectively. Using the relationship IU/mg defined in the 
certificate of analysis, each cytokine solution was further diluted to 1x105 IU/mL with 
Dulbecco’s Phosphate Buffer Saline (DPBS; Sigma, UK) supplemented with FBS (10% 
volume/volume), aliquoted in to single use aliquots and stored at -80 °C for up to 12 
months. 
PBMCs were cultured in a complete medium constituted of X-VIVO 15 without 
gentamycin or phenol red (Lonza, UK) supplemented with 10000 IU of penicillin and 
10000 g/mL streptomycin and IL-2 to a final concentration of 30 IU/mL.  
Primary human MM CD138+ plasma cells were cultured in AIM-V medium (Life 
Techologies, UK) supplemented with 10000 IU of penicillin and 10000 g/mL of 
streptomycin. IL-6 (100 ng/mL) was added every 3-4 days (Cignetti et al. 2005).  
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Freezing medium was prepared as a mixture of FBS and dimethyl sulfoxide 
(DMSO; 20% volume/volume; Sigma, UK). 
For magnetic cell sorting, a separation buffer composed of DPBS, FBS 
(0.5% volume/volume) and 2 mM Ethylenediaminetetraacetic acid (EDTA; Sigma, UK) 
was used. 
A staining buffer composed of DPBS supplemented with FBS 
(1% volume/volume) was used during antibody staining and washing procedures. 
2.1.2 Cell lines 
The human cell lines employed in this study were purchased from ATCC 
(American Type Culture Collection) and cultured according to the supplier’s 
recommendations in humidified incubators at 37 °C, 5% CO2. Cells were tested once 
every two weeks for mycoplasma contamination (as described in 2.1.2.5) 
2.1.2.1 K562 
The chronic myeloid leukaemia cell line K562 was established in 1970 from the 
pleural effusion of a 53 year-old woman with chronic myeloid leukemia (CML) in blast 
crisis (Koeffler and Golde 1980). The principal characteristics of this cell line are 
summarised in Table 2-1.  
K562 is used as a highly sensitive target for in vitro NK cell cytotoxic assays as it is 
devoid of the inhibitory MHC class I molecules whilst overexpressing activating ligands 
for NK cells (e.g: MICA, MICB, ULBP-1, and ULBP-2) (Li et al. 2008; Muntasell et al. 
2010). 
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2.1.2.2 MM cell lines 
The establishment of MM cell lines, which took place mainly in the late ’60s and 
‘70s, has allowed major advances in the understanding of myeloma. So far, 112 MM cell 
lines have been established (Drexler and Matsuo 2000). MM cell lines display unique 
biological features: morphology of plasma cell appearance, medium requirements (often 
including cytokines, feeder cells or a higher percentage of FBS), slow growth rate (about 
54 hours), low maximum cell density, poor cloning ability, “mature B cell immune-
phenotype” and specific chromosomal aberrations (mostly including 14q32) (Drexler and 
Matsuo 2000).  
Features of the different MM cell lines used in this work are shown in Table 2-2.  
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MM cells were cultured in complete RPMI1640 medium supplemented with FBS (20% 
v/v). The identity of these cells was also confirmed by evaluation of known surface 
phenotypic markers (Bataille et al. 2006) and reported in Table 2-3.  
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These results show that CD138 and CD28 may be used as selective markers for MM 
cells.  
On the basis of the high levels of expression of CD56 by RPMI-8226 cells, which 
may represent an issue for the isolation of NK cells (defined as CD138-CD3-CD56+) from 
the co-culture with MM cells, the cell line RPMI-8226 was not used in co-culture 
experiments with PBMCs.  
2.1.2.3 293T cells 
The 293T cell line is a variant of the adherent human embryotic kidney cell line 
HEK293. The widespread use of this cell line is due to its high transfectability, which is 
essential since the production of third generation lentiviral vectors requires the 
co-transfection of three or four plasmids. Additionally, these cells were generated by 
transformation of the parental cell line with a fragment of the adenovirus genome, which 
results in the constitutive expression of the SV40T antigen. This allows the accumulation 
at high copy number of plasmids carrying the SV40 origin of replication, which results in 
very high expression levels of the proteins encoded by the plasmids (DuBridge et al. 
1987; Louis et al. 1997). 
Cells were cultured in DMEM medium supplemented with FBS (10% volume/volume). 
2.1.2.3.1 BL-15 cells 
These cells are HEK293T cells co-expressing the LNGFRBAP fusion protein, 
which is constituted by the biotin acceptor peptide (BAP) fused to the extracellular 
domain of the low-affinity nerve growth factor receptor, together with the bacterial biotin 
ligase (BirA) (Nesbeth et al. 2006). In the presence of biotin-supplemented medium (100 
M; Sigma, UK), this allows the endogenous metabolic biotinilation of a lysine residue in 
the BAP domain of the fusion protein, which is then transported to the cell surface. This 
characteristic is exploited to generate biotin-labelled lentiviral particles that can then be 
easily purified from the cell culture medium. In fact, when the lentiviral particles bud from 
these cells, they retain part of the cell-biotinilated surface and can therefore be purified 
using streptaviding paramagnetic particles (PMPs; see 2.2.2.2.2). Cells were cultured in 
complete DMEM medium supplemented with FBS (10% volume/volume). 
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2.1.2.4 Mycoplasma test by polymerase chain reaction (PCR) 
All cells lines were routinely tested every two weeks for mycoplasma 
contamination by using the EZ-PCR mycoplasma test kit (Biological Industries, Israel). 
This procedure is based on the amplification of genus and species-specific mycoplasmal 
16S ribosomal RNA (rRNA) sequences, which are naturally present in high copy 
numbers and are independent of gene expression (van Kuppeveld et al. 1992). The 
primer set allows the detection of various mycoplasma species: M. fermentans, M. 
hyorhinis, M. arginini, M. orale, M. salivarium, M. hominis, M. pulmonis, M. arthritidis, M. 
bovis, M. pneumoniae, M. pirum and M. capricolum, as well as Acholeplasma and 
Spiroplasma species. 
Culture supernatant (0.5 to 1 mL) was harvested from confluent cell cultures and 
centrifuged at 250 x g for 5 minutes to pellet cellular debris. The resulting supernatant 
was transferred to a sterile microcentrifuge tube (Eppendorf, UK) and centrifuged at 
20000 x g for 10 minutes in a microcentrifuge (Epependorf, UK) to sediment 
mycoplasma. After carefully decanting the supernatant, the pellet was resuspended with 
50 L of the Buffer Solution provided with the kit and heated to 95 °C for 3 minutes in a 
heating thermo block (Bibby, UK). PCR reaction mixtures were then prepared in PCR 
tubes according to Table 2-4. 
Table 2-4 Mycoplasma PCR reaction mix 




Reaction Mix 10 
Test Sample 5 
Total volume 50 
 
The efficiency of this protocol was tested by substituting the test sample with 1 L of the 
provided positive template control or molecular biology grade H20 (Sigma, UK) 
respectively as a positive control and negative controls. 
PCR reactions were performed in DNA thermal cycler (G-Storm GS1, UK) set for the 
conditions detailed in Table 2-5. 
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Table 2-5 Mycoplasma PCR cycle 
Temperature ( °C) Time (seconds) Comments 
94 30  
94 30  
35 cycles 60 120 
72 60 
94 30  
60 120  
72 5  
4 Infinite  
 
The presence of any amplified fragment was detected by agarose gel electrophoresis. 
2.1.2.5 Agarose gel preparation and electrophoresis 
This technique is based on the separation of PCR amplified products in an 
agarose gel, which allows to determine the presence and size of these products by 
comparison with DNA ladders.  
Agarose gel was generated by adding agarose powder (Sigma, UK) to 1x Tris 
Acetate-EDTA (TAE) buffer (Sigma, UK) at a 1 to 100 ratio (weight/volume). The 
agarose in the solution was subsequently melted in a microwave at maximum power and 
stirred until the solution became clear. After letting the gel cool for approximately 2 
minutes, ethidium bromide (Sigma, UK) was added (8 L per 100 mL of solution) and the 
gel was poured into assembled gel trays with a casting comb. The gel was left to solidify 
for 30 minutes and the combs were carefully removed. 
The gel and tray were placed into a gel rig and 1x TAE buffer was added until the 
entire gel was covered. Subsequently, the gel was loaded with a mixture containing 
15 L of the PCR product and 3L of 6x gel loading dye (New England Biolabs, USA). 
DNA ladder (5L; O’Gene Ruler, New England Biolabs, USA) was loaded in the first and 
last well to help determining the sizes of the PCR amplified DNA fragments. The gel was 
then run for 1 hour at 120 volts. 
The gel was gently removed from the rig and placed on a UV light box (UVP 
GelDoc-IT, UVP, Cambridge, UK). After turning the UV light box on, the gel was 
photographed using the Polaroid camera. 
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2.1.3 Peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear 
cells (BMMCs) 
2.1.3.1 Isolation of PBMCs  
MM patients and age-matched healthy donors were included in the study 
following the local ethics committee approval and written informed consent in 
accordance with the Declaration of Helsinki and the specifications of the Human Tissue 
Authority prior to sample donation.  
For healthy donors, peripheral blood was obtained in the form of anonymised 
leukocyte cones of apheresis collection, supplied by the United Kingdom Blood 
Transfusion Service, after institutional review board approval. For MM patients, both 
peripheral blood and bone marrow aspirates were taken by a qualified nurse or 
consultant using ethylenediaminetetraacetic acid (EDTA) blood collection tubes (Becton 
Dickinson, Oxford, UK). 
 PBMCs from peripheral blood and BMMCs from bone marrow aspirates were 
isolated by density gradient centrifugation. Samples were diluted in a 1:1 ratio with DPBS 
and mixed gently. In a 50 mL falcon tube, 30 ml of this mix were overlaid onto 15 ml of 
Histopaque density gradient solution (Sigma, UK) and centrifuged at 800 x g for 20 
minutes at room temperature with no brake. The resulting interface layer, containing 
PBMCs, was then aspirated into a new sterile 50 ml tube (BD Biosciences, UK) using a 
pasteur pipette (Elkay, UK). Histopaque was removed by diluting the obtained PBMCs in 
a 1:5 ratio with DPBS and by centrifuging the resulting solution at 300 x g for 10 minutes 
at room temperature with maximum brake. Cell pellets were then washed two more 
times with DPBS, centrifuged at 250 x g for 10 minutes and resuspended in X-VIVO 15 
complete medium. Viability and cell counts were determined by trypan blue exclusion 
method, as this dye is able to selectively traverse the membrane of dead cells. 20 μl of 
the cell suspension was stained with 60 μl of 0.4% Trypan blue (Sigma, UK). 10 L of 
this mix was then loaded onto a haematocytometer, and a microscope (Leika 
Microsystem, Germany) with magnification x40 was used to count the viable cells. Cells 
in four of the large squares were counted and the average number of cells per large 
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square was used to determine the cell count per mL of cell culture according to the 
formula illustrated below. 
                                                                                 
2.1.3.2 Selection of cryopreserved MM patients PBMCs 
Patient samples stored in the departmental tissue bank were selected on the 
basis of the availability of peripheral blood low-density cells stored in DMSO (n=77 
products corresponding to n=32 patients). Of these samples, only those taken at 
presentation were considered for this study (corresponding to n=18 patients). This 
decision was made in order to avoid the possibility that the immunomodulatory 
therapeutic regimen received by the patient may contribute or interfere with the results of 
this study. A final exclusion criterion was the availability of at least 1x107 cells, as this 
was the minimum number of cells required for the planned assays. This left n=10 
patients (corresponding to n=14 samples). However, 4 patients were subsequently 
excluded due to insufficient number of cells recovered after thawing or because of 
bacteria contamination of the samples.  
Table 2-6 reports diagnosis and World Health Organisation (WHO) classification 
for the MM patients considered for this study, which were also confirmed by morphology, 
cytogenetics and molecular analysis at the Department of Haematological Medicine, 




Table 2-6 Characteristics of MM patients 
Research 
Code 
Sample type Date sample 
taken 
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Merck 088 Trial- 
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Myeloma panel probes tested on CD138
+
 cells (PC): 
13q14,13q34, 1q21, 1p32.3, IGH@, t(4;14), 
t(11;14),t(14;16), TP53  and ploidy for chromosomes 5, 9, 
15, and 12, 5q deletion and ETV6. ABNORMAL RESULT: 
Gain of one copy of CCND1 [24/76], loss of one copy of 
the 13q14 and 13q34 loci [34/100], IGH//MAF fusion 
present [100/100]. All other probes normal.  
The molecular cytogenetic 
abnormalities seen are consistent 
with a clonal plasma cell disorder.  
The signature is compatible with 
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Myeloma panel probes tested on CD138
+
 cells (PC): 
1q21, 1p32.3, t(4;14), t(11;14),t(14;16) and TP53 . 
ABNORMAL RESULT: Loss of one copy of 1p32[88/100], 
gain of one copy of CCND1[82/100], gain of two to three 
copies of MAF[62/80]. All other myeloma probes normal.  
The molecular cytogenetic 
abnormalities seen are consistent 
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our facility from 
fresh peripheral 






Myeloma panel probes tested on CD138
+
 cells (PC): 
13q14,13q34, 1q21, 1p32.3, IGH@, t(4;14), 
t(11;14),t(14;16), TP53 and ploidy for chromosomes 5, 9, 
15, and 12, 5q deletion and ETV6. ABNORMAL result, 
gain of one copy of chromosome 5 and loss of one copy of 
chromosome 15 [90/100], gain of one copy of the CCND1 
locus [71/100]. All other probes normal.  
The molecular cytogenetic 
abnormalities are consistent with a 
clonal plasma cell disorder.  The 
signature is compatible with 
standard risk disease but should be 
considered in the context of 






Cells were thawed as described in 2.1.4.1 and resuspended in X-VIVO 15 
complete medium for immediate cell culture in the presence of 30 IU/mL of IL-2.  
2.1.4 Primary MM cells 
Between 2006 and 2010, CD138+ cells from MM patients were stored in the 
departmental tissue bank as cell pellets and tryzol lysates only as there were not enough 
cells to produce viable products. After 2010 the protocol was dropped due to the reduced 
number of patient samples received. However, it was possible to receive 10 mL of bone 
marrow aspirate from one MM patient (RC-12-0781). MM plasma cells were isolated by 
density gradient centrifugation as described in 2.1.3.1 and, subsequently, CD138+ cells 
were purified from bone marrow mononuclear cells using magnetic microbeads (Miltenyi 
Biotech, UK), as explained in 2.4.1. Cells were then cryopreserved as described in 
2.1.4.1. 
2.1.4.1 Cryopreservation and thawing of PBMCs and CD138+ cells 
 Freezing medium (see 2.1.1) and Nalgene® “Mr Frosty” box (Nunc International, 
UK) filled with isopropanol (Sigma, UK) were cooled to 4 °C. PBMC and CD138+ cells 
were resuspended in X-VIVO 15 complete medium and diluted 1:1 with cold (4 °C) 2x 
freezing medium to give a concentration of 0.5-1x107 cells/mL. The cell suspension was 
immediately aliquoted into labeled cryovials (Greiner, UK). Cryovials were then placed in 
pre-cooled “Mr. Frosty” and stored at -80 °C for 24 hours. After 24 hours cryovials were 
moved into a freezer box and kept in vapour phase liquid nitrogen storage (-196 °C) until 
required. 
Cells were thawed using an unstirred waterbath (Nickel-Electro, UK) set at 37 °C 
as rapidly as possible and slowly resuspended in 50 mL of DPBS, supplemented with 
Benzonase (Merk Millipore, Germany) to a final concentration of 50 IU/mL to prevent cell 
clumping. Cells were immediately centrifuged at 300 x g for 10 minutes. Cell pellets were 
resuspended with 1 mL of DPBS, the resulting cell suspension was passed through a 70 
m cell strainer (BD Biosciences, UK) to eliminate clumps and debris and washed once 
more with DPBS. Cell numbers and viability were determined using the trypan blue 
exclusion method described in section 2.1.3.1. 
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2.2 Lentiviral vectors 
2.2.1 Construction of lentiviral vectors 
All lentiviral vectors were designed and optimised by Dr. Chan, King’s College 
London, who kindly provided the plasmids necessary to produce the virus.  
Lentiviruses are composed of two copies of RNA, a system of capsids, 
membrane associated matrix, envelope proteins and transmembrane proteins (encoded 
by Gag gene) and enzymes such as integrase (ecoded by Pol gene), protease, reverse 
transcriptase and accessory proteins. Due to safety concerns regarding the infectious 
nature of HIV, recent lentiviral packaging systems have the viral components separated 
into 3 or 4 plasmids. In this study, lentivirus particles were produced by co-transfecting 
293T cells with three plasmids, using the calcium phosphate co-precipitation method. 
I. The helper construct, p8.9, which encodes structural and enzymatic proteins 
essential for the minimal packaging of a lentiviral vector (GAG-POL-ENV-TAT).  
II. The envelope construct, MDG, expressing the surface glycoprotein of an 
unrelated virus (VSV-G) to replace HIV-1 ENV. VSV-G also expands the tropism 
of the vectors and allows concentration of the vector by ultracentrifugation. 
III. The transfer vectors (Figure 2.1), which contain: the packaging signal Ψ, which is 
required for efficient encapsidation, the Rev-responsive element RRE, which is 
necessary for reverse transcription and the central polypurine tract cPPT, which 
is required for nuclear transport and integration into the target cell genomic DNA. 
Additionally, to ensure biosafety, the cis-regulatory sequences in the 3' LTR are 
completely removed from the U3 region. This deletion is copied to 5' LTR after 








For this study, the following transfer vectors were used:  
1) R'SINctwSVB71 (LV.CD80) encodes human CD80 (1074-bp) 
2) HR'SINctwSVIL-2 (LV.IL-2) encodes human IL-2 (459-bp) 
3) HR'SINctwSVIL-2B71 (LV.IL-2/CD80) encodes the human fusion IL-2/CD80 protein 
separated by a furin cleavage site (Arg.Gly.Arg.Arg). Endoplasmic Reticulum (ER) 
transport of chimeric IL-2/CD80 protein is mediated by the signalling peptide located 
at the N-terminus of the protein. 
 
Figure 2-1 Schematic maps of the transfer vectors (Chan et al. 2005a) 
 
The three plasmids also contain the Bla gene, which confers 
ampicillin/carbenecillin resistance and allows the plasmid to be expanded in Stbl3 E.coli 
cells in the presence of carbenicillin (see 2.2.2.1). 
2.2.2 Lentivirus production 
2.2.2.1 Plasmid expansion and purification 
 The plasmids described in 2.2.1, were expanded in Stbl3 E. coli cells. This strain is 
derived from the HB101 E. coli strain (Hanahan 1983) and was chosen as it is 
recommended for cloning unstable inserts such as lentiviral DNA.  
2.2.2.1.1 E. coli transformation 
 The competent Stbl3 E. coli cells were purchased from Invitrogen (UK) and stored 
at -80 °C. On the day of the transformation, cells were thawed on ice and inoculated with 
the plasmid DNA (1-5 L, corresponding to approximately 10-100 ng) or the pUC19 
control plasmid, to check transformation efficiency, or water as a negative control. After a 
30 minute incubation on ice, the mixture was heated for 45 seconds at 42 °C. This step 
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disrupts the membrane, allowing the DNA to enter the cell. The heated mixture was then 
placed back on ice to retain the plasmids inside the bacteria.  
 The transformed bacteria were subsequently resuspended in Super Optimal broth 
with Catabolite repression (S.O.C) medium (Invitrogen, UK) and shaken horizontally at 
37 °C for 1hr at 225 rpm in a shaking incubator (Cole-Parmer, UK).  
 Each transformation mixture (25 and 100 L) was then spread on pre-warmed 
Lysogen Broth (LB) agar plates (20g/L in dH2O; Sigma, UK) supplemented with 
carbenicillin, an ampicillin analog (100 g/mL; Sigma, UK) and incubated overnight at 
37 °C.  
2.2.2.1.2 Mini prep 
In order to check that the carbenicillin resistant bacteria colonies were 
successfully transformed, at least two well-spaced single colonies were expanded in 
5 mL of LB medium supplemented with carbenicillin (100 g/mL) overnight at 37 °C, 225 
rpm, in a shaking incubator.  
Plasmid DNA was isolated by using the PureLink® Quick Plasmid Miniprep Kit 
(Life Technologies, UK) and tested for the presence of the desired insert by diagnostic 
restriction digestion (as described 2.2.2.1.3). 5 mL of the transformed and expanded 
cultures were lysed using an alkaline buffer provided with the kit (Life Technologies, UK). 
Subsequently, lysate was applied to a silica membrane column that selectively binds 
plasmid DNA while contaminants were removed using Wash Buffer. The plasmid DNA 
was then eluted in TE Buffer (Life Technologies, UK).  
2.2.2.1.3 DNA purity and concentration evaluation 
This procedure uses the absorption properties of DNA, which are detected by 
NanoDrop spectrophotometer (Thermo Scientific, UK), for quantification and assessment 
of DNA purity.  After initialising the instrument using purified molecular biology grade 
water (Sigma, UK), the NanoDrop was blanked using 2 L of the sample elution buffer. 
Subsequently, 2 L of each sample were acquired and the absorbance, measured at 
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260 nm, was used to calculate the concentration of nucleic acids, based on the fact that 
at a concentration of 1 g/ml and a 1 cm path length dsDNA has a 260 nm absorption of 
50 units. Table 2-7 shows an example of the spectrometric profile obtained for IL-2/CD80 
plasmid DNA.  
Table 2-7 Spectrometric profile of IL-2/CD80 plasmid DNA 
Sample ID Concentration 
(ng/L) 
A260 A280 260/280 260/230 
pLV.IL-2/CD80_1 1077 21.548 11.759 1.83 2.27 
pLV.IL2/CD80_2 1099 21.973 11.950 1.84 2.28 
pLV.IL-2/CD80_3 1117 12.235 12.235 1.83 2.23 
 
Additionally, the A260/A280 ratio was used to determine protein (λmax=280 nm) 
contamination. Pure DNA preparations have an A260/A280 ratio of greater than or equal 
to 1.8. The A260/A230 ratio was used as a secondary measure of nucleic acid purity as 
a strong absorbance around 230 nm can indicate that organic compounds or chaotropic 
salts are present in the purified DNA. As a guideline, the A260/A230 ratio should be 
greater than 1.8, ideally close to 2.  
2.2.2.1.4 Diagnostic restriction digestion 
Two versions of the vector construct pLV.IL-2/CD80 were available in our 
department, which differ in the presence of the enhancer WPRE. Therefore, a diagnostic 
restriction digestion using appropriate endonucleases was carried out in order to check 
the identity of the expanded plasmid.  
Using the DNA analysis tool Clone Manager (SciEd, USA), the restriction sites 
present in the plasmids and the predicted sizes of the resulting fragments were identified 




Figure 2-2 Restriction map of pLV.IL-2/CD80. 
 
The enzymes EcoRI and SalI (New England Biolabs, MA, USA) were selected for their 
ability to excise part of the insert from the plasmid, which will have different sizes 
according to the presence or absence of WPRE (600bp). 
The digestion reaction was carried in two steps, as the optimal buffer for the two 
enzymes differ for salt concentration, using a thermal cycler (GS1, G-storm UK).  
Firstly, 200 ng of plasmid DNA was digested with the enzyme EcoRI using the reaction 
mix described in table 2-8. After 30 minutes at 37 °C, 0.5 L of SalI were added to the 
mix and a higher salt concentration, which is required for the optimal activity of this 
enzyme, was generated by adding NaCl (1M; Sigma, UK). The reaction was run for 
another 30 minutes at 37 °C. Control samples were generated by digesting the plasmid 







Table 2-8 Diagnostic restriction digestion mix 
 Volume (L) 






DNA (200ng) 9 9 9 - 
Buffer (NEB2; 10X) 2 2 2 1 
BSA (1X) 2 2 2 - 
NaCl 1M - 1.5 - 1.5 
Enzyme(s) 0.5 0.5 0.5 0.5 
dH2O 6.5 5 6.5 7 
Total volume 20 20 30 
 
20 L of the digested plasmid were then resolved by agarose gel electrophoresis as 
described in 2.1.2.6. 
No further plasmid verification was performed, as all plasmids had already been 
tested by sequencing analysis (Chan et al. 2005a).  
2.2.2.1.5 Maxi prep 
Plasmids were further expanded by aliquoting 500 L of one of the verified 
colonies (previously expanded, see 2.2.2.1.2) in 500 mL of LB medium overnight at 37 
°C, 225 rpm in a shaking incubator. Cells were then pelleted by centrifugation at 4000 x 
g for 10 min and processed using the PureLink® HiPure Plasmid Maxiprep Kit (Life 
Technologies, UK).  
Pellets were subjected to an alkaline lysis and lysates were then processed 
through a filter column, which includes a lysate filtration cartridge integrated into an ion-
exchange column for single-step lysate clarification and plasmid DNA binding. Impurities 
such as RNA, proteins, and other contaminants were removed with a single wash, and 
plasmid DNA was eluted with a high-salt buffer (Life Technologies, UK). To precipitate 
and desalinate the DNA, isopropanol was added to the eluted DNA and the mixture was 
then applied to the HiPure precipitator using a syringe. After a subsequent washing and 
drying step, the plasmid DNA was eluted from the HiPure precipitator with TE buffer.  
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The obtained DNA was then tested for purity and concentration by absorbance 
spectroscopy, as described in 2.2.2.1.3. 
2.2.2.2 Lentivirus production in helper cells 
Lentivirus vectors (LV.CD80, LV.IL-2 and LV.IL2/CD80) were produced by co-
transfection of helper cells (293T or BL15 cells) with three plasmids using the calcium 
phosphate precipitation principle. Details of the reaction mix are outlined in Table 2-9.  
Table 2-9 Transfection reaction mix 
Cell culture container pMDG p8.9 Transfer vector H2O CaCl2 HeBS 2x 
55 cm
2
 (10cm cell culture 
dishes) 
3.5 g 6.5 g 10 g 250 L 250 L  500 L 
435 cm
2
 (triple layer flask) 28 g 52 g 80 g 1977.3 L 1977.3 L 3954.5 L 
 
Plasmid DNAs were mixed with water and CaCl2 (Sigma, UK) and the mixture was slowly 
added drop-wise to a tube containing HeBS 2x (Sigma, UK) while vortexing the mixture 
continuously. The solution was then incubated at room temperature for 30 minutes to 
allow the formation of DNA precipitates and then added drop-wise to DMEM complete 
medium, which was used to replace the helper cells culture medium.  
2.2.2.2.1 Lentivirus production and concentration using 293T cells 
After 14-16 hours the culture medium was replaced with fresh complete DMEM to 
remove the excess DNA. Although the majority of the peak of accumulation of viral 
particles in the medium is at 24 hours post re-feeding, the data reported in Figure 2-3 
suggested it is worth performing a second harvest. Therefore, supernatants were 
collected after 24 and stored at 4 °C and the medium substituted with fresh one. A 
second harvest was performed in the same way after another 24 hours (48 hours after 




Figure 2-3 Detection of viral particles in first and second harvest following transfection of 293T 
cells. 
293T cells were transfected with the appropriate plasmids as described in 2.2.2.2. 0.5 mL of 
supernatant, harvested after 24 (1
st
 harvest) or 48 hours (2
nd
 harvest) from the first re-feeding was 
used to infect K562 cells. After 24 hours, cells were washed twice and cultured for 72 hours prior 
to analysis of CD80 expression by flow cytometry. Bars represent the mean and standard 
deviation obtained from replicate wells.  
 
Supernatants were then passed through a 0.45 m filter (Millipore, Germany), to 
avoid contamination by 293T cells, and concentrated in appropriately sized silicon tubes 
(Nalgene, Sigma, UK) by overnight ultracentrifugation at 8000 x g and 4 °C. Pellets were 
resuspended in AIM-V medium to achieve a total volume reduction of 100 fold, and 
frozen in 50 L aliquots at -80 °C. 
2.2.2.2.2 Lentivirus production and concentration using BL-15 cells (Nesbeth et al. 
2006) 
24 hours after transfection (see 2.2.2.2), BL15 cells were washed three times 
with serum-free DMEM and cultured for 48 hours. Supernatants were harvested every 4 
hours, stored at 4 °C and then passed through a 0.45 m filter. Calcium chloride (Sigma, 
UK) was added to the pooled supernatants and the mix was then incubated in an 
unstirred waterbath (Nickel-Electro, UK) at 37 °C for 30 minutes, resulting in a 
co-precipitated calcium phosphate-lentivirus preparation. This precipitate was then 
pelleted by centrifugation at 4000 x g for 5 minutes and resuspended in 900 L of 
modified solubilization buffer (100 mM EDTA, 50mM NaCl, 0.2% BSA, pH 6.5, all Sigma, 
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UK). Streptavin paramagnetic particles (PMPs) (2.5x108, Promega, UK) were added and 
the mix was incubated overnight at 4 °C under agitation using a roller mixer (Stuart 
Scientific, UK). After washing twice using a Dynal MPC-E (Invitrogen, UK), PMPs were 
resuspended in Hank's Balanced Salt Solution (HBSS; Sigma, UK) supplemented with 
FBS (0.1% volume/volume) to achieve a total volume reduction of 100 fold, and stored at 
4 °C for further use.  
2.2.2.3 Target cell transduction 
2.2.2.3.1 Lentivirus titration 
 Target cells (K562, U937 and U266) were resuspended in complete RPMI1640 
medium at 5x105/ml and seeded in triplicate in 12-well culture plates. The infection 
enhancers diethylaminoethyl (DEAE)-dextran (10 g/mL; Sigma, UK) or polybrene (4 
g/mL; Sigma, UK) was added to the medium and cells were cultured for 1 hour in 
humidified 37 °C, 5% CO2 incubators. The polycation counters the repulsive electrostatic 
forces between the virus and target cells, thereby stabilising virus-cell interactions and 
thus virus adsorption to the cells (Platt et al. 2010). Serial dilutions of lentivirus particles 
or lentivirus-PMP complexes were added to the target cells. After 24 hours, cells were 
washed twice with fresh medium by centrifugation or by using a Dynal MPC-E (when 
PMPs-conjugated virus was used), re-fed with complete RPMI1640 medium and cultured 
for a further 48 hours. Cells were then washed and re-seeded at 1x106/mL for a further 
24 hours.  
 Flow cytometric analysis of cells for CD80 expression was performed (see 2.5.2) 
and supernatant removed for measurement of IL-2 concentration by Enzyme-Linked 
Immunosorbent Assay (ELISA), as described in 2.6. 
Virus titer was calculated according to the following formula: 
      (
  
  
)                                               
                
   
                   
2.2.2.3.2 Lentivirus infection of target cells 
Cell lines U266 and RPMI8226 were seeded at a density of 5x105 cells/mL in complete 
RPMI1640 medium. Aliquots of the appropriate lentivirus were thawed and added at a 
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multiplicity of infection (MOI) of 20 in the presence of polybrene.  
 Cryopreserved CD138+ MM cells were thawed and cultured in complete AIM-V 
medium. Cells were then transduced with LV.IL-2/CD80 at an MOI of 20 in the presence 
or absence of the effector enhancer polybrene (4g/mL). 
 After 24 hours, both infected primary CD138+ MM cells and cell lines were washed 
twice, re-fed with the appropriate complete medium and cultured for a further 48 hours. 
Cells were then washed and re-seeded at 1x106 cells/mL for a further 24 hours, 
supernatants were removed for measurement of IL-2 concentration (as described in 2.6) 
and flow cytometric analysis of cells for CD80 expression was performed (see 2.5.2). 
2.2.2.3.3 Target cells biotinilation and treatment with PEI 
The polymeric transfection agent polyethylenimine (PEI; Sigma, UK) was 
combined with PMP-conjugated LV.IL-2/CD80 with the aim of maximising the lentivirus-
target cell interaction (Chan et al. 2005b). Additionally, target cells were biotinilated to 
increase their ability to interact with PMP-lentiviral particles through the establishment of 
biotin (cells)-steptavidin (PMP) interactions.  
 U266 cells were resuspended in DPBS and incubated with a concentration of3 mM 
of biotin for 30 minutes, washed twice and resuspended in fresh RPMI1640 complete 
medium. The presence of biotin linked to the cell surface was detected through staining 
with FITC-labelled avidin (Invitrogen, UK). U266 and biotinilated U266 cells were 
resuspended at a concentration of 5x105 cells/mL in RPMI-1640 complete medium 
supplemented with polybrene (4g/mL) and aliquoted in a 24 well plate (1mL/well). Each 
well then received an appropriate volume of PMP-conjugated LV.IL-2/CD80 in the 
presence or absence of PEI. After 24 hours, cells were washed twice using a Dynal 
MPC-E, re-fed with RPMI-1640 complete medium and cultured for a further 48 hours. 
Cells were then washed and re-seeded at 1x106 cells/ml for a further 24 hours. 
Afterwards, supernatant were removed for measurement of IL-2 concentration and flow 




2.3.1 Co-cultures of PBMCs or NK cells with MM cell lines 
Healthy donor PBMCs or isolated NK cells (see 2.4.1) were cultured for various 
durations in the presence of the MM cell lines KMS12PE, U266 and RPMI-8226 at a 
PBMCs to MM cells ratio of 1 to 1 and at an NK cell to MM cell ratio of 10 to 1. Typically, 
healthy donor PBMCs or isolated NK cells and MM cell lines were resuspended in their 
respective complete media at 2x106 cells/mL. 1 mL of each cell suspension was then 
aliquoted in a 12-well plate and IL-2 was added to a final concentration of 30 IU/mL. 
Cells were incubated in humidified 37 °C, 5% CO2 incubators for 24 hours unless 
otherwise specified. CD20+ B cells isolated from HD PBMCs (as described in 2.4.1) or 
complete RPMI-1640 medium were used as negative control wells. In one experiment, 
contact-dependent interactions between PBMCs and U266 cells or CD20+ B cells were 
prevented through the use of transwell with 0.4 m polycarbonate membrane insert 
(Corning, USA). 
In order to prove the potential relevance of these in vitro results, MM patient 
PBMCs (2x106 at 2x106 cells/mL in complete XVIVO 15 medium) were cultured for 24 
hours in 1 mL of complete RPMI-1640 medium.  
2.3.2 Co-culture of PBMCs with unmodified or genetically-modified MM cells 
Unmodified or genetically modified U266 cells, or primary unmodified or LV.IL-
2/CD80-modified primary CD138+ MM cells were washed twice in DPBS, resuspended in 
complete medium, -irradiated at 30 gray (Gy) and used as stimulator cells in co-culture 
experiments with healthy donor and MM patient PBMCs at a PBMCs to MM cell ratio of 2 
to 1. Typically, PBMCs and MM cells were resuspended in the appropriate complete 
medium at 2x106 cells/mL and at 1x106 cells/mL, respectively. The cell suspension was 




Cells were incubated in humidified 37 °C, 5% CO2 incubators for 7 days unless 
otherwise specified. X-VIVO 15 complete medium was added in the negative control 
wells (PBMCs alone).  
2.3.3 Culture of PBMCs in the presence of immunomodulatory drugs (IMiDs) 
The immunomodulatory drugs pomalidomide (Actimid or CC-4047) and 
lenalidomide (Velcade or CC- 5013) were purchased from Sigma (UK), aliquoted as a 
powder in 3 mL polypropylene tubes (Eppendorf, UK) and weighted under sterile 
conditions. The aliquoted drug was stored at 4 °C and, when needed, resuspended in 
the appropriate amount of DMSO to reach a final concentration of 100 mM. Freshly 
isolated and thawed HD PBMCs were washed twice in DPBS and resuspended in 
complete X-VIVO 15 medium. The appropriate volume of drug resuspension or DMSO 
was then added to the culture medium and resuspended well by pipetting up and down 




















2.4 Cell sorting 
2.4.1 Magnetic cell sorting 
Cell isolation was achieved by using a magnetic labelling system (Miltenyi 
Biotech, UK). This method is based on the use of biotin-conjugated antibodies to 
specifically label cells of interest. The labelled cells can then be depleted or enriched 
from a heterogeneous cell population by retaining them within a column in the magnetic 
field of a separator. Unlabelled cells run through the column while labelled cells are held 
into suspension within the column and can be subsequently eluted by removing the 
column from the magnetic field.  
After determining cell numbers and calculating the quantity of reagents needed, 
cells were washed once with DPBS, resuspended in 5 mL of DPBS and passed through 
a pre-moistened 70 m nylon cell strainer (BD Biosciences, UK) to remove cell clumps 
that may clog the column. Cells were centrifuged at 300 x g for 10 minutes and, after the 
supernatant was completely aspirated, resuspended in 80 L of staining buffer (see 
2.1.1) per 107 total cells. 20 L of microbeads per 107 total cells were added and cells 
were incubated for 15 minutes at 4 °C. Cells were then washed using 10 mL of staining 
buffer and up to 108 cells were resuspended in 500 L of staining buffer.  
After choosing an appropriate MACS Column and MACS Separator (all from 
Milteyi Biotech, UK), the columns were placed in the magnetic field of the MACS 
separator and rinsed with staining buffer. The cell suspension was then applied onto the 
column. After two washes the total flow through, representing the unlabeled cells, was 
collected and stored for further processing or use. The column was removed from the 
separator and placed on a suitable collection tube. The labelled fraction was immediately 
flushed out by firmly applying the plunger supplied with the column.  
Table 2-10 describes the strategies used to isolate NK cells and CD20+ B cells 
from HD and MM patient PBMCs, CD138+ cells from MM patient BMMCs and NK cells 




Table 2-10 Magnetic cell sorting strategy 
 NK cells CD20+ B cells CD138+ MM cells NK cells after co-culture with MM 
cells 
Microbeads anti-CD3  anti-CD20  anti-CD138  anti-CD3 and anti-CD138  
 
 
Cell selection Negative fraction Positive fraction Positive fraction Negative fraction 
 
 
Microbeads anti-CD56   anti-CD56 
 
  
Cell selection Positive fraction   Positive fraction 
 
Purity of the product and efficiency of the procedure was then evaluated by Flow 
Cytometry as described in 2.5.2 (Figure 2-4, 2-5 and 2-6). 
 
Figure 2-4 Purity of CD138
+
 cells before and after magnetic cell sorting.  
Flow cytometry plots showing CD138
+
 cells in the PBMCs before (left) and after (right) CD138
+
 
cell selection using Miltenyi microbeads. 
 
 
Figure 2-5 Purity of CD20
+
 B cells before and after magnetic cell sorting.  
Flow cytometry plots showing CD19
+
 cells (first, second and third panel) in the PBMCs before 
(first panel) and after CD20 B-cell isolation (second panel: positive fraction; third panel: negative 
fraction) using Miltenyi microbeads. The positive fraction was also tested for CD20 expression 









 NK cells before and after magnetic cell sorting.  




) in the PBMCs before (first panel) 
and after CD3 depletion and CD56 enrichment (second panel: positive fraction; third panel: 
negative fraction) using Miltenyi microbeads.  
 
2.4.2 Fluorescence activated cell sorting (FACS) 
LV.IL-2/CD80 and LV.CD80 U266 cells were washed twice in DPBS. 5 x 105 cells 
were aliquoted in two polypropylene tubes (BD Biosciences, UK), one of which served as 
unstained control while the second received isotype control antibody (BD Biosciences, 
UK). The rest of the cells were stained with anti-CD80PE monoclonal antibody (BD 
Biosciences, UK). After 30 minutes incubation in the dark at room temperature, cells 
were washed twice with separation buffer and resuspended at 10-15 x 106 cells/mL. As it 
is fundamental that cells are in a single-cell suspension, cell clumps were removed right 
before the sorting by passing cells through a 70 m cell strainer (BD Biosciences, UK). 
Cells were resuspended in a buffer containing cation-free DPBS with 1 mM EDTA, 25 
mM HEPES (Sigma, UK) at pH 7, supplemented with FBS (1% volume/volume) and 
penicillin streptomycin. Cells were kept on ice to help maintaining a monodispersed 
suspension. 
Collection tubes were prepared by aliquoting complete medium supplemented 
with FBS (50% volume/volume). FACS was performed using BD FACSAriaTM III (BD 
Biosciences, UK). 
Firstly, unstained and negative control samples were run to identify the positive and 
negative cell populations. The sample was subsequently run and the positive and 
negative populations were collected in the appropriate tubes. As part of the quality 
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control, both tubes were re-acquired to check the efficiency of the procedure and the 
































2.5 Flow cytometry 
Flow cytometry is a technique based on the use of multiple beams of laser light 
characterised by a specific wavelengths, to detect physical information about a cell 
suspension in the form of a hydrodynamically focused stream of liquid. A number of 
detectors are positioned at the point where the stream passes through the light beams: 
one in line with the light beams (Forward Scatter or FSC) and several perpendicular to 
them (Side Scatter or SSC) and one or more fluorescence detectors, which can detect 
any light emitted by fluorescent molecules excited by the light source. By analysing 
fluctuations in brightness at each detector it is then possible to derive information about 
the physical and chemical structure of each individual particle passing the light beams. 
FSC correlates with the cell volume, while SSC depends on the inner complexity of the 
particles (i.e., shape of the nucleus, the amount and type of cytoplasmic granules or the 
membrane roughness) as the light is scattered off the internal components of the cell.  
Cells were acquired using the BD Canto II flow cytometer (BD Biosciences, UK) 
and data analysed using FlowJo Software (Treestar, USA). 
2.5.1 Quality control of flow cytometric assays (Mahnke and Roederer 2007) 
Cytometer Setup and Tracking beads (BD Biosciences, UK) were run once a 
week to control the performance levels of the cytometer. These beads consist of equal 
concentrations of 3 m bright, 3 m mid and 2 m dim polystyrene beads in PBS with 
FBS in a stream-tip dropper vial. They were originally used to define the cytomer 
baseline, in particular to adjust the cytometer settings for maximising population 
resolution in each detector. Once baseline values were defined, 1 drop of beads diluted 
with 150 L of DPBS was used weekly and after every machine servicing to evaluate 
cytometer performance. 
Prior to each acquisition, compensation beads (BD Biosciences, UK) were run 
with the purpose of establishing compensation corrections for spectral overlaps for any 
combination of fluorochrome-labeled antibodies. BD™ CompBead particles are 
polystyrene microparticles coupled to an antibody specific for the kappa light chain of 
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mouse immunoglobulin. Each CompBead set also includes a negative control with no 
binding capacity, which consists of particles labeled with BSA or FBS. When mixed with 
any kappa-bearing fluorochrome-conjugated antibody, the beads can provide distinct 
positive and negative (background fluorescence) stained populations that can be used to 
set compensation levels. This method has the advantage to provide a bright and distinct 
population of positive cells, thereby overcoming the problems associated with the dim or 
rare expression of a marker on normal cells and avoiding the use of valuable cell 
samples.  
A separate FACS tube (BD Biosciences, UK) for each fluorochrome-conjugated 
mouse Ig,k antibody to be used was labeled. 100 L of staining buffer was added to 
each tube followed by 1 full drop of previously vortexed BD CompBeads Anti-Mouse Ig,k 
and 1 drop of previously vortexed BD CompBeads Negative Control. 5 l of each 
antibody was then added to the appropriate tube and immediately vortexed. Tubes were 
incubated in the dark at room temperature for 20 minutes, washed twice with staining 
buffer and then acquired using the BD Canto II flow cytometer (BD Biosciences, UK).  
2.5.2 Staining of cell lines and primary MM plasma cells 
Surface staining of MM cell lines was performed to determine the expression of 
the surface markers described in Table 2-11. Panel A was used to characterise MM cells 
and confirm their identity on the basis of results present in the literature (Drexler and 
Matsuo 2000). Panel B was used to investigate transgene expression following infection 
with lentiviral vectors. Panel C was used to evaluate changes in the expression of CD80 
ligands in a sorted CD80+ U266 cell population. Cells were counted and 0.5 x106 to 
1x106 cells were washed with staining buffer, resuspended in the residual volume of 
buffer and directly labeled with fluorochrome-conjugated monoclonal antibodies (mAbs) 
for 30 minutes in the dark at room temperature. Cells were then washed twice, 
resuspended in 250 l of staining buffer and then acquired using the BD Canto II flow 




Table 2-11 MM cells antibody stain mix. 
Panel Antibody Clone Fluorochrome Manufacturer 
A CD138 MI15 Pacific Blue BD Biosciences, UK 
CD28 CD28.2 FITC BD Biosciences, UK 
CD56 B159 PerCPCy5.5 BD Biosciences, UK 
CD20 L27 Pacific Blue BD Biosciences, UK 
CD19 HIB19 APC BD Biosciences, UK 
HLA-ABC DX17 PE BD Biosciences, UK 
HLA-DR G46-6 APC-H7 BD Biosciences, UK 
B CD80 L307.4 PE BD Biosciences, UK 
Isotype control 
for CD80 
MOPC-21 PE BD Biosciences, UK 
C PD-L1 MIH1 PE BD Biosciences, UK 
CD28 CD28.2 FITC BD Biosciences, UK 
 
2.5.3 Staining of PBMCs and NK cells 
Cells were washed, resuspended in DPBS at a concentration of 0.5x106 to 1x106 
cells/mL and aliquoted in polypropylene tubes. Each tube then received the appropriate 
antibody mixture according to the panel investigated (see 2-11) and cells were incubated 
in the dark at room temperature for 30 minutes. Anti-CD14, anti-CD19 and anti-CD138 
antibodies were added in order to exclude B cells, monocytes and MM cells during the 
gating strategy. 
2.5.3.1 PBMCs 
The antibody panel described in Table 2-12 was created and optimised to 
investigate NK and T cell proliferation following co-culture with unmodified and 
genetically modified cells. NKG2D was added as a shared activation maker between NK 
and T cells. The total numbers of NK and T cells were determined by multiplying the 
number of stained lymphocytes (defined as trypan blue negative cells) by the percentage 
of NK or T cells (calculated using results from flow cytometry staining and expressed as 
percentage of lymphocytes). 
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Table 2-12 PBMCs proliferation antibody stain mix. 
Panel Antibody Clone Fluorochrome Manufacturer 
PBMCs 
proliferation 
CD138 MI15 Pacific Blue BD Biosciences, UK 
CD19 HIB19 Pacific Blue BD Biosciences, UK 
CD14 Pg Pacific Blue BD Biosciences, UK 
CD56  B159 PerCPCy5.5 BD Biosciences, UK 
CD3 UCHT1 Pacific Orange BD Biosciences, UK 
CD4 RPA-T4 FITC BD Biosciences, UK 
CD8 RPA-78 PeCy7 BD Biosciences, UK 
NKG2D 1D11 APC BD Biosciences, UK 
 
2.5.3.2 NK cells and T cells 
The antibody panels described in Table 2-13 and 2-14 were created and 
optimised to investigate NK cell activation and inhibition and T cell activation following 
co-culture with unmodified and genetically modified cells. Live/Dead stain (Invitrogen, 
UK) discrimination marker was added in order to avoid false positive signals caused by 
the non-specific binding of antibodies to dead cells. Activation markers were included on 















Table 2-13 NK cell activation antibody stain mix. 
Panel Antibody Clone Fluorochrome Manufacturer 
A CD138 MI15 Pacific Blue BD Biosciences, UK 
CD19 HIB19 Pacific Blue BD Biosciences, UK 
CD14 Pg Pacific Blue BD Biosciences, UK 
CD56  B159 PerCPCy5.5 BD Biosciences, UK 
CD3 SK7 PeCy7 BD Biosciences, UK 
NKG2D 1D11 APC BD Biosciences, UK 
DNAM-1 DX11 FITC BD Biosciences, UK 
NKp30 P30-15 PE BD Biosciences, UK 
Live/Dead stain n/a Aqua (V500) Invitrogen 
B CD138 MI15 Pacific Blue BD Biosciences, UK 
CD19 HIB19 Pacific Blue BD Biosciences, UK 
CD14 Pg Pacific Blue BD Biosciences, UK 
CD56  B159 PerCPCy5.5 BD Biosciences, UK 
CD3 SK7 PeCy7 BD Biosciences, UK 
NKp46 9E2/NKp46 APC BD Biosciences, UK 
NKp44 P44/81 PE BD Biosciences, UK 
CD69 L78 FITC BD Biosciences, UK 
Live/Dead stain n/a Aqua (V500) Invitrogen 
 
 
Table 2-14 T cell activation antibody stain mix. 
Panel Antibody Clone Fluorochrome Manufacturer 
T cells CD138 MI15 Pacific Blue BD Biosciences, UK 
CD56  B159 PerCPCy5.5 BD Biosciences, UK 
CD3 UCHT1 Pacific Orange BD Biosciences, UK 
CD8 RPA-78 PeCy7 BD Biosciences, UK 
CD154 PE TRAP1 PE BD Biosciences, UK 
CD69 FITC L78 FITC BD Biosciences, UK 






2.5.4 Detection of NK cell cytotoxicity 
NK cell cytolytic activity was measured by different flow-cytometry based 
techniques.  
2.5.4.1 Non-radioactive killing assay 
A non-radioactive flow cytometry-based method was used as an alternative to 
chromium-release assay, to detect NK cell-induced apoptosis. This technique is based 
on the measurement of naked DNA in tumour cells after a 4 hour incubation with 
different PBMCs or purified NK cells as effector cells, at multiple effector to target ratios.  
In order to distinguish target cells from effector cells, the former were washed 
twice in DPBS and pre-labeled with 1M of carboxyfluorescein succinimidyl ester (CFSE) 
(Sigma, UK). CFSE crosses intact cell membranes and, once inside the cells, is cleaved 
by intracellular esterases and retained inside the cells, where it cross-links to intracellular 
proteins. The resulting molecules have a peak excitation at 494 nm and peak emission at 
521 nm, normally measured on the FITC channel by flow cytometry. After an eight 
minute incubation with CFSE, cells are washed twice in complete RPMI1640 medium 
and frozen at 2x106 cells per aliquot as described in 2.1.4.1 On the day of the assay, 
these cells are thawed as described in 2.1.4.1 and resuspended in complete RPMI-1640 
medium supplemented with 60 IU/mL of IL-2 at 2x104 cells/mL. Effector cells are washed 
twice, resuspended in X-VIVO 15 complete medium at 1x106 cells/mL (when PBMCs 
were used as effector cells) and 1x105 cells/mL (when NK cells were used as effector 
cells). 
Effector and target cells were seeded in triplicates in a U-bottom 96 well plate. Each well 
received an appropriate volume of cell suspension in order to obtain effector to target 
ratios of 50 to 1, 25 to 1 and 12.5 to 1, when PBMCs were used as effectors. Instead, 
when NK cells were used as effectors, 5 to 1, 2.5 to 1 and 1.25 to 1 effector to target 
ratios where used, to reflect the NK cells proportion within the PBMCs population 
(Cooper et al. 2001). An appropriate volume of X-VIVO 15 complete medium was also 
added to each well to achieve a final volume of 200 L. Negative control wells were 
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seeded in order to quantify spontaneous target cell death by aliquoting 100 L of target 
cell suspension and 100 L of X-VIVO 15 complete medium supplemented with IL-2, 60 
IU/mL. The seeded cells were then gently pelleted by centrifuging the plate at 120 x g 
with low brake and incubated in humidified 37 °C, 5% CO2 incubators for four hours. 
At the end of the incubation, cells were pelleted by centrifuging the plate at 300 x 
g with low brake, the supernatant was discarded and cells were resuspended in 100 L 
of DPBS plus 4L of 7-aminoactinomycin D (7-AAD; BD Biosciences, UK) per well. This 
fluorescent chemical compound is able to enter only the compromised membranes of 
dead cells and, once inside the cells, it intercalates in double stranded DNA. 7-AAD has 
a peak excitation at 488 nm and peak emission at 650 nm, normally measured on the 
APC or PerCP channel and characterised by a minimal overlap with FITC (CFSE). A 
minimum of 20000 CFSE positive events were acquired using BD Canto II flow 
cytometer (BD Biosciences, UK) and NK cell cytolytic activity was calculated according 
to the following formula 
           
                                          
                             
   
 
2.5.4.2 NK cell degranulation and IFN- production 
Another method to investigate NK cell activation is based on the measurement of 
CD107a expression and IFN- production by NK cells following co-culture with target 
cells.  
CD107a, also known as lysosomal-associated membrane protein (LAMP-1), is a 
receptor that lays in the luminal membrane of pre-formed cytolytic granules in NK cells 
(Winchester 2001). When the granules are released following NK cell activation, they 
fuse with the NK cell membrane where CD107a can then be detected on the outer cell 
surface. Recently, CD107a has been described as a marker for the activation of CD8+ T-
cells and NK cells (Alter et al. 2004). As a strong relationship exists between the 
information provided by the killing assay (chromium release assay and 7-AAD assay) 
and CD107a expression, an assay to evaluate NK cell degranulation was developed with 
the aim of confirming the results obtained using the killing assay and to further 
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characterise the level of activation of the effector population. IFN- release was also 
included as an additional activation marker, as it is significantly associated with CD107a 
expression (Alter et al. 2004). 
Effector and target cells were resuspended at 5x106 cells/mL in complete X-VIVO 15 
and RPMI1640 medium supplemented with 60 IU/mL of IL-2 respectively. Based on 
preliminary results using K562 cells as targets (Figure 2-7), an effector to target cell ratio 



























Figure 2-7 Optimisation of CD107a/intracellular IFN- detection assay.  
Assays were performed as described in 2.5.4.1 and 2.5.4.2. The X axis indicate the effector 
(PBMCs) to target (K562) ratio and the culture conditions. The graphs represent the median and 
range obtained from 2 healthy donors. 
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Each well of the 96 wells flat-bottom plate received 100 L of effector cells and 100 L of 
target cells. In order to quantify spontaneous NK cell degranulation and IFN- release, 
negative control wells were seeded by aliquoting 100 L of effector cell suspension and 
100 L of RPMI-1640 complete medium supplemented with 60 IU/mL IL-2. Positive 
control wells were also set by aliquoting 100 L of effector cell suspension and 100 L of 
RPMI1640 complete medium supplemented with 60 IU/mL IL-2, phorbol 12-myristate 13-
acetate (PMA) (10 g/mL) and ionomicin (1 g/mL) (both Sigma, UK). Each condition 
was performed in triplicate and each well received 2 L of anti-CD107a antibody. Cells 
were then gently pelleted by centrifuging the plate at 120 x g with low brake and 
incubated in humidified 37 °C, 5% CO2 incubators for one hour.  
At the end of this incubation time each well received an appropriate volume of 
monensin (BioLegend, USA) to achieve a final concentration of 2 M. Monensin is a 
protein-transport inhibitor commonly used to enhance intracellular cytokine staining 
signals and inhibiting protein recycling, by blocking transport processes at the Golgi level 
and neutralising the acidic pH of endosomes (Mollenhauer et al. 1990; Chan and Kaur 
2007). Plated cells were then cultured for a further five hours in humidified 37 °C, 5% 
CO2 incubators. Cells were then resuspended and transferred to a V bottom well plate, 
which is more suitable for the following staining and washing steps. Plated cells were 
centrifuged at 300 x g for 5 minutes with maximum brake and 150 L of the supernatant 











Cell pellets were resuspended and stained according to Table 2-15. 
Table 2-15 CD107a-IFN- antibody staining mix  
Antibody Clone Fluorochrome Manufecturer 
CD138 MI15 Pacific Blue BD Biosciences, UK 
CD19 HIB19 Pacific Blue BD Biosciences, UK 
CD14 Pg Pacific Blue BD Biosciences, UK 
CD56  B159 PE BD Biosciences, UK 
CD3 SK7 PeCy7 BD Biosciences, UK 
CD107a H4A3 APC BD Biosciences, UK 
IFN- 4S.B3 FITC BD Biosciences, UK 
 
After a 30 minute incubation at room temperature, cells were washed twice with 
200 l of staining buffer, resuspended in 100 L of Fix Buffer (BD Biosciences, UK), 
mixed well and incubated for 20 minutes at room temperature. After two further washes 
with 200 l of staining buffer, cells were resuspended in 100 l of perm/wash buffer (1:10 
diluted with dH20; BD Biosciences, UK), mixed well and incubated for 15 minutes at room 
temperature. The plate was then centrifuged at 300 x g for 5 minutes with maximum 
brake, the supernatant was discarded and cells were resuspended with FITC-labelled 
IFN- diluted in 30 mL of perm/wash buffer. After a 30 minute incubation, cells were 
washed twice with perm/wash buffer, resuspended in 200 l of staining buffer and 
acquired using the BD Canto II flow cytometer (BD Biosciences, UK). A minimum of 












ELISA (Enzyme-Linked Immunosorbent Assay) is a widely used biochemical 
technique for the detection of a specific antigen in a sample. For this study, we used a 
variant of this technique, called sandwich ELISA, which utilises two antigen-specific 
antibodies: a capture antibody bound to a solid phase and an enzyme-linked detection 
antibody.  
A microtiter plate (R&D System, UK) was coated with the capture antibody, 
sealed with the provided plate cover and incubated overnight at room temperature. In the 
case of Granzyme B ELISA, a ready-to-use pre-coated plate was employed. 
Subsequently, each well was aspirated and washed three times with ELISA wash buffer 
(DPBS with 0.05% Tween; Sigma, UK) using a squirt bottle, and after the last wash, any 
remaining wash buffer was removed by inverting and blotting the plate against clean 
paper towels. Each well then received 100 L of blocking buffer (DPBS 1% BSA, all 
Sigma, UK) and was incubated at room temperature for a minimum of 1 hour. Multiple 
sample dilutions were applied in triplicates to the plate and incubated for 2 hours to allow 
the antigen in the sample to bind to the capture antibody. As part of the assay quality 
control and assay validation, a standard curve was prepared by aliquoting serial dilutions 
of a known concentration of the protein standard in duplicates, and negative control wells 
containing the sample diluent were also set up. After the incubation, unbound 
compounds were removed by performing the washing procedure previously described. 
100 L of diluted detection antibody were added to each well and incubated for 2 hours 
to allow the antibody to bind to a second epitope on the antigen. Unbound antibodies 
were removed by a washing step. Subsequently, 100 L of HRP-Conjugated Streptavidin 
were added to the wells. This compound consists of streptavidin protein, which binds to 
the biotinilated dectection antibody, and is covalently conjugated to the horseradish 
peroxidase (HRP) enzyme. After a 20 minute incubation and the following washing step, 
100 L of the chromogenic substrate 3’,3’,5,5’ Tetramethylbenzidine (or TMB) was 
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added to each well. This molecule is oxidated by the HRP causing the solution to take on 
a blue colour. After 10 to 20 minute incubation, the reaction was stopped by adding 
50 L of 1N sulphuric acid, which offers a yellow end product and the plate was read at 
450 nm using a spectrophotometer (BioTeck, UK).  
Data were analysed using the Gene5 Data Analysis Software (BioTeck, UK). 
Through this program, it was possible to generate a three or four parameter logistic 
curve fit, which plots the mean absorbance for each standard on the y axis against the 
known concentration present in the well on the x axis (Figure 2-8). The coefficient of 
determination (R2) was used as an indication of the inter-assay reproducibility, with 
values from 0.98 to 1 representing the best result. 
 
Figure 2-8 ELISA standard curve fit.  
The standard curve was drawn by plotting the mean absorbance at 450 nm against the known 
protein concentration present in the standard dilutions as indicated on the plate layout. The table 
below the graph reports the curve formula used for the fitting and the R
2
 value. 
The concentration of the sample of interest was then determined by 
interpolation using the curve described above. This value was then subtracted of the 
antigen concentration detected in the negative control wells (background) and, when 





























2.7 MTT assay 
The MTT assay is a non-radioactive cell proliferation assay (Promega, UK) based 
on the cellular conversion of a tetrazolium salt into a formazan product, which is then 
detected using a 96-well plate reader.  
Cells were washed twice in complete fresh medium and centrifuged at 300 x g for 
5 minutes with maximum brake. Cells were resuspended in complete medium and cell 
numbers and viability were determined. Cell concentration was adjusted to 1x106 
cells/mL and each well of a 96-well plate received 100 L of cell suspension. The plate 
was incubated in humidified 37°C, 5% CO2 incubators. After 48 hours, 15 L of the dye 
solution was added to each well and the plate was incubated in humidified 37°C, 5% CO2 
incubators. During this time live cells convert the tetrazolium component of the dye 
solution into a formazan product. After 4 hours, 100 L of the Solubilisation Solution/Stop 
mix were added to each well to solubilise the formazan product and its absorbance at 
570 nm was recorded using a spectrophotometer (BioTek, UK).  

















2.8 Statistical analysis 
 Computer software GraphPad Prism® (version 5.0, La Jolla, California, USA) was 
used for the statistical calculations and to plot graphs. Data are visually presented as 
mean with standard deviation, or median with range, or grand median, which represents 
the combined samples median.  
 The distribution of the data was determined using the SPSS software (IBM). 
Due to the non-normal distribution of data, statistical significance was calculated by 
comparing the medians, using the non-parametric matched paired analysis Wilcoxon 
signed rank-test, when considering two parameters, and the Friedman test when 
performing a One-way Anova analysis on more than two parameters. Results are 




























3.1 Multiple myeloma-mediated inhibition of NK cells 
3.1.1 Introduction 
Like many other malignancies, MM is associated with a profound impairment of 
immune functions (see 1.3.3), allowing the tumour to escape immune surveillance. So 
far, studies investigating this phenomenon have mainly addressed the impact of 
cytokines and other soluble immunomodulatory factors on the adaptive arm of the 
immune system (Godfrey and Benson 2012). However, in the past 20 years, numerous 
works have also highlighted the fundamental contribution of NK cells to the control of 
malignant plasma cell clones and have started to investigate the mechanisms used by 
malignant MM plasma cells to escape NK cell recognition and killing (as described in 
Chapter 1.3).  
The work described in this chapter aims to further elucidate the biology 
underlying MM-induced inhibition of NK cells and to test the hypothesis that MM cells are 
able to specifically inhibit NK cell functions and that this inhibition is achieved through 
contact-dependent interactions between NK and MM cells.  
These hypotheses are supported by recent studies (reviewed in 1.3.2), which have 
showed the modulation of the receptor-ligand interactions that mediate NK cell 
surveillance and cytotoxicity. After findings obtained in various tumour setting, El-
Sherbiny and colleagues (El-Sherbiny et al. 2007) described, through 
immune-phenotypic analysis and the use of monoclonal antibodies during cytotoxic 
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assays, the requirement for DNAM-1, NKG2D and NKp46 in the NK cell-mediated killing 
of MM cells, using both healthy donor and patient samples. Subsequently, a reduced 
expression of NKG2D in MM patients was shown and the use of co-culture experiments 
suggested a casual link to cell-to-cell interactions, rather than to the release of soluble 
factors by MM cells (von Lilienfeld-Toal et al. 2010). This finding was then extended to 
other NK activating receptors and was confirmed also in other malignancies such as 
melanoma (Balsamo et al. 2009; Pietra et al. 2012), breast cancer (Mamessier et al. 
2011), cervical cancer (Garcia-Iglesias et al. 2009) and acute myeloid leukaemia 
(Sanchez et al. 2011). 
On the basis of these findings, an in vitro model was optimised in order to 
investigate MM-induced inhibition of NK cells. Transwell co-cultures were employed in 
order to elucidate the role of cytokines and other soluble factors versus contact-mediated 
interactions. Isolated NK cells were used to investigate the direct effect of MM cells on 
NK cell phenotype and cytolytic activity.  
The optimised in vitro system was able to reproduce the functional inhibition of 
NK cells and the decreased expression of NKG2D and NKp30, which are characteristic 
of NK cells isolated from MM patients (El-Sherbiny et al. 2007; von Lilienfeld-Toal et al. 
2010; Pietra et al. 2012). The data highlighted the importance of receptor-ligand 
interactions in MM-induced immunosuppression as, when cell-to-cell contact was 
prevented, NK cells retained the phenotypic characteristics and activity of NK cells 
isolated from healthy donors. Finally, the results from the co-culture of isolated NK cells 
with the MM cell line U266 showed that MM-induced impairment of NK cell function is 
directed specifically on NK cells and is not dependent on the presence of other 








3.1.2.1 MM cell lines inhibit NK cell activity 
To investigate whether MM cells could affect NK cell activity in vitro, PBMCs from 
healthy donors were cultured either with medium alone or in the presence of three 
different MM cell lines (KMS12PE, RPMI8226, and U266). NK cells were subsequently 
isolated and analysed for their cytolytic activity against the Natural-Killer sensitive cell 
line K562. 
As shown in Figure 3-1, preliminary assays showed that the cytolytic activity of 
NK cells isolated from PBMCs co-cultured with MM cell lines was variably impaired. 
The MM cell lines U266 and RPMI8226 caused a greater than two-fold reduction in the 
cytolytic activity of NK cells, from 54.9% 7-AAD+CFSE+ K562 cells to median of 25.2% 
and 25.45% 7-AAD+CFSE+ K562 cells respectively (P ≤ 0.01 and P ≤ 0.05). NK cytolytic 
activity after co-culture with KMS12PE cells did not show a statistical significance 












Figure 3-1 Impaired cytolytic activity of NK cells following co-culture with MM cell lines. 
PBMCs from three healthy donors were cultured for 24 hours either in complete medium alone or 
in the presence of three different MM cell lines (KMS12PE, RPMI8226, U266). Purified NK cells 
(as described in 2.4.1) were tested for cytolytic activity against K562 target cells at an effector to 
target ratio of 5 to 1. Results represent the percentage of lysis mediated by NK cells cultured in 
the indicated conditions. Data are represented as the median and range obtained from three 
independent experiments. * P ≤ 0.05; **, P ≤ 0.01 
 
Additionally, a concurrent significant downregulation in the expression of the 
activating receptor NKG2D on the stimulated NK cells was observed (Figure 3-2). In fact, 
when incubated with U266 and RPMI8226 MM cells, the percentage of NK cells 
expressing NKG2D decreased from a median of 73.7% when considering PBMCs 
cultured in complete medium to a median of 31.2% and 51.4% for PBMCs co-cultured 
with U266 and RPMI8226 cells respectively (P ≤ 0.01 and P ≤ 0.05). The reduction in 





Figure 3-2 Effect of MM cell lines on the expression of the activating NK receptor NKG2D. 
PBMCs from three healthy donors were cultured as described in Figure 3-1. NK cells were 
purified and the expression of NKG2D was analysed by flow cytometry. Data are represented as 
median and range obtained from three independent experiments. * P ≤ 0.05; **, P ≤ 0.01. 
 
The U266 cell line was chosen as reference cell line for subsequent assays on 
the basis of its ability to consistently induce a profound inhibition of NK cell activity and 
downregulation of NKG2D expression. The RPMI8226 cell line, despite producing similar 
results, was not considered due to its expression of CD56 and low expression of CD138 
(as described in 2.1.2.2), which make their depletion for subsequent assays problematic.  
The downregulation of NKG2D expression was used as a marker to determine 
the best incubation time to study the MM-induced inhibition of NK cells. As allo-reactions 
of T cells against U266 cells may occur during the co-culture, it was decided to screen 
time points up to 72 hours.  
Additionally, to test whether the impairment of NK cell activity was specific to MM 
cells, an experiment was designed to compare their inhibitory ability with that of plasma 
B cells from healthy donors. However, as the number of circulating plasma cells is very 
limited (Horst et al. 2002), it was decided to use allogeneic CD20+ B cells, which belong 




Figure 3-3 Effect of incubation time on the expression of NKG2D on NK cells following incubation 
with the MM cell line U266.  
PBMCs were cultured either in complete medium alone or in the presence of the MM cell line 
U266 or allogeneic CD20
+
 B cells. The expression of NKG2D on NK cells was analysed by flow 
cytometry at the time points indicated. Results represent the median with range obtained from two 
independent experiments. ***P ≤ 0.001. 
 
The results shown in Figure 3-3 suggest 24 hours and 48 hours as suitable time points to 
study MM-induced inhibition of NK cells. However, in order to be consistent with previous 
studies (von Lilienfeld-Toal et al. 2010), 24 hours was chosen for subsequent assays. 
Furthermore, this inhibition can be considered specific to the MM model as it was not 
observed when using B cells from healthy donors as a negative control.  
3.1.2.2 The MM-induced inhibition of NK cells activity is not caused by the 
exhaustion of NK cells 
NK cell impairment can be caused by various mechanisms, including extensive 
degranulation by NK cells in the presence of its target cells, which may heavily reduce 
their availability for subsequent lysis processes. Therefore, the ability of NK cells to 
release granzyme B while in co-culture with MM cells was measured. Granzyme B was 
chosen as it is considered to be a major effector of target-cell killing by NK cells 
(Rousalova and Krepela 2010). K562 cells, known to trigger the release of Granzyme B 
from NK cells, were used as a positive control. 
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As demonstrated in figure 3-4, after a 24 hour co-culture with the MM cell line U266, the 
levels of Granzyme B in the culture medium were still increasing, demonstrating that NK 
cells had not been depleted of Granzyme B.  
 
Figure 3-4 Granzyme B release from PBMCs cultured either in complete medium alone or in the 
presence of the MM cell line U266 or K562 cells.  
Supernatants were harvested at the indicated time points and tested for the presence of 
Granzyme B by ELISA assay. Results are a representative example (triplicates   standard 
deviation) of two independent experiments. 
  
Therefore, inhibition of NK cell cytolytic activity is unlikely to be due to exhaustion of 
Granzyme B levels. It is also worth noting that the MM U266 cell line is able to induce a 
higher although slightly delayed Granzyme B release compared to K562 cells. 
3.1.2.3 The MM cell line U266 is able to inhibit NK cell activity through contact-
dependent interactions 
Because a number of soluble and non-soluble factors are known to be involved in 
tumour-mediated suppressive effects on the immune system (Oppenheim et al. 2005; 
Kloss et al. 2008; von Lilienfeld-Toal et al. 2010), the mechanisms involved in 
MM-induced inhibition of NK cells was next examined.  
As shown in figure 3-5, prevention of contact-dependent interactions between 
U266 cell and NK cells through the use of a transwell system blocked U266 cell-induced 
inhibition of NK cell cytolytic activity. When contact between PBMCs and U266 was 
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prevented, the percentage of K562 killing was, in fact, restored from a median of 16.2% 
to 55.2% (P ≤ 0.001). 
 
Figure 3-5 Contact-dependent inhibition of NK cells following co-culture with U266 MM cell line. 
Healthy donor PBMCs were cultured either in complete medium alone or in the presence of the 
MM cell line U266 or allogeneic CD20
+
 B cells. In one condition, contact-dependent interactions 
were prevented through the use of a transwell system. Data are represented as the median of 
purified NK cell cytolytic activity obtained from four independent experiments. *** P ≤ 0.001. 
 
3.1.2.4 MM cell-induced impairment of NK cells is associated with decreased 
expression of the activating receptors NKG2D, NKp30 and DNAM-1 
The next aim was to examine whether the decrease in the cytolytic activity of NK 
cells was associated with changes in the extracellular expression of NK cell activating 
receptors other than NKG2D. 
Figure 3-6 shows that, after co-culture with the MM cell line U266, NK cells 
displayed a decrease in the expression of NKG2D, NKp30 and DNAM-1, when 
compared with those isolated from PBMCs incubated in complete medium alone or in the 
presence of allogeneic B cells. Specifically, the percentage of NK cells expressing 
NKG2D decreased from a median of 74.35% to 22.5% (p ≤ 0.001), whereas NKp30 was 
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down-regulated 1.6 fold (median of 77.85% compared to 47.15%; p ≤ 0.01) and DNAM-1 
expression went from a median of 85.85% to 60.7% (p ≤ 0.01). Interestingly, the intensity 
of NKG2D expression on NK cells was reduced from a mean fluorescence intensity 
(MFI) of 2746 to 1592.5 (p ≤ 0.05). Once again, this effect was specific to MM cells and 
required contact-dependent cell-to-cell interactions. 
 
Figure 3-6 Effect of MM cell line U266 on the expression of activating NK receptors. 
Healthy donor PBMCs were cultured as described in Figure 3-5. Subsequently, the expression of 
NCR on NK cells was analysed by flow cytometry. Data are represented as the median of the 








3.1.2.5 Primary NK cells isolated from MM patients display impaired cytolytic 
activity and an immune phenotype similar to healthy donor NK cells co-cultured 
with MM cell lines 
Next, the phenotype and functional activity of NK cells from MM patients were 
compared to those of healthy donor PBMCs prior and following in vitro co-culture with 
MM cells.  
As illustrated in figure 3-7 and confirming the existing literature (Matsuzaki et al. 
1985; Ogmundsdottir 1988; Jurisic et al. 2007), NK cells from MM patients displayed a 
suppressed cytolytic activity comparable to that observed when healthy donor PBMCs 
were co-cultured with the MM cell line U266. In fact, the percentage of K562 cells killing 
decreased from a median of 63.7% when considering healthy donor PBMCs, to 16.17% 
and 20.36% 7-AAD+CFSE+K562 when using healthy donor NK cells co-cultured with MM 
cells or MM patient NK cells respectively (p ≤ 0.01). 
 
Figure 3-7 Impairment of NK cell activity by MM in healthy donor and MM patients.  
Healthy donor PBMCs were cultured for 24 hours either in complete medium alone or in the 
presence of the MM cell line U266. PBMCs from MM patients were cultured for 24 hours in 
complete medium. Data are represented as the median and range of purified NK cell cytolytic 
activity obtained from four independent experiments. ** P ≤ 0.01. 
 
Additionally, our data showed that NK cells from MM patients, as well as healthy 
donor NK cells co-cultured with MM cells lines, are characterised by a reduced 
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expression of NKG2D and NKp30. The expression of NKG2D decreased from a median 
of 74.35% in healthy donors to 22.5% in the presence of U266 cells (P ≤ 0.001) and to 
36.3% in MM patients PBMCs (P ≤ 0.05). A similar effect was seen when considering 
NKG2D MFI, which was reduced from a median of 2374.5 in healthy donors to 1592.5 
and 2072 in in vitro inhibited PBMCs (P ≤ 0.05) and in MM patients PBMCs. The 
percentage of NK cells expressing NKp30 in HD was 77.85% but dropped to 47.15% (P 
≤ 0.01) after incubation with U266 cells and was measured around 59.05% (P ≤ 0.05) in 
MM patients PBMCs. Although NK cells from MM patients showed a trend towards a 
reduction in DNAM-1 expression, the results obtained did not reach statistical 
significance (Fig. 3-8). 
 
 
Figure 3-8 Effect of the MM cell line U266 on the expression of activating NK receptors.  
Cells were cultured as described in 3-7. Subsequently, the expression of NCR on NK cells was 
analysed by flow cytometry. Data are represented as the median of the expression of activating 





3.1.2.6 MM-induced impairment of NK cell activity does not depend on the 
presence of other peripheral blood mononuclear cells 
Tumour-induced immune suppression of NK cells may be due to direct effects on 
NK cells or, alternatively, may be mediated by other mononuclear cells present in the 
peripheral blood such as monocytes, macrophages and Treg (Kloss et al. 2008), which 
might have been activated by MM cells. To investigate this possibility, MM-induced 
inhibition on purified NK cells and on NK cells in the presence of other peripheral blood 
mononuclear cells was compared.  
Similar results were obtained with regard to NK cell activation (Fig. 3-9 and 3-10) 
and NKG2D expression (Fig. 3-11), whether NK cells were cultured with PBMCs or 
isolated.  
 
Figure 3-9 Effect of peripheral blood cell components on the MM cell-induced functional inhibition 
of NK cells.  
Healthy donor PBMCs or purified NK cells were cultured for 24 hours either in complete medium 
alone or in the presence of the MM cell line U266 or allogeneic CD20
+
 B cells. Bars represent the 





Figure 3-10 Effect of peripheral blood mononuclear cells on the MM cell-induced functional 
inhibition of NK cells.  
Cells were cultured as described in Figure 3-9. Bars represent median with range of the fold 
decrease of NK cell cytolytic activity, obtained from three independent experiments. Results were 




Figure 3-11 Effect of peripheral blood mononuclear cells on MM cell-induced downregulation of 
NKG2D.  
Cells were cultured as described in Figure 3-9. Subsequently, the expression of NKG2D on NK 
cells was analysed by flow cytometry. Bars represent the median with range of the fold decrease 
of the percentages (left) and MFI (right) of NKG2D
+
 NK cells obtained from three independent 
experiments. Results were normalised to those obtained from effector cells co-cultured alone.  
 
These data show that the presence or absence of peripheral blood components 
does not influence the MM-mediated impairment of NK cell function, thereby suggesting 






In vitro and in vivo cytolytic activity of NK cells against MM cells has been widely 
demonstrated (Godfrey and Benson 2012) (and reviewed in Chapter 1.4). However, NK 
cell-based immunotherapeutic strategies have resulted in limited clinical benefit, possibly 
reflecting the mechanisms that tumour cells have developed to avoid NK cell-mediated 
recognition and killing (Pietra et al. 2012).  
The results described in this chapter show that a 24 hour co-culture of healthy 
donor PBMCs with three human MM cell lines was able, with various efficiencies, to 
impair NK cell cytolytic activity against the NK cell-sensitive cell line K562 and to induce 
the downregulation of NKG2D expression on NK cells. This is in agreement with the 
work published by von Lilienfeld-Toal and colleagues (von Lilienfeld-Toal et al. 2010). In 
addition, this effect was also specific to MM cells, as the co-culture with allogeneic 
CD20+ B cells, which belong to the same lineage of MM cells, was not able to suppress 
NK cell function. Finally, the levels of Granzyme B release following co-culture with U266 
cells showed that the inhibition observed in NK cell cytolytic activity is not likely to be 
caused by NK cell exhaustion.  
Recent studies using different malignancy models have shown that the 
downregulation of important NK cell receptors can be induced by persistent contact with 
tumour cells (Balsamo et al. 2009; Garcia-Iglesias et al. 2009; von Lilienfeld-Toal et al. 
2010; Mamessier et al. 2011; Sanchez et al. 2011). Experiments performed using a 
transwell co-culture system demonstrated that both NK cell functional impairment and 
NKG2D downregulation, following co-culture with MM cells, require contact-dependent 
cell-to-cell interactions. In addition to the suppression of NKG2D levels, the present 
studies demonstrated the downregulation of other important activating receptors such as 
DNAM-1 and NKp30. These results are in agreement with previous works showing the 
expression of Natural Cytotoxic Receptor (NCR) ligands on MM cells (Soriani et al. 2009; 
von Lilienfeld-Toal et al. 2010) and are particularly relevant as DNAM-1 and NKG2D 
have been shown to be essential in the NK cell-mediated killing of MM (El-Sherbiny et al. 
2007) and in the control of other malignancies (Balsamo et al. 2009; Carrega et al. 2009; 
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Mamessier et al. 2011; Sanchez et al. 2011). The importance of the downregulation of 
NKp30 on NK cell activation has also been extensively demonstrated in different in vitro 
(Spaggiari et al. 2008; Balsamo et al. 2009; Carrega et al. 2009; Mamessier et al. 2011; 
Pietra et al. 2012) and in vivo (Garcia-Iglesias et al. 2009; Sanchez et al. 2011) systems.  
The potential relevance of these in vitro results was demonstrated by 
experiments showing that NK cells from MM patients display reduced cytolytic activity 
and lower cell surface expression of the activating receptors NKG2D and NKp30 similar 
to those characteristic of healthy donor NK cells co-cultured with MM cell lines. These 
results confirm findings published by von Lilienfeld-Toal and colleagues (von Lilienfeld-
Toal et al. 2010) in the context of MM, and by Sanchez-Correa (Sanchez et al. 2011) in 
the context of other tumours, and may be indicative of immune selective mechanisms 
developed and shared by cancer cells. No statistically significant difference was, 
however, observed in the downregulation of DNAM-1 expression NK cells from MM 
patients. This could depend on the levels of expression of DNAM-1 ligands on MM cells, 
as suggested by von Lilienfeld-Toal and colleagues in the context of NKG2D (von 
Lilienfeld-Toal et al. 2010). Further studies are needed to test this hypothesis. 
The role of peripheral blood components, such as monocytes, DCs and T cells, in 
the context of MM-induced impairment of NK cells was subsequently examined. The 
co-culture of isolated NK cells with MM cells resulted in a decrease of cytoloytic activity 
and NKG2D expression comparable to that recorded when the whole PBMCs population 
was used as target of the inhibition. It is therefore possible to conclude that NK cell 
inhibition, as observed after a 24 hour co-culture with MM cells, is directed specifically to 






3.2 The production of high lentivirus titers for genetic modification of 
MM cells  
3.2.1 Introduction 
In view of the immunosuppressive effect shown in Chapter 3.1, new strategies 
should be developed to prevent and rescue myeloma-induced suppression of immune 
responses.  
Autologous whole-cell vaccines may provide an attractive tool for the stimulation 
of immune responses against a wide range of tumour-associated antigens (Pratt et al. 
2007; Rosenblatt and Avigan 2008; Rosenblatt et al. 2011). The use of 
genetically-modified tumour cells has, in fact, been shown to induce immunological 
responses against MM and other malignancies in vitro and in vivo (as reviewed in 
1.4.2.4.2). In previous studies, MM cells have been successfully genetically-modified 
with adenoviral (Wen et al. 2001a; Ren et al. 2006) and retroviral (Tarte et al. 1999; Lu et 
al. 2007) vectors and shown to activate T cell stimulation. However, the problematic 
infection of primary tumour cells requires the use of high amounts of viral particles (Wen 
et al. 2001a; Ren et al. 2006) or the subsequent selection of the modified cells through 
the use of a selective marker and cell sorting (Tarte et al. 1999; Lu et al. 2007). This 
poses a challenge to the clinical application of these promising approaches as these long 
and stressful selection procedures may dramatically decrease the number of cells 
available for vaccination. Additionally, the use of great amounts of viral particles is 
restricted by the limits in the production of high titers of virus and by the potential 
cytotoxic effect of the lentiviral vector on target cells. 
Therefore, a self-inactivating lentiviral vector (Chan et al. 2005a) was tested for 
its ability to genetically-modify human MM cell lines to stably express high levels of the 
immunoregulatory factors CD80 and IL-2.  
An important feature contributing to this vector’s efficiency is the unique advantage of 
lentiviral vectors to stably transduce non-dividing cells such as haematopoietic cells 
(Dropulic 2011). Additionally, the vescicular stromatitis virus G glycoprotein envelope 
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(VSV-G) used in this construct allows the transduction of a wide variety of mammalian 
cells (Dull et al. 1998) and remains infective after ultracentrifugation. This facilitates the 
concentration of high titers of virus and, consequently, the transduction of target cells.  
Two similar vectors were used by Cignetti’s group (Cignetti et al. 2005) to successfully 
co-infect primary MM cells. However in this case the fusagene strategy, which enables 
the monocistronic expression of multiple proteins as a single precursor (Gaken et al. 
2000), was incorporated. This allows the transduction of target cells with multiple 
transgenes using only one lentiviral vector, providing a solution to the potential 
inefficiency and instability of gene transfer procedures and the problems linked to vector 
cytotoxicity (Gaken et al. 2000).   
The results herein described show that the use of high titers of ultracentrifuge-
concentrated virus, corresponding to a multiplicity of infection (MOI)1 of 20, in 
combination with the infection enhancer polybrene represents the best strategy to obtain 
viable, stable and highly genetically-modified MM cell lines and CD138+ MM primary 
cells.  
The genetically-modified MM cells were also sorted on the basis of their levels of 
CD80 expression to isolate a pure genetically-modified cell population for subsequent 
functional assays (see Chapter 3.3). These cells were also characterised in terms of 
viability and expression of CD28 and PD-L1, as their expression could potentially be 
affected by the transgene CD80 (Haile et al. 2011).  
The results obtained demonstrate that lentiviral transduction and cell sorting have a 
minor impact on cell viability and that the expression of CD80 does not change the levels 




                                                     
1
 The multiplicity of infection (MOI) is defined as the ratio of virus genomes to infection target (in 
this case, MM cells) during infection (Gonzàles-Jara et al, 2009). 
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3.2.2 Results 
3.2.2.1 Construction and production of lentiviral vectors 
 The HIV-based lentiviral vectors LV.CD80, LV.IL-2 and LV.IL-2/CD80 (described in 
2.2.1), were generated by transfection of the correspondent plasmid constructs in helper 
cells.  
 Before this step the plasmids, which were kindly provided by Dr. Chan, were 
expanded in Stbl3 E. coli cells and purified by Maxi Prep technique (as described in 
2.2.2.1.5). The obtained DNA was tested for purity and concentration (as described in 
2.2.2.1.3) and the identity of pLV.IL-2/CD80 was confirmed by diagnostic restriction 
digestion (as explained in 2.2.2.1.4 and illustrated in Figure 3-12). This last step was 
necessary as two versions of pLV.IL-2/CD80 were available in our department: one in 
which the enhancer WPRE was included to achieve high levels of transgene expression, 
and a second, which lacked this element in order to comply with the safety regulations 
required to be employed in phase I clinical studies. In order to compare the results with 
those previously obtained by Chan (Chan et al. 2005a), Ingram (Ingram et al. 2009) and 
Cignetti (Cignetti et al. 2005), the version that included WPRE was used in all the 
experiments. 
 The diagnostic restriction digestion carried out on pLV.IL-2/CD80 using the 
enzymes EcoRI and SalI, yielded four bands of expected sizes (7702bp, 992bp, 878bp, 
603bp; Figure 3-12). An additional band of 1870bp was also noted. This represents an 
expected product when EcoRI is the only restriction enzyme present, and may suggest a 
higher efficiency of cut by the enzyme EcoRI compared to SalI. Nevertheless, this 
restriction pattern confirmed the presence of the correct construct of the human 
IL-2/CD80 cDNA in the plasmid. 
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Figure 3-12 Gel electrophoresis pattern of plasmid restriction fragments.  
The products of the diagnostic restriction digestion (see 2.2.2.1.4) were resolved in agarose gel. 
The sizes of the fragments are indicated in kilobases (Kb).  
 
After validating the plasmids, they were used to produce lentiviral vectors (as 
described in 2.2.2.2) and their concentration, defined as titer, was determined by 
infecting K562 cells and calculating the percentage of genetically-modified cells after 96 
hours from the infection (Figure 3-13). 
 
Figure 3-13 Lentiviral vectors titration in human erythroleukemic cell line K562.  
K562 cells were seeded at 5x10
5
 cells/mL and infected as described in 2.2.2.3.2 using the 
indicated volumes of the appropriate vector. After 24 hours, cells were washed twice and cultured 
for 72 hours prior to analysis of CD80 expression by flow cytometry. All labelling was performed 
with matched isotype and unstained controls for each sample. * indicates results below the 
detection limit of the assay. Bars represent the mean and standard deviation from replicate wells.  
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Virus titers were calculated according to the following formula: 
      (
  
  
)                                               
                   
   
                           
Based on the flow cytometry results and the formula illustrated above, this protocol was 
able to concentrate 6.8x107 infective units (IU)/mL for LV.CD80 and 5.5x107 IU/mL for 
LV.IL-2/CD80 from a starting volume of 150 mL. Although no data is available on the titer 
before concentration, this result appears to be in line with that obtained by Chan and 
colleagues who, using the same technique, concentrated 5-7x108 IU of lentivirus vector 
starting from 450mL of 293T culture supernatant (Chan et al. 2005b). On this basis, it is 
possible to conclude that the vector concentration was successfully performed.   
For cells infected with LV.IL-2, alternative techniques can be used to determine 
virus titer: estimation of genome copy number by quantitative PCR, p24 ELISA, which 
detects HIV-1 p24 antigen, or intracellular staining for IL-2. However, as the ultimate aim 
was not to evaluate the percentage of infected cells, but to compare IL-2 release in the 
culture medium from uninfected, LV.IL-2/CD80 and LV.IL-2 K562 cells, culture 
supernatants were tested by IL-2 ELISA  (Figure 3-14). 
 
Figure 3-14 IL-2 production following infection with lentiviral vectors.  
K562 cells were seeded at 5x10
5
 cells/mL and infected as described in 2.2.2.3.2 using the 
indicated volumes of the appropriate vector. After 24 hours, cells were washed twice, seeded at 
1x10
6
 cells/mL and cultured for another 24 hours. Culture supernatants were then harvested and 
tested for IL-2 concentration by ELISA. * indicates results below the detection limit of the assay. 
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137 
The results showed that infection with LV.IL-2/CD80 or LV.IL-2 induced IL-2 secretion, 
with equivalent volumes of LV.IL-2 resulting in significantly higher levels of IL-2 
transgene expression: 13 ng/mL per 1x106 cells/24hours compared to 3 ng/mL per 1x106 
cells/24hours obtained from LV.IL2/CD80 infected cells.  
Taken together, these results confirmed the functional activity of the generated 
vectors and their ability to transduce target cells.  
3.2.2.2 Optimisation of a protocol to transduce the MM cell line U266 
The LVIL-2/CD80 vector was initially used to transduce U266 and K562 cells at a 
MOI of 5, representing a 5:1 ratio between the number of lentivirus infective units (IU) 
and the number of cells infected. For LV.IL-2 the same volume of lentiviral suspension 
calculated for LV.IL-2/CD80 was added. 
The histograms reported in figure 3-15 show that U266 cells naturally express low levels 
of CD80 (about 9% CD80+ cells). This was taken into account when calculating virus 
titers and the efficiency of cell transduction. Infection with LV.IL-2/CD80 vector was able 
to transduce the MM cell line U266, although K562 cells appeared to be more readily 
infectable (77.3% CD80+ K562 cells compared to 30.8% of CD80+ U266 cells).  
 
Figure 3-15 Comparison between K562 and U266 cell permissivity to LV.IL-2/CD80.  
K562 (left) and U266 cells (right) were infected as described in 2.2.2.3.2 and Figure 3-13 at an 
MOI of 5 and cultured for 96 hours prior to analysis of CD80 expression by flow cytometry. All 
labelling was performed with matched isotype and unstained controls. Flow cytometry plots are 
representative of three independent experiments. 
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The staining of genetically-modified cells with a viability dye revealed that the 
transduction protocol had a cytotoxic effect on U266 cells (Figure 3-16). This 
phenomenon was not observed when using K562 cells. In fact, following infection with 
LV.IL-2/CD80 the percentage of dead U266 cells increased of a factor of 3 to reach 
61.2% trypan blue positive cells, whereas the mean of percentage of dead K562 cells 
remained stable around 21.8%.  
 
Figure 3-16 Effect of lentiviral transduction on cell viability.  
K562 and U266 cells were infected with LV.IL-2/CD80 as described in 2.2.2.3.2 and Figure 3-13 
at an MOI of 5 and cultured for 96 hours prior to analysis of cell viability by trypan blue test. Bars 
show the mean and standard deviation from replicate wells. 
 
Subsequently, the cytotoxic effect of the virus, added alone or in combination with 
cationic polymers to the cell cultures, was investigated.  
As shown in Figure 3-17, the presence or absence of the lentiviral vector alone does not 
account for the increase in cell death, whereas the presence, type and concentration of 
the infection enhancer seem to have a major impact. Of all the combinations screened, a 
low concentration of polybrene (4 g/mL) was able to reduce the infection-related 
cytotoxicity while not impacting the transduction efficiency (Figures 3-17 and 3-19). 
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Figure 3-17 Impact of infection enhancers on U266 cell permissivity and viability.  
Human MM U266 cells were infected with LV.IL-2/CD80 as described in 2.2.2.3.2 and Figure 3-13 
at an MOI of 5 and in the presence of different concentration of infector enhancers and cultured 
for 96 hours prior to analysis of cell viability by flow cytometry (7-AAD staining). Bars show the 
mean and standard deviation from replicate wells. 
 
The decreased cytotoxic effect induced by this concentration of polybrene was 
also confirmed using the MTT assay (Figure 3-18) as an alternative method to detect cell 
viability and proliferation. 
 
Figure 3-18 Impact of infection enhancers on U266 cell proliferation and viability.  
Human MM U266 cells were infected with LV.IL-2/CD80 as described in 2.2.2.3.2 and 
Figure 3-13 at an MOI of 5 in the presence of polybrene (4 g/mL) or DEAE-dextran (2 g/mL) 
and cultured for 96 hours before evaluation of cell proliferation and viability by MTT assay. Bars 
represent the mean and standard deviation of 570nm absorbance readings, which positively 
correlates with cell viability, obtained from replicate wells. 
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However, despite the improvement in cell viability, it was not possible to reach levels of 
transduction similar to those of K562 cells (Figure 3-19). 
 
Figure 3-19 Effect of different infection enhancers on U266 cell transduction.  
U266 cells were infected as described in 2.2.2.3.2 and Figure 3-13 at an MOI of 5 in absence or 
presence of the infection enhancer polybrene (4g/mL) or DEAE-dextran (2g/mL). Cells were 
cultured for 96 hours prior to analysis of CD80 expression by flow cytometry. All labelling was 
performed with matched isotype and unstained controls for each sample. Bars represent the 
mean and standard deviation of the percentage of CD80
+
 cells obtained from replicate wells. 
 
Although Chan and colleagues (unpublished data) presented evidence 
supporting the hypothesis that even a small population of genetically-modified AML cells 
(as low as 20% of CD80+ cells) is able to trigger T cell expansion and activation, there 
were still concerns that, in this MM system, the levels of activation induced by 
genetically-modified cells may strongly vary according to the expression of the 
transgenes. On the basis of these considerations and with the aim to compare this whole 
cancer cell vaccine strategy with other strategies expressing high levels of transgenes 
(Tarte et al. 1999; Wen et al. 2001a; Cignetti et al. 2005; Ren et al. 2006; Lu et al. 2007) 
different methods to achieve higher and comparable transduction levels were 
investigated. 
As shown in figure 3-15, permissivity to viral infection appears to be cell-line 
specific and could depend, amongst other factors, on the virus-induced cytotoxicity and 
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the interaction between the virus and the cell surface (Chan et al. 2005b). Therefore, 
alternative strategies to maximise the interaction of viral particles with the target cell 
surface were evaluated.  
Biotin-labelled lentiviral vectors were generated through the use of the BL-15 
293T-derived human packaging cell line (Nesbeth et al. 2006) (see 2.2.2.2.2). The 
lentivirus concentration was then increased 56 fold (concentrating 56 mL of lentiviral 
suspension to 1 mL of lentiviral-PMP suspension) and virus titers were determined on 
the basis of the detection of CD80 on the surface of K562 and U266 cells (Figure 3-20) 
and by using the formula reported in paragraph 3.2.2.1.  
This analysis showed that the starting titer was concentrated 160 times for K652 (from 
1.75x106 IU/mL to 2.8x108 IU/mL) and 50 times for U266 (from 7.5x105 to 5x107IU/mL).  
Figure 3-20 also shows that the PMP-conjugated LV.IL-2/CD80 vector was able to 
effectively transduce the myeloma cell line U266, achieving 58% of transgene 
expression, when using 100 L of PMP-LV.IL-2/CD80 (corresponding to an MOI of 48) 
and 43% when using 10 L of PMP-LV.IL-2/CD80 (corresponding to an MOI of 4.8). The 
results obtained, whilst confirming the low permissivity of U266 cell, also suggest that 
PMP-conjugated virus may improve viral presentation to target cells. In fact, when using 
comparable MOI of virus (4.8 versus 5) the use of PMP-LV.IL2/CD80 lead to a higher 
percentage of genetically-modified cells when compared with LV.IL2/CD80 (43% 
compared to 25%).  
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Figure 3-20 Comparison between K562 and U266 cell permissivity to LV.IL-2/CD80-conjugated 
with PMP and evaluation of lentiviral concentration efficiency.  
K562 and U266 cells were seeded at 5x10
5
 cells/mL and incubated in the presence of 4 g/mL of 
polybrene and infected as described in 2.2.2.3.1 using the indicated volume of PMP-conjugated 
LV.IL-2/CD80 vector. Cells were then washed twice and cultured for 72 hours prior to analysis of 
CD80 expression by flow cytometry. All labelling was performed with matched isotype and 
unstained controls for each sample. * indicates results below the detection limit of the assay while 
n/a stands for “not available” as that particular condition was not performed. Bars represent the 
mean and standard deviation of the percentage of CD80
+
 cells obtained from replicate wells. 
 
 Interestingly, increasing volumes of PMP-conjugated virus did not result in a 
comparable increase in the percentage of transduced U266 as happened with K562 
(Figure 3-20). The high infection-related cytotoxicity to U266 cells (Figure 3-21) may 
explain this phenomenon and the reason why the percentage of genetically-modified 
U266 cells reaches a plateau at approximately 60% of CD80 positive cells. 
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Figure 3-21 Effect of lentiviral transduction with PMP-conjugated virus on cell viability.  
K562 and U266 human cells were infected as described in 2.2.2.3.1 and Figure 3-20. PMPs were 
then removed through the use of a magnet and the cells were washed twice and cultured for 72 
hours prior to analysis of cell viability by flow cytometry (7-AAD staining). n/a stands for “not 
available” as that particular condition was not performed. Bars represent the mean and standard 
deviation of the percentage of live (7-AAD
-
) cells obtained from replicate wells. 
 
Since the percentage of viable U266 cells infected with 10 L of PMP-conjugated 
lentivirus was similar to that of uninfected cells (81.6% 7-AAD- cells for U266 cells 
compared to 69.4% 7-AAD- cells for LV.IL-2/CD80 U266 cells), an alternative 
transduction strategy was tested with the aim of achieving a better transgene expression 
while using a smaller volume of PMP.  
The polycation polyethylenimine (PEI) was combined with PMP-conjugated 
LV.IL-2/CD80 to maximise virus interaction with target cells. Additionally, target cells 
were biotinilated to increase their interaction with PMP-lentiviral particles (Figure 3-22). 
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Figure 3-22 Biotinilation of U266 cells.  
U266 cells were resuspended in DPBS and incubated with 3mM of biotin for 30 minutes, washed 
twice and resuspended in fresh RPMI complete medium. The presence of biotin linked to the cell 
surface was detected through staining with FITC-labelled avidin. All labelling was performed with 
unstained controls for each sample.  Histograms are representative of replicate wells. 
 
Figure 3-22 confirms the successful biotinilation of U266 cells. The shift in the peak of 
non-biotinilated avidin-labelled U266 cells is likely to be due to the non-specific binding of 















Next, the advantage of this strategy was evaluated by calculating the fold 
increase in the percentage of genetically-modified U266 cells over untreated cells, 
following the described treatments (Figure 3-23). The results show that none of the 
strategies considered was able to increment the transduction efficiency.  
 
Figure 3-23 Effect of PEI treatment and target cells biotinilation on the percentage of genetically-
modified cells following infection with LV.IL-2/CD80.  
U266 and biotinilated U266 cells were resuspended at a concentration of 5x10
5
 cells/mL in RPMI 
complete medium. Cells then received an appropriate amount of PMP-conjugated LV.IL-2/CD80 
in the presence of 4g/mL of polybrene. When indicated, PEI was added to the cultures. Results 
are expressed as fold increase in the percentage of CD80
+
 cells over untreated (non-biotinilated 
cells infected with the correspondent amount of PMP-LV.IL-2/CD80 in the absence of PEI). Bars 
represent the mean obtained from replicate wells. 
 
Nevertheless, the results obtained using 100 L of PMP-lentiviral particles (which 
correspond to an MOI of 48; Figure 3-19) suggested that the use of higher MOI might 
increase the percentage of infected U266 cells. Considering the high cytotoxicity levels 
induced by the use of large quantities of lentiviral-PMP suspension, a new batch of 
lentiviral vector was generated and concentrated by ultracentrifugation. Specifically, a 
240 fold concentration was performed, obtaining 1mL of lentivirus suspension from a 
starting volume of culture supernatant of 240 mL. 
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The titration results showed that this protocol was able to produce functional 
viruses characterised by a titer of 3.06x108 IU/mL for LV.IL-2/CD80 and 3.39x108 IU/mL 
for LV.CD80, when K562 are used as target cells, and 5.58x107 IU/mL for 
LV.IL-2/CD80 and 1.47x108 IU/mL for LV.CD80, when U266 cells are used as target 
cells (Figure 3-24). 
 
Figure 3-24 Lentiviral vector titration in K562 and U266 cell lines.  
K562 (left) and U266 cells (right) were infected as described in 2.2.2.3.2 and Figure 3-13 using 
the indicated volume of vector resuspension. Cells were washed twice and cultured for 72 hours 
prior to analysis of CD80 expression by flow cytometry. All labelling was performed with matched 
isotype and unstained controls for each sample. * indicates results below the detection limit of the 
assay. Bars represent the mean and standard deviation from replicate wells.  
 
U266 cells were then infected with LV.IL-2/CD80 at an MOI of 20 in the presence 
of the infection enhancer polybrene. The histograms in Figure 3-25 show that this 
lentiviral vector successfully transduces U266 cells resulting in high levels of transgene 
expression.  
 
Figure 3-25 CD80 expression levels following infection with lentiviral vectors.  
U266 cells were infected as described in 2.2.2.3.2 and Figure 3-13 at an MOI of 20. Cells were 
cultured for 96 hours prior to analysis of CD80 expression by flow cytometry. All labelling was 
performed with matched isotype and unstained controls for each sample. The flow cytometry plots 
are representative of three replicate wells. 
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Although approximately 90% of U266 cells were successfully modified when 
using LV.CD80, it was possible to distinguish two different populations of genetically 
modified cells on the basis of CD80 expression levels (Figure 3-25).  
Follow up studies showed that the different expression levels of CD80 appear to be cell 
specific, as infected RPMI8226 cells (3-27) present a homogeneous and stable 
phenotype in terms of transgene expression. This phenomenon is also not transient, as 
CD80 levels and MFI were stable for 30 days in both the CD80high and CD80dim cell 
populations (Figure 3-26).  
 




 peaks over time.  
LV.CD80 U266 cells were analysed for CD80 expression by flow cytometry 96 hours post 
infection and 30 days post-infection. All labelling was performed with matched isotype and 




Figure 3-27 CD80 expression levels in RPMI8226 cells following infection with lentiviral vecors. 
RPMI8226 cells were infected as described in 2.2.2.3.2 and Figure 3-13 at an MOI of 20. Cells 
were cultured for 96 hours prior to analysis of CD80 expression by flow cytometry. All labelling 
was performed with matched isotype and unstained controls for each sample. The flow cytometry 
plots are representative of three replicate wells. 
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To exclude that the CD80 expression profile observed in modified U266 (Figure 
3-25 and 3-26) was caused by the use of a heterogeneous cell line, the U266 cells in use 
were phenotypically examined by flow cytometer. The obtained data suggest that the cell 
line in use is homogeneous in terms of granularity and size (Figure 3-28).  
Additionally, CD80high and CD80dim cells cannot be segregated on the basis of their FSC 
and SSC profiles, which could have indicated the presence of two different populations 
characterised by a different permissivity to lentiviral infection (Figure 3-28).  
 




 peaks.  
LV.CD80 U266 cells were analysed for CD80 expression (center) 96 hours post infection by flow 
cytometry using an anti-CD80PE antibody. The CD80
high
 (top right panel) and CD80
dim
 (bottom 
right panel) positive cells were then characterised for their FSC vs SSC profiles and compared 
with the FSC vs SSC profile of the whole cell population (left). Flow cytometry plots are 
representative of three replicate wells. 
 
Secondly, its identity and purity were confirmed by the homogeneous expression of 








3.2.2.3 Generation of genetically-modified U266 cells for functional assays 
As subsequent assays required the genetically-modified MM cell to express 
comparable levels of the transgene(s), transduced cells were sorted on the basis of their 
CD80 expression levels. When choosing whether to sort the high or the dim population 
within LV.CD80 U266 cells it was considered that, in order to be able to compare the 
stimulatory ability of CD80 alone or in the presence of IL-2, the percentage and MFI of 
LV.CD80 U266 cells should be equivalent or greater than those of LV.IL-2/CD80 cells. 
Consequently, the CD80high population was selected, as the MFI of the CD80dim 
population of LV.CD80 U266 was lower compared to that of CD80+ LV.IL-2/CD80 U266 
cells.  
The histograms shown in figure 3-29 demonstrate the successful isolation of CD80high 
positive cells. 
 
Figure 3-29 CD80 expression levels pre and post-fluorescence-activated cell sorting.  
Previously modified cells, as described in 2.2.2.3.2 and Figure 3-13, were expanded and CD80 
positive cells were isolated using fluorescence activated cell sorting. The histograms show the 
levels of CD80 expression in the pre and post-sorted cells. All labelling was performed with 




Sorted cells were subsequently tested for IL-2 production. Figure 3-30 shows that 
LV.IL-2 U266 cells produce considerably higher quantities of IL-2 when compared to 
LV.IL-2/CD80 U266 cells. 
 
Figure 3-30 IL-2 production following infection with lentiviral vectors.  
LV.IL-2 U266 and sorted LV.IL-2/CD80 and LV.CD80 U266 cells were seeded at 1x10E
6
 cells/mL 
and cultured for 24 hours. Culture supernatants were then harvested and tested for IL-2 
concentration by ELISA. * indicates results below the detection limit of the assay. Bars represent 
the mean and standard deviation from replicate wells. 
 
In order to be able to compare the stimulatory ability of LV.IL-2/CD80 with IL-2 
genetically-modified U266 cells, serial dilutions of LV.IL-2 infected cells with unmodified 
U266 cells were performed to achieve IL-2 levels in the culture supernatant comparable 
to those secreted by LV.IL-2/CD80 U266 cells.  
The results reported in figure 3-31 demonstrate that a 1:10 dilution of LV.IL-2 modified 
U266 cells with unmodified U266 cells is able to reduce IL-2 secretion to levels 
comparable to those of LV.IL-2/CD80 modified cells. 
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Figure 3-31 Comparison and normalisation of IL-2 secretion levels for LV.IL-2 and LV.IL-2/CD80 
modified U266 cells.  
Unmodified (UM), LV.CD80, LV.IL-2 and LV.IL2/CD80 U266 cells were seeded at 1x10
6
 cells/mL. 
U266 LV.IL-2 cells were also mixed with U266 UM cells at different ratios. After 24 hours 
supernatants were harvested and tested for IL-2 concentration by ELISA. (Left) IL-2 release by 
LV.IL-2 U266 cells mixed with UM U266 cells at the indicated ratios. (Right) IL-2 release by UM, 
LV.CD80, LV.IL-2/CD80, LV.IL-2 U266 cells and LV.IL-2 U266 mixed with U266 UM cells at 
different ratios. * indicates results below the detection limit of the instrument. Bars show the mean 
and standard deviation from three independent experiments. 
 
3.2.2.4 Characterisation of genetically-modified U266 cells 
Next, characteristics of uninfected and infected U266 MM cells were compared 
using a panel of different parameters. 
Firstly, the effect of lentiviral transduction on cell viability was evaluated through 7-AAD 
staining. Figure 3-32 shows that lentiviral transduction has a minor effect on cell viability. 
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Figure 3-32 Effect of lentiviral transduction on cell viability.  
Uninfected and infected U266 cells were cultured in complete RPMI medium and analysed for cell 
viability by 7-AAD staining. Bars represent the mean and standard deviation of three independent 
experiments. 
 
The stability of CD80 and IL-2 expression over time was also examined in 
genetically-modified U266 cells. Figure 3-33 shows a comparison between the CD80 
flow cytometry profiles of LV.IL-2/CD80 and LV.CD80 U266 cells at day 1 and day 30 
after cell sorting. Although there appears to be a decrease in the intensity of the CD80 
positive peak, the controls indicate that this decrease is an artifact most likely caused by 




Figure 3-33 Stability of CD80 expression levels after fluorescence-activated cell sorting of CD80 
positive cells.  
Previously modified cells (see Figure 3-25) were cultured and expanded in complete RPMI 
medium for one day or 30 days. Cells were then washed twice and stained with anti-CD80PE. All 
labelling was performed with matched isotype and unstained controls for each sample. The 
histograms are representative of three independent experiments. 
 
These studies demonstrated the stability of CD80 expression for at least 30 days of 
continuous in vitro culture both in LV.CD80 and LV.IL-2/CD80 modified U266 cells.  
Likewise, Figure 3-34 shows that the levels of IL-2 production from LV.IL-2 and 
LV.IL-2/CD80 modified cells remain stable the same period after transduction. Only a 
slight increase in IL-2 secretion was noted after 30 days (about 1.17 fold) for both 
LV.IL-2/CD80 and LV.IL-2 modified cells. 
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Figure 3-34 IL-2 production levels from uninfected or infected U266 cells on day 1 and day 30 
post-sorting.  
Previously modified cells (see Figure 3-25) were cultured and expanded in complete RPMI 
medium for one day or 30 days. On day 0 and on day 29 cells were seeded at 1x10
6
 cells/mL and 
cultured for 24 hours. Culture supernatant were then harvested and tested for IL-2 concentration 
by ELISA. * indicates results below the detection limit of the assay. Bars represent the mean and 
standard deviation from replicate wells. 
 
Based on the stability studies, modified and un-modified U266 cells were used for only 
up to 30 days of continuous culture. After this time, frozen aliquots of the original batch of 
cells were thawed and used for subsequent studies. 
In a similar melanoma transduced system, Haile and colleagues showed that 
CD80 expression blocks the cell surface expression of the immunosuppressive receptor 
PD-L1 (Haile et al. 2011). To test this hypothesis on our genetically-modified cells, 
PD-L1 upregulation on the surface of U266 cells following culture with IFN- was 
evaluated. Healthy donor PBMCs were used as a comparison.  
However, as shown in figure 3-35, the MM cell line U266 did not express a detectable 
level of PD-L1, even in the presence of IFN- levels able to trigger a profound up-
regulation of PD-L1, from 1.55% to 84% PDL-1+ cells, on healthy donor PBMCs. 




Figure 3-35 Evaluation of PD-L1 expression on U266 MM cell line and healthy donor PBMCs 
before and after treatment with IFN-.  
U266 cells and PBMCs were cultured in RPMI complete medium. When specified, 500 IU/mL of 
IFN- was added to the culture medium and cells were incubated for 24 hours. Cells were washed 
twice and analysed for PD-L1 expression by flow cytometry. All labelling was performed with 
matched isotype and unstained controls for each sample. * indicates results below the detection 
limit of the assay. The bars are representative of three independent experiments. 
 
Finally, the expression of CD28, one of the main receptors for CD80 (Azuma et 
al. 1992), on the surface of the infected and uninfected MM cells was evaluated. The 
results demonstrated that the transduction of U266 cells with CD80 does not modify 
either the proportion of CD28 positive cells or the intensity of CD28 expression (Figure 3-
36). 
 
Figure 3-36 CD28 expression levels on U266 cells following transduction with LV.CD80 or LV.IL-
2/CD80.  
Uninfected and previously modified U266 cells (see Figure 3-25) were cultured and expanded in 
complete medium for 72 hours. Cells were then washed twice and analysed for CD28 expression 
by flow cytometric analysis. All labelling was performed with matched isotype and unstained 




3.2.2.5 Genetic modification of CD138+ MM plasma cells 
Purified CD138+ MM cells from one MM patient (see paragraph 2.1.4) were 
infected with LV.IL-2/CD80 in order to show the ability of the vector to transduce primary 
MM cells as well as MM cell lines. This was achieved using a protocol previously 
optimised in Cignetti (Cignetti et al. 2005), which utilises an MOI comparable to that used 
in the previous assays with U266 cells. 
Analysis of CD80 expression confirmed that primary MM cells can be efficiently 
genetically-modified with the lentiviral vector LV.IL-2/CD80 (Figure 3-37).  
The use of the infection enhancer polybrene was able to increase the MFI of CD80+ cells 
of about 5 fold (from 2593 to 10019), which suggest the integration of multiple vectors 
into once single cell, in these conditions. 
 
Figure 3-37 CD80 expression levels following infection of MM primary cells with the lentiviral 
vector IL-2/CD80.  
CD138
+
 primary MM cells were infected as described in 2.2.2.3.2 at MOI of 20, under standard 
culture conditions. Cells were then washed twice and cultured for 72 hours prior to analysis of 
CD80 expression by flow cytometry. All labelling was performed with matched isotype and 











The transduction of primary CD138+ MM cells with LV.IL-2/CD80 resulted in the 
production of 1.5 ng/mL of IL-2 in 24 hours by 1x106 cells (Figure 3-38). 
 
Figure 3-38 IL-2 production by LV.IL-2/CD80 CD138
+
 primary MM cells following infection with 
lentiviral vectors.  
LV.IL-2/CD80 CD138
+
 cells were seeded at 1x10E
6
 cells/mL and cultured for 24hours. Culture 
supernatant were then harvested and tested for IL-2 concentration by ELISA. * indicates results 
below the detection limit of the assay. Bars represent the mean and standard deviation from 
replicate wells. 
  
Viability staining with 7-AAD showed that the lentiviral infection did not cause any 
significant change in MM cell viability (Figure 3-39).  
 
Figure 3-39 Effect of lentiviral transduction primary MM cells viability.  
CD138
+
 primary MM cells were infected as described in 2.2.2.3.2 at MOI of 20, under standard 
culture conditions. Cells were then washed twice and cultured for 72 hours prior to analysis of cell 
viability through 7-AAD staining by flow cytometry. Results represents the means and standard 
deviation obtained from three replicate wells. Abbreviations: w/o: without. 
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3.2.3 Discussion 
Gene therapy represents a promising strategy for the generation of tumour 
vaccines able to induce immune responses against cancer. However, this approach has 
been challenged by the relative inefficiency of gene transfer strategies in haematopoietic 
cells using retro and adenoviral vectors (Gaken et al. 2000), which require the 
application of multiple rounds of infection as well as the use of selective markers and cell 
sorting to obtain highly transduced cell populations.  
This chapter described the use of third-generation HIV-derived lentiviral vectors 
in conjunction with strategies to improve the transduction efficiency of target cells, with 
the aim of obtaining a population of MM cells expressing high levels of CD80 and/or IL-2.  
The first version of this vector, concentrated by ultracentrifugation and tested on 
K562 cells, was able to successfully induce high levels of transgene expression. 
However, when infecting the MM cell line U266, low levels of transduction and high 
levels of cytotoxicity were observed. This prompted the evaluation of different strategies 
for the concentration of the lentiviral vectors and the use of infection enhancers with the 
aim of increasing the percentage of genetically-modified cells without compromising cell 
viability. The results showed that the cationic polymer polybrene, already tested in (Lu et 
al. 2007) and (Wen et al. 2001a), has a minimal cytotoxic effect on U266 cells when 
compared to DEAE-dextran (Chan et al. 2005a) whilst allowing the transduction of up to 
25.5% cells. 
In order to compare the stimulatory ability of this vaccination strategy with others 
based on higher transgene expression levels and to avoid the possibility that the vaccine 
efficacy could be limited by the proportion of genetically-modified cells, alternative 
strategies to improve viral presentation to target cells were evaluated. The use of PMP-
conjugated lentiviral vectors allowed the concentration of high titers of virus 
concentration. Additionally, in agreement with previous studies (Chan et al. 2005b), the 
use of PMP increased target cell transduction by promoting additional vector-target 
interactions. In fact, the fold increase in vector concentration (160 fold, based on the 
titers calculated when using equivalent volumes of un-concentrated and PMP-
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concentrated vectors to infect K562 cells) cannot be completely explained by the fold 
reduction of the volume of lentivirus resuspension (56 fold), suggesting that this increase 
is substantially derived from improved viral presentation to target cells. This 
consideration could not be extended to U266 cells, as a 56 fold reduction in the volume 
of the lentiviral suspension translated to only a 50 fold increase in virus titer. However, 
when using equivalent MOI the PMP-concentrated lentiviral vector was able to transduce 
a higher percentage of cells compared to the vector concentrated by ultracentrifugation, 
thus supporting the hypothesis that PMP-conjugated vectors may allow additional vector-
target cell interactions. Yet, the use of this strategy was limited by the high levels of 
cytotoxicity associated with the use of high volumes of PMP.  
Therefore, with the aim of increasing cell transduction efficiency and, 
consequently, reducing the amount of PMP-conjugated vector necessary for the infection 
infection with PMP-conjugated lentiviral vectors was performed on biotinilated cells in the 
presence of PEI. Although this combination did not succeed in increasing the proportion 
of genetically-modified cells, the results obtained using increased MOI of PMP-
conjugated lentiviral vectors suggested that the use of high titers of virus might alleviate 
the problematic infection of U266 cells.  
The use of a lentiviral vector concentrated by ultracentrifugation at an MOI of 20 
was able to induce high levels of transgene expression in U266 cells (68% for 
LV.IL-2/CD80 and 90.3% for LV.CD80), which were stable for at least 30 days.  
However, when comparing these results with those described in previous studies (Hirst 
et al. 1997; Wendtner et al. 1997; Tarte et al. 1999; Wen et al. 2001a; Koya et al. 2002; 
Chan et al. 2005a; Cignetti et al. 2005; Ren et al. 2006) it is possible to note two main 
discrepancies. Firstly, while LV.CD80 is able to induce similar percentages of CD80+ 
cells in both U266 and K562 cells, LV.IL-2/CD80 seems to transduce a significantly lower 
percentage of U266 cells compared to K562 cells. This result, together with the 5 fold 
lower secretion of IL-2 obtained when comparing LV.IL-2/CD80 U266 with LV.IL-2 U266 
cells, may suggest a low efficiency of the furin endoprotease in these cells. The resulted 
un-cleaved protein IL-2/CD80 may then not be detected by the anti-CD80 antibody, while 
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IL-2 would not be secreted. Nevertheless, this phenomenon seems to be cell-line 
specific as the MM cell line RPMI8226 does not show any difference in transgene 
expression when infected with equivalent MOI of LV.IL-2/CD80 and LV.CD80.   
Secondly, although approximately 90% of U266 cells were successfully genetically-
modified when using LV.CD80, two different populations of genetically modified cells 
could be distinguished on the basis of CD80 expression levels. This phenomenon was 
again shown to be cell line specific, as LV.CD80 K562 and LV.CD80 RPMI8226 cells 
presented homogeneous phenotypes in terms of transgene expression. Additionally, it 
was demonstrated not to be the product of pseudo-transduction or unstable infection as 
the percentage and MFI of CD80high and CD80dim cells were stable for 30 days. The 
existence of a heterogeneous U266 cell line was investigated as a potential cause of this 
phenomenon, but results based on of cell granularity, size and phenotypic markers 
characterisation were not conclusive.  
However, despite its reduced permissivity to virus transduction and its unusual 
transgene expression profile, the U266 cell line was maintained as the target cell for 
virus transduction owing to its ability to inhibit NK cells (as demonstrated in chapter 3.1) 
and to its extracellular marker phenotype, which is essential for the design of the 
functional assay that are used to characterise the effectiveness of this vaccination 
strategy. 
In order to be able to compare the immunomodulatory potential of CD80 and 
IL-2 with other strategies, genetically-modified U266 cells were successfully sorted on 
the basis of CD80 expression. It is interesting to note that, even after sorting of CD80+ 
positive cells, IL-2 concentration secreted by LV.IL-2/CD80 U266 cells was still 
substantially lower than that produced by LV-IL2 U266 cells. However, these levels of 
secreted proteins could not be compared with the results obtained from other MM 
genetically-modified cancer vaccines (Wen et al. 2001a; Ren et al. 2006), as this was the 
first study using the fusagene strategy and neither of these works evaluated cytokine 
production from single-gene transduced cells. Nevertheless, these data are in 
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accordance with those reviewed in Chan (2005a), where they were similarly explained by 
the reduced rates of transcription, translation and processing of the fusion protein.  
Finally, in order to be able to evaluate the advantage of using the combination of CD80 
and IL-2, LV.IL-2 U266 cells were mixed with unmodified U266 cells to generate 
comparable amounts of IL-2 as LV.IL-2/CD80 U266 cells.  
Cell viability and phenotype of genetically-modified U266 cells were evaluated 
and compared with uninfected cells, in particular considering the expression of its ligands 
CD28 and PD-L1. The results show that infection with lentiviral vectors does not cause a 
significant change in cell viability (70% live cells for infected and sorted cells compared 
to 80% live cells for uninfected cells) or in the expression of these markers. The 
influence of the transduction of MM cells with CD80 and IL-2 on the expression and 
levels of extracellular markers involved in immunosuppression and cancer survival (such 
as CTLA-4, Fas and FasL and HLA-I) should be evaluated in future assays. 
Finally, following the same protocol used by Cignetti (Cignetti et al. 2005) it was 
possible to successfully infect CD138+ cells isolated from a MM patient. Due to the low 
number of cells available, infection was performed using LV.IL-2/CD80 only. The 
infection did not cause any major change in cell viability, supporting the feasibility of this 
strategy using frozen MM plasma cells. Modified cells were characterised by higher 
levels of CD80 expression compared with Cignetti’s and colleagues’ results 
(approximately 94% CD80 positive cells compared to approximately 74%) (Cignetti et al. 
2005) while secreting lower quantities of IL-2 compared to those obtained using a MM 
cell line, possibly owing to the low viability of CD138+ cells post-thawing. Future 
experiments will aim to confirm this result using more patient samples and will 
concentrate on strategies to increase CD138+ cells recovery post-thawing and to 
improve transgene expression in infected MM cells. Additionally, genetically modified 
cells will be evaluated for any change in the expression of immunomodulatory molecules 




3.3 Enhanced immune responses to stimulation with IL-2/CD80 
genetically-modified cells 
3.3.1 Introduction 
Having successfully optimised a protocol to genetically-modify myeloma cells, the 
next step was to test the ability of these genetically-modified cells to act as antigen-
presenting cells and to recover immune functions against MM. 
Several immunotherapeutic strategies have been tested in recent years for MM. 
Most of them focused, thanks to the continuous identification of tumour specific antigens 
and proteins, on targeting idiotype-specific immunity (as reviewed in 1.4.2.3.1) and on 
the employment of monoclonal antibodies (as described in 1.4.1.2). While these 
strategies have been shown in pre-clinical tests to induce anti-tumour effects, the 
induction of clinically significant response is rare (Danylesko et al. 2012) suggesting that 
their immunomodulatory ability, in the context of a suppressed immune system and 
inhibitory environment, is too weak to cause significant tumour destruction. 
The use of a whole cancer cell vaccine offers the potential for an effective presentation 
of a broader spectrum of tumour antigens, compared to peptide or protein-based 
vaccination. In order to counteract the inhibitory activity of myeloma cells, their antigen-
presenting ability can be boosted, by inducing the expression of immunomodulatory 
molecules through genetic manipulation (as outlined in 1.4.2.4.2). Wendtner and 
colleagues were the first to show the potential of CD80 gene transfer in activating MM 
cell lysis by allogeneic T and NK cells in vitro (Wendtner et al. 1997). On the basis of 
previous studies describing the in vivo rejection of CD80-expressing animal tumours 
(Geldhof et al. 1995; Yeh et al. 1995), they speculated that this effect could be partially 
due to NK cells. Tarte and colleagues subsequently confirmed and expanded these 
results by describing the activation of allogeneic CD8+ T-lymphocytes after co-culture 
with CD80-expressing MM cells (Tarte et al. 1999). Following these promising findings, 
several groups have addressed the potential of different cytokines and receptors to 
increase CD80-mediated stimulation. Wen and colleagues showed enhanced allogeneic 
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lympho-proliferation in response to co-culture of PBMCs with CD80/IL-12 modified U266 
cells (Wen et al. 2001a). Cignetti and Ren, instead, demonstrated the feasibility of 
lentiviral and retroviral transduction of primary MM cells and that the genetic transfer of 
CD80-CD40L or CD80-p53-GM-CSF could turn MM cells into efficient APCs, able to 
expand and activate autologous cytotoxic CD8+ cells (Cignetti et al. 2005; Ren et al. 
2006). Finally, in 2007, it was shown that a T cell repertoire recognising myeloma tumour 
antigens persisted in the peripheral blood of MM patients, and that it could be activated 
and amplified by autologous tumour cells transduced with CD80 and 4-1BBL (Lu et al. 
2007).  
Due to the controversial role of CD80 in NK cell activation (Geldhof et al. 1995; Galea-
Lauri et al. 1999; Wilson et al. 1999; Luque et al. 2000; Terrazzano et al. 2002), none of 
these studies evaluated NK cell expansion and function after stimulation of PBMCs with 
genetically modified myeloma cells. However, Ingram and colleagues (Ingram et al. 
2009) demonstrated NK cell expansion and activation following co-culture with 
IL-2/CD80 expressing AML cells.  
Given the importance of NK cells in MM control (as outlined in chapter 3.1) and 
their role in the onset of the adaptive immune response (reviewed in chapter 1.3), this 
chapter evaluates the immunostimulatory ability of MM cells that are genetically-modified 
to express CD80 and IL-2 (as described in chapter 3.2), to stimulate the expansion and 
activation of NK cells. Concurrently, T cell expansion and activation was also 
characterised. 
This immunomodulatory strategy presents several advantages compared with 
those previously experimented (reviewed in chapter 1.3). Firstly, the choice of two 
immunomodulatory molecules whose importance in the context of anti-tumour immune 
response has been widely established: the co-stimulatory molecule CD80, which is 
poorly expressed on MM cell surface and has been shown to be down-regulated on DCs 
from MM patients, and the pro-inflammatory cytokine IL-2, which is known for its 
important role in the activation of NK and CTL responses. The combination of these 
molecules has already been proven to be effective in stimulating T and NK cell functions 
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in the context of AML (Chan et al. 2005a; Ingram et al. 2009) and its safety and efficacy 
is currently being evaluated in a Phase I clinical trial.  
A second potential improvement relies on the choice of a self-inactivating lentiviral vector 
coupled with the fusagene strategy for the expression of CD80 and IL-2, whose 
advantages in terms of safety and efficient cell transduction have been discussed in 
Chapter 3.2. Finally, this study examines NK cell activation following stimulation with 
genetically-modified myeloma cells, in the context of the biological mechanisms involved 
in MM-induced inhibition of NK cells, as shown and described in chapter 3.1.  
The results reviewed in this chapter show that the allogeneic stimulation of 
healthy donor PBMCs with IL-2/CD80 expressing MM cells is able to expand NK and T 
cell numbers, and to induce a significant increase in the fraction of NK cells expressing 
the activating receptors NKp44, NKp30 and CD69, when compared to unmodified MM 
cells. This was also substantiated by data obtained when using PBMCs isolated from 
MM patients.  
Finally and more importantly for potential therapeutic application of this strategy, NK cells 
from healthy donors stimulated with IL-2/CD80 modified MM cells showed increased 
cytolytic activity against unmodified MM cells.  
As previous studies have shown the potential of IMiDs to activate the immune 
system and, in particular, NK cells (Schey et al. 2004; Harrison and Cook 2005), this 
immunomodulatory strategy was combined with IMiDs such as pomalidomide and 
lenalidomide in order to evaluate potential beneficial synergistic effects. In particular, 
given the indication that IMiDs co-stimulate T cells via the CD80-CD28 pathway (LeBlanc 
et al. 2004) experiments have been performed with the aim of comparing the ability of 
the IMiDs pomalidomide and lenalidomide to activate and restore NK cell functions 
against MM, either alone or in combination with the IL-2/CD80 whole cell vaccines. 
However, the protocol used in this study failed to show any synergistic effect between 





3.3.2.1 Set-up of optimal conditions for co-culture of PBMCs and genetically-
modified MM cells 
Genetically-modified MM cells (generated as described in chapter 3.2) were used 
to stimulate PBMCs isolated from healthy donors and MM patients. However, in order to 
comply with the biosafety standards, modified tumour cells were required to be gamma-
irradiated before administration. Therefore, the optimal amount of radiation needed to 
stop cell proliferation was evaluated. As shown in figure 3-40, 50grays (Gy) constitutes a 
sufficient dose of radiation to ensure the arrest of cell proliferation. 
 
Figure 3-40 LV.IL-2/CD80 U266 cells viability after irradiation. 
LV.IL-2/CD80 U266 cells were -irradiated using different doses of radiation (Gy). Seven days 
after irradiation, cells were harvested and a trypan-blue based cell viability count was performed. 
Bars represent the mean and standard deviation from replicate wells. 
 
Following irradiation, cells were also monitored for CD80 and IL-2 expression for 
7 days, which represents the maximal duration of co-culture tested in previous works 
(Wendtner et al. 1997; Wen et al. 2001a; Chan et al. 2005a; Cignetti et al. 2005; Ren et 
al. 2006; Lu et al. 2007; Ingram et al. 2009). The results illustrated in figure 3-41 
demonstrate that CD80 continues to be expressed until day 5. After this time, it is no 
longer possible to detect the presence of live cells.  
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Figure 3-41 CD80 expression of LV.-modified and uninfected cells after irradiation.  
Cells were -irradiated at 50 Gy. Cells were then harvested at the indicated time points and tested 
for CD80 expression (left) and viability (right) through the use of a live/dead (L/D) stain by flow 
cytometry. CD80 expression was calculated as percentage of live/dead stain negative U266 cells. 
* indicates results below the detection limit of the instrument. Bars represent the mean and 
standard deviation from replicate wells. 
 
Figure 3-42 shows that IL-2 continues to accumulate in the medium until the end of the 
timeframe tested. 
 
Figure 3-42 IL-2 production after irradiation by LV.IL-2/CD80 U266 cells.  
LV.IL-2/CD80 U266 cells were seeded at 5x10
5
 cells/mL and -irradiated at 50 Gy. Supernatants 
were harvested at the indicated time points and stored at -20°C. At the end of the co-culture 
period, supernatants were thawed and analysed for IL-2 concentration. * indicates results below 







































* * * * * * * *
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To identify the most suitable co-culture period and evaluate NK cell activation in 
response to stimulation with genetically-modified cells, a time-course experiment was 
performed. Healthy donor PBMCs were co-cultured with unmodified or LV.IL-2/CD80 
modified U266 cells, and NK cell numbers and the expression of activating receptors 
(Ingram et al. 2009) were evaluated at day 0, day 1, day 3, day 5 and day 7 by flow 
cytometry. The indicated time points were chosen on the basis of co-culture periods 
adopted in previous studies (Wen et al. 2001a; Chan et al. 2005a; Cignetti et al. 2005; 
Ren et al. 2006; Lu et al. 2007; Ingram et al. 2009).  
As shown in Figure 3-43, NK cell numbers and expression of activating receptors appear 
to reach a peak around day 5 and day 7. This support the hypothesis that day 7 is an 
appropriate time point to evaluate NK cell responses to stimulation by LV.IL-2/CD80 
U266 cells. Of all the receptors investigated, NKp44 and CD69 showed the greatest 
increase. Although CD69 expression plateaued at day 3, its levels remained higher than 
those observed after co-culture with un-modified cells on day 5 and 7 as well. When 
evaluating DNAM-1, NKG2D and NKp46, no differences were detected between the 
















Figure 3-43 Effect of in vitro co-culture of healthy donor PBMCs with unmodified U266 (right 
column) or IL-2/CD80 cells (left column) on NK cell numbers and phenotype. 
NK cell numbers and phenotype were determined as described in 2.5.3.1 and 2.5.3.2 on day 0 
and at different time points following co-culture with modified or unmodified U266 cells at a ratio of 





3.3.2.2 Allogeneic stimulation of healthy donor (HD) PBMCs with IL-2/CD80 
genetically-modified U266 MM cells allows the in vitro expansion and activation of 
NK cells 
In order to prove that genetically-modified MM cells are better stimulators 
compared with their unmodified counterparts, their ability to stimulate NK cell 
proliferation was investigated. Concurrently, it was also evaluated whether simultaneous 
expression of both transgenes (CD80 and IL-2) would result in increased stimulation 
compared to single transgene expression.  
As shown in figure 3-44, the presence of unmodified U266 cells in the co-culture 
alone induced the expansion of NK cells, which increased from 11.7 cells/L, when 
PBMCs were cultured in medium alone, to 44.8 cells/L. Interestingly, although the 
expression of these immunomodulatory molecules did further boost NK cell numbers to 
58.4 cells/L, in response to LV.CD80 U266 cells, and to 58.34 cells/L, in response to 
LV.IL-2 U266 cells, this increase reached statistical significance  only when comparing it 
with LV.IL-2/CD80 modified cells, which stimulated NK cell proliferation to 91.3 cells/L 
(P ≤ 0.01). 
 
Figure 3-44 Effect of in vitro co-culture of HD PBMCs with un-modified of modified U266 cells on 
NK cell numbers.  
Healthy donor PBMCs were co-cultured either with complete medium alone or in the presence of 
un-modified or LV.CD80, LV.IL-2 and LV.IL-2/CD80 U266 cells. The absolute number (left) and 
the stimulation index (right, calculated as increase over unstimulated PBMCs) of NK cells were 
determined after 7 day co-culture as described in 2.5.3.1. The plots illustrate the distribution and 
the grand median for each of the conditions performed on seven HD. ** P ≤ 0.01; ***, P ≤ 0.001.  
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The antibody panel developed in chapter 3.1 to describe MM-induced 
downregulation of NCRs was subsequently used to evaluate changes in the expression 
of these receptors on NK cells after co-culture with unmodified or genetically-modified 
U266 cells. However, following previous findings (Figure 3-43), NKp46 was not 
considered as a suitable marker. As for NKG2D, NKp30 and DNAM-1, the decision to 
include them in the panel was made based on their importance in MM cell recognition 
and killing by NK cells (Chapter 3.1). 
Figure 3-45 shows that, of all the receptors screened, only NKp44, CD69 and NKp30 
were upregulated in the presence of modified U266 cells. In particular, a statistically 
significant increase in the expression of NKp44 was detected when comparing the 
stimulatory ability of LV.IL-2/CD80 U266 cells, characterised by a median of 57.05% 
NKp44+ cells, with that of unmodified cells, which showed a median of 17.26% NKp44+ 
cells (P ≤ 0.01). The percentage of CD69 expressing NK cells increased from 21.65% in 
unstimulated PBMCs, to 78.8% and 83% CD69+ cells after stimulation with LV.IL-2 U266 
and LV.IL-2/CD80 U266 cells respectively (P ≤ 0.05). Similar increases were reported 
when testing NKp30 expression, from 25.2% in the presence of unmodified U266 to 
70.6% and 70.4% NKp30+ cells when PBMCs were co-cultured with LV.IL-2 U266 and 
LV.IL-2/CD80 U266 cells respectively (P ≤ 0.05). In agreement with preliminary data 














Figure 3-45 fect of in vitro co-culture of healthy donor (HD) PBMCs with un-modified or modified 
U266 cells on NCR expression.  
Healthy donor (HD) PBMCs were co-cultured as described in Figure 3-44. The percentage of 




 NK cells was examined after 7 days by flow cytometry. 
Plots illustrate the distribution and the grand median for each of the conditions performed on 
seven HD * P ≤ 0.05, ** P ≤ 0.01; ***, P ≤ 0.001 
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A parallel increase in NK cell cytolytic activity following co-culture with 
genetically-modified cells was next investigated. Unmodified U266 cells were chosen as 
target cells in this assay as one of the aims of this vaccination strategy is to increase NK 
cell cytotoxicity against unmodified cells. The results show that co-cultures with LV.IL-2 
and LV.IL-2/CD80 U266 cells were able to significantly increase NK cytolytic activity 
towards unmodified U266 cells from a median of 31.8% 7-AAD+ U266 cells in the 
presence of unmodified stimulator U266 cells to a median of 49.7% 7-AAD+ U266 cells in 
the presence of LV.IL-2 U266 (P ≤ 0.05) and 54.26% 7-AAD+ U266 cells in the presence 
of LV.IL-2/CD80 (P ≤ 0.01). Although it was not possible to show a statistically significant 
difference between LV.IL-2 and LV.IL-2/CD80 modified cells, the trends reported in 
Figure 3-46 suggest that the combination of these factors provide a better stimulation 
compared to IL-2 alone. 
 
Figure 3-46 Effect of in vitro co-culture of healthy donor (HD) PBMCs with un-modified of modified 
U266 cells on NK cell cytolytic activity towards unmodified U266.  
Healthy donor PBMCs were co-cultured as described in Figure 3-44. After 7 days NK cells were 
purified and tested for cytolytic activity against U266 target cells at an effector to target ratio of 5 
to 1. Results represent the distribution and the grand median for each of the conditions 




3.3.2.3 Allogeneic stimulation of HD PBMCs with IL-2/CD80 genetically-modified 
U266 MM cells induces the in vitro expansion and activation of T cells 
Although not the primary aim of this investigation, the stimulatory ability of 
genetically-modified cells on T cells was evaluated following allogeneic co-culture. This 
interest arose from the important role of CD80 in T cell stimulation (Allison, 1994), from 
the evidence of T cell expansion and activation reported in similar studies (Tarte et al. 
1999; Wen et al. 2001a; Chan et al. 2005a; Cignetti et al. 2005; Ren et al. 2006; Lu et al. 
2007) and from the need to assess the potential role and influence of this activation on 
the NK cell phenotype and activity following co-culture with genetically-modified MM 
cells. After co-culture with LV.CD80 and LV.IL-2/CD80 U266 cells, the number of CD3+ T 
cells increased from a median of 61 cells/L to 153 and 119 respectively (P ≤ 0.05). This 
corresponds to stimulation indices of 1.9 and 2.3 when compared to untreated PBMCs. 
The presence of IL-2 alone, instead, did not seem to contribute to T cell expansion 
(Figure 3-47). 
 
Figure 3-47 Effect of in vitro co-culture of healthy donor (HD) PBMCs with un-modified of modified 
U266 cells on T cell numbers.  
Healthy donor PBMCs were co-cultured either as described in Figure 3-44. The absolute number 







 cells, were determined after 7 days. Plots illustrate the distribution 





 T cells were next evaluated for the expression of the activation markers HLA-DR 
and CD69 (Figure 3-48), chosen as late and early activation markers for T cells (Speiser 
et al. 2001; Chan et al. 2005a). No statistically significant difference between the 
different treatments was measured when considering CD69 expression, whereas the 
stimulation with LV.CD80 and LV.IL-2/CD80 U266 cells induced a significant up-
regulation of HLA-DR. The median of HLA-DR+CD8+ T cells, in fact, rose from 30.7% in 
the presence of unmodified cells, to 52.5% and 47.9% when PBMCs were stimulated 
with LV.CD80 and LV.IL-2/CD80 U266 cells respectively (P ≤ 0.05).  
 
Figure 3-48 Effect of in vitro co-culture of healthy donor (HD) PBMCs with un-modified or modified 
U266 cells on CD8
+
 T cells HLA-DR and CD69 expression.  
Healthy donor PBMCs were co-cultured as described in Figure 3-44. The percentage of CD69 
and HLA-DR positive CD8
+
 T cells was examined after 7 days by flow cytometry. Bars illustrate 










3.3.2.4 IMiDs (Pomalidomide, Lenalidomide) fails to show synergy with IL-2/CD80 
genetically-modified U266 MM cells for the induction of NK cell cytolytic activity in 
Healthy Donors 
IMiDs such as pomalidomide and lenalidomide have been subsequently tested 
for their ability to activate and restore NK cell functions against MM, either alone or in 
combination with the IL-2/CD80 whole cell vaccines. 
However, experiments aiming to identify the best dose of IMiDs, in terms of 
concentration and frequency of treatment, failed to confirm the results previously 
obtained in the literature (Figure 3-49 and 3-50). 
 
Figure 3-49 Effect of in vitro co-culture of healthy donor PBMCs with IMiDs on NK cell cytolytic 
activity against U266 cells.  
NK cell activity after stimulation with IMiDs (B) was compared with results obtained by Hayashi 
(Hayashi et al. 2005) (A). Healthy donor PBMCs were co-cultured with either medium alone or in 
the presence of IMiDs (1M). After 5 days PBMCs were tested for cytolytic activity against U266 
(B) target cells at different effector to target ratios. Graph B represent the median and range 










Figure 3-50 Effect of in vitro co-culture of healthy donor PBMCs with IMiDs on NK cell cytolytic 
activity against K562 and U266 cells.  
NK cell activity after stimulation with IMiDs (C-D) was compared with results obtained by Hsu 
(Hsu et al. 2011) (A-B). Healthy donor PBMCs were co-cultured with either medium alone or in 
the presence of IMiDs (10M). After 3 days PBMCs were tested for cytolytic activity against K562 
(C) or U266 (D) target cells at different effector to target ratios. Results represent the median and 
range obtained from three healthy donors. 
 
In subsequent assay, it was possible to observe a trend towards an increase in 
NK cell cytolytic activity when treating healthy donor PBMCs with pomalidomide (3M) 
for 3 days (Figure 3-51), but this increase did not reach statistical significance. 
 
Figure 3-51 Effect of in vitro co-culture of healthy donor PBMCs with IMiDs on NK cell cytolytic 
activity against U266 MM cells.  
Healthy donor PBMCs were co-cultured with either medium alone or in the presence of IMiDs 
(3M). After 3 days PBMCs were tested for cytolytic activity against U266 target cells at an 
effector to target ratio of 50:1. Results represent the median obtained from five healthy donors. 
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In a pilot experiment, this drug concentration was subsequently administered in 
conjunction with genetically-modified U266 cells but failed to show synergy with CD80/IL-
2 expressing myeloma cells for the induction of NK cell cytolytic activity (Figure 3-52). 
 
Figure 3-52 Effect of in vitro co-culture of healthy donor PBMCs with un-modified or modified 
U266 cells on NK cell cytolytic activity against unmodified U266.  
Healthy donor PBMCs were co-cultured with either medium alone or in the presence of un-
modified or LV.CD80, LV. IL-2 and LV.IL-2/CD80 U266 cells. On day 2, IMiDs or DMSO were 
added at a final concentration of 5M. After 7 days NK cells were purified and tested for cytolytic 
activity against U266 target cells at an effector to target ration of 5 to 1. Results represent the 












3.3.2.5 Allogeneic stimulation of MM patient PBMCs with IL-2/CD80 genetically-
modified U266 MM cells allows the in vitro expansion of NK cells  
The stimulatory ability of genetically-modified U266 cells on PBMCs from MM 
patients was next investigated. De novo patient samples were used to minimise the 
introduction of confounding variables such as the treatment with immunomodulatory 
drugs, which may interfere with this immunostimulatory strategy. A total of 9 patients 
were considered but, due to the limited numbers of available PBMCs, only 4 sets of 
cultures were stimulated with unmodified and genetically-modified cells. Patient 
characteristics are summarised in Table 2-6. 
Due to patient-to-patient variability in the number of NK cells retrieved after a 7 
days co-culture in complete medium alone, the results are reported as fold increase over 
unstimulated PBMCs, defined as stimulation index. The data show that co-culture of MM 
patient PBMCs with LV.IL-2/CD80 U266 cells induced a statistically significant increase 
in the stimulation index of NK cell, which rose from 484.7 in the presence of unmodified 
U266 cells to 1147 when PBMCs were co-cultured with LV.IL-2/CD80 U266 cells (P ≤ 




Figure 3-53 Effect of in vitro co-culture of MM patient PBMCs with un-modified of modified U266 
cells on NK cell numbers.  
PBMCs from MM patients were co-cultured in the presence of un-modified or LV.CD80, LV. IL-2 
and LV.IL-2/CD80 U266 cells for 7 days. The stimulation index of NK cell numbers was 
determined after 7 days. Plots illustrate the distribution and the grand median for each of the 
conditions performed on four MM patient samples. * P ≤ 0.05. 
 
The close proximity of the stimulation indices obtained following co-culture with LV.IL-2 
and LV.IL-2/CD80 U266 cells suggests the important role of IL-2 in NK cell proliferation. 
The importance of CD80 remains unclear, although it is possible to note an increase in 
NK cell numbers when MM patient PBMCs were stimulated with LV.CD80 U266 cells, 
which lead to a stimulation index of 705 compared the 484.7 obtained in the presence of 
unmodified U266 cells. This effect, although diminished, is still visible when comparing 
the fold increase in the presence of LV.IL-2 (1085.9) and LV.IL-2/CD80 U266 cells 
(1147).  
NK cells were also tested for the upregulation of NCR in response to stimulation 
with unmodified and genetically modified U266 cells. As the number of NK cells retrieved 
after a 7 day co-culture with medium alone did not provide enough events to perform a 
flow cytometry phenotypic analysis, this condition was not considered in the context of 
this assay.  
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The limited number of patients tested did not provide enough data to evaluate the 
significance of these differences (Figure 3-54). However, it is possible to observe a trend 
towards an increase in the percentage of NKp30 expressing NK cells, which increased 
from a median of 39.9% in the presence of unmodified cells to 88.6% when PBMCs were 
co-cultured with LV.IL-2/CD80 U266 cells. Similar increases were reported when testing 
NKp44 expression, from 63.5% in the presence of unmodified U266 to 87.5% NKp44+ 
cells when LV.IL-2/CD80 U266 cells were used as stimulator cells.  
NK cells were also tested for the mean fluorescent intensity (MFI) of these 
receptors, to determine whether genetically-modified cells might have an effect on their 















Figure 3-54 Effect of in vitro co-culture of MM patient PBMCs with un-modified or modified U266 
cells on NCR expression.  
PBMCs from MM patients were cultured as described in Figure 3-53. The expression of NCRs 
was examined after 7 days by flow cytometry. Plots illustrate the distribution and the grand 
median for each of the conditions performed on four MM patient samples 
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Figure 3-55 Effect of in vitro co-culture of MM patient PBMCs with un-modified or modified U266 
cells on NCR expression levels.  
PBMCs from MM patients were cultured as described in Figure 3-53. The mean fluorescence 
intensity (MFI) for each NCR was examined after 7 days by flow cytometry. Plots illustrate the 
distribution and the grand median for each of the conditions performed on four MM patient 
samples. 
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Finally, the cytolytic activity of stimulated NK cells was tested against unmodified 
U266 cells (Figure 3-56). 
 
Figure 3-56 Effect of in vitro co-culture of MM patient PBMCs with un-modified of modified U266 
cells on NK cell cytolytic activity towards unmodified U266 cells.  
PBMCs from MM patients were cultured as described in Figure 3-53. After 7 days NK cells were 
purified and tested for their cytolytic activity against U266 target cells at an effector to target ration 
of 5 to 1. Results represent the distribution and the grand median for each of the conditions 
performed on four MM patient samples.  
 
The results show a high cytolytic activity of NK cells after co-culture with unmodified 
U266 (42.9% of 7-AAD+U266 cells), which was not significantly increased by the co-
culture of MM patient PBMCs with genetically-modified U266.  
An alternative in vitro assay was therefore employed as an additional method to 
investigate NK cell activation. This was based on the evaluation of NK cell degranulation 
through the measurement of CD107a expression on the cell surface and IFN- secretion 
levels. However, as shown in Figure 3-57, the results obtained were consistent with 
those observed using the 7-AAD based-killing assay, as there was no indication of a 
statistically significant difference either in the percentage or absolute levels of expression 








Figure 3-57 Effect of in vitro co-culture of MM patient PBMCs with un-modified or modified U266 
cells on NK cell degranulation and IFN- secretion levels.  
PBMCs isolated from MM patients were co-cultured either with medium alone or in the presence 
of un-modified or LV.CD80, LV. IL-2 and LV.IL-2/CD80 U266 cells. After 7 days PBMCs were 
harvested and incubated with X-VIVO 15 complete medium alone or U266 cells at an effector to 
target ratio of 1 to 1. CD107a and IFN- expressions were examined by flow cytometry as 







3.3.2.6 Allogeneic stimulation of MM patient PBMCs with IL-2/CD80 genetically-
modified U266 MM cells allows the in vitro expansion of T cells 
The effect of the co-culture of MM patient PBMCs with genetically-modified cells 
on T cell populations was next investigated. The co-culture of MM patient PBMCs with 
genetically-modified U266 cells induced the proliferation of CD3+ and further analysis 
indicated this was due mainly to the CD8+CD3+ cell compartment (Figure 3-58). 
However, statistical significance was only reached when comparing PBMCs co-cultured 
in the presence of unmodified or LV.IL-2/CD80 U266 cells (P ≤ 0.05). No statistically 
significant difference was observed when comparing CD4+ T cell numbers following the 
different stimulation strategies. 
 
Figure 3-58 Effect of in vitro co-culture of MM patient PBMCs with un-modified of modified U266 
cells on T cell numbers.  
PBMCs isolated from MM patients were cultured with medium alone (unstimulated PBMCs) or in 
the presence of un-modified or LV.CD80, LV. IL-2 and LV.IL-2/CD80 U266 cells. Stimulation 















 T cells) and CD4
+




 T cells) were determined by flow 
cytometry on day 7 following in vitro culture as indicated. Plots illustrate the distribution and the 
grand median for each of the conditions performed on four MM patients. * P ≤ 0.05. 
 
When investigating the expression of activating receptors on CD8
+
T cells, CD154 
was added to the antibody panel as it is a marker of late T cell activation (Mackey et al. 
1998). The results reported in Figure 3-59 show a trend towards the up-regulation of 
HLA-DR and CD69 expression when MM patient PBMCs are co-cultured in the presence 
of LV.CD80 and LV.IL-2/CD80 modified U266 cells. Although it is possible to see a trend 
toward an increase in CD154 expression levels (MFI) following stimulation with 
LV.IL-2/CD80 U266 cells, this did not reach significant statistical difference. 
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Figure 3-59 Effect of in vitro co-culture of MM patient PBMCs with un-modified of modified U266 
cells on CD8
+
 T cell receptor expression.  
PBMCs from MM patients were cultured as described in Figure 3-58. The percentage of positive 
cells and expression levels (MFI) for each receptor were examined at day 7 by flow cytometry. 




 Vaccination of MM patients with newly identified multiple MM antigens represents 
an interesting immunotherapeutic strategy, but the number of “universal” MM antigens 
presently known is limited (Pellat-Deceunynck, 2003). Vaccination with whole tumour 
cells might then represents an attractive alternative. The use of malignant cells as 
antigen presenting cells has, in fact, the potential to allow the effective presentation of 
both shared and unique tumour antigens.  
 After investigating the molecular mechanisms underlying MM-induced NK cells 
inhibition and highlighting a link between downregulation of Natural Cytotoxicity 
Receptors (NCR) and suppression of NK cell cytolytic activity (Chapter 3.1), a MM cell 
line was successfully genetically-modified with a lentiviral vector to express IL-2 and 
CD80, with the aim of stimulating NK cell function against MM (Chapter 3.2).  
 The results illustrated in this chapter demonstrate that NK cell activity can be 
enhanced following allogeneic stimulation with genetically-modified MM cells.  
Specifically, a 7 day allogeneic co-culture of healthy donor PBMCs with LV.IL-2/CD80 
U266 cells resulted in a statistically significant expansion of NK cells, compared to 
unmodified U266 cells. The data shown in this chapter also suggest a role for CD80 in 
the increase in NK cell numbers, as noted when comparing LV.IL-2 and LV.IL-2/CD80 
U266 cells as stimulators. Nevertheless, the difference did not reach statistical 
significance, possibly reflecting the predominant role of IL-2 in NK cell activation. A larger 
cohort of samples is needed to provide additional data to support or reject this 
hypothesis.  
The expanded NK cells also demonstrated an activated phenotype, as they 
expressed increased levels of the activating receptors NKp44, NKp30 and CD69. Some 
of the trends observed in the kinetics of NCR up-regulation suggest the possibility to 
retrieve higher levels of proliferation and activation after day 7. This would be in 
agreement with the results obtained by Chan (Chan et al. 2005a), Ren (Ren et al. 2006), 
(Tarte et al. 1999), Wen (Wen et al. 2001a), Cignetti (Cignetti et al. 2005) and Lu (Lu et 
al. 2007), who demonstrated the activation of T cells after multiple rounds of stimulation. 
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However, considering that NK cells, by their definition, can efficiently be activated without 
prior stimulation and on the basis of the results obtained in a similar AML setting after 
one round of stimulation (Ingram et al. 2009), it was decided to adopt 7 days as the 
incubation period for subsequent assays. It was also encouraging to observe that the 
fold increase in NCR expression is similar to that seen by Ingram (Ingram et al. 2009) 
when using IL-2/CD80-modified AML cells. Additionally, in this MM setting, the 
up-regulation in the expression of NKp44 and NKp30 was observed not only when 
comparing un-stimulated and LV.IL2/CD80 stimulated PBMCs, as described by Ingram 
(Ingram et al. 2009), but also when comparing modified and unmodified U266 cells. This 
observation supports the role of CD80 and IL-2 stimulation in NK cell activation. 
The downregulation of NKp30 following co-culture with unmodified U266 cells confirms 
the data presented in Chapter 3.1. The ability of genetically-modified U266 cells to 
recover its expression to levels comparable with healthy donor PBMCs is therefore 
important, particularly in the light of the role of NKp30 in MM-induced inhibition of NK 
cells (Chapter 3.1). However, no statistically significant difference was measured 
between the stimulatory ability of LV.IL-2 and LV.IL-2/CD80 U266 cells suggesting, once 
again, a predominant role for IL-2 in NK cell activation. A similar increase in the 
expression of CD69 was induced by co-culture of PBMCs with LV.IL-2 and LV.IL-2/CD80 
U266 cells, which is in agreement with the role of IL-2 in the up-regulation of this 
receptor (Borrego et al. 1999). Finally, it was not possible to demonstrate any change in 
DNAM-1 and NKG2D expression following co-culture with genetically-modified or 
unmodified cells. This could be a result of the kinetics of up-regulation of these 
receptors, suggesting that their levels may plateau after a 3 day co-culture or an impact 
of allogeneic reactions on their expression.  
LV.IL-2/CD80 genetically modified U266 cells showed the ability to activate MM 
patients NK cell expansion. However, when evaluating the up-regulation of NCRs on the 
expanded NK cells, the data did not reach statistical significance. Further experiments 
using a larger cohort of patients are needed to confirm these observations.  
 Importantly in the light of a possible clinical application of this strategy, the 
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stimulation with LV.IL-2/CD80 and LV.IL-2 modified U266 cells appears to confer the 
greatest augmentation of cytolytic activity against unmodified U266 cells. This result 
confirms the data published by Ingram (Ingram et al. 2009) in an AML setting but, in 
addition, show an increase in NK cell cytolytic activity following co-culture with LV.CD80 
U266 cells. The increase of cytolytic activity due to the presence of CD80 is also 
supported by the trend towards an increase in the levels of U266 cell death induced by 
PBMCs following stimulation with LV.IL-2/CD80 compared to LV.IL-2 U266 cells. 
However, this difference did not reach statistical significance and further studies are 
needed to establish the precise role and possible interplay of CD80 and IL-2 in NK cell 
activation.  
 No significant change was observed in NK cell activity following co-culture of MM 
patient PBMCs with unmodified or genetically-modified U266 cells. However, in contrast 
to the results reported by Ingram (Ingram et al. 2009), high levels of background in NK 
cell activation were observed after 7 day co-culture with unmodified MM cells. This result 
was not expected considering the functional inhibition which characterises NK cells from 
MM patients (described in Chapter 3.1), but might be a consequence of a strong 
response to the allogeneic co-culture, or of the need for a shorter or longer co-culture 
period. Further studies should be performed to clarify the causes underlying this 
phenomenon.  
 As CD80 is mainly known as a co-stimulatory molecule for T cells, T cell expansion 
and phenotype following allogeneic co-culture were also evaluated. The aim was to 
determine whether the observed NK cell activation could be the consequential to T cell 
stimulation by the vaccine. The results showed that, as expected, stimulation of healthy 
donor PBMCs with CD80-expressing MM cells induced the expansion of CD3+ T cells. 
However, published data have reported different test methods and variable stimulator to 
responder ratios, making it difficult to compare stimulation indexes. Nevertheless, the 
results from co-cultures of MM patient PBMCs with LV.IL-2/CD80 U266 cells showed a 
trend towards an increase in CD3+ cell numbers, which was mostly due to the 
proliferation in the CD8 compartment. This is in line with findings obtained by Tarte 
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(Tarte et al. 1999) and Chan (Chan et al. 2005a) and suggests an important role for 
CD80 in T cell expansion and activation, as previously shown using CD80 expressing 
AML (Chan et al. 2005a) and MM cells (Tarte et al. 1999; Wen et al. 2001a; Cignetti et 
al. 2005; Ren et al. 2006; Lu et al. 2007). CD8+ T cells from co-cultures of both healthy 
donor and MM patient PBMCs, also presented higher levels of expression of the 
activation marker HLA-DR when LV.CD80 and LV.IL-2/CD80 U266 cells were used as 
stimulators. However, overall, the combination of CD80 and IL-2 was not proven to be 
significantly better than the stimulation by CD80 alone. Further studies considering 
multiple rounds of stimulation of PBMCs with genetically-modified cells and the functional 
characterisation of the stimulated T cells by IFN- and Granzyme B ELISPOT technique 
should be performed. 
Our results so far failed to demonstrate any effect of IMiDs, either alone or in 
combination with IL-2/CD80 modified MM cells, on NK cell activity. This was mainly due 
to the high background levels of NK cell cytolytic activity in the presence of DMSO, which 
was used to resuspend the drugs. Future studies should aim to optimise lenalidomide 
and pomalidomide treatment protocol on healthy donor PBMCs, possibly starting with 
sourcing the drug from alternative suppliers. The optimised protocol should then be 


















In vitro and in vivo cytolytic activity of NK cells against MM cells has been widely 
demonstrated (Godfrey and Benson 2012) (and reviewed in Chapter 1.2). However, NK 
cell-based immunotherapy has resulted in limited clinical benefit, possibly reflecting the 
mechanisms that tumour cells have developed to avoid NK cell-mediated recognition and 
killing (Pietra et al. 2012). Progress in the understanding of the these mechanisms has 
the potential to lead to new opportunities to recover or augment NK cell function as 
therapeutic interventions for the treatment of MM. 
This thesis provides new data on the molecular mechanisms responsible for the 
MM-mediated inhibition of NK cells and how to recover and activate NK cell functions 
against tumour cells.  
The results presented in Chapter 3.1 supports the importance of 
contact-dependent interactions and the role of the activating NK receptors NKG2D, 
DNAM-1 and NKp30 in the control and recognition of MM cells. The requirement for 
different receptors, shown here and in the literature in various tumour settings may be 
suggestive of immune selection events that, following direct cell-to-cell interactions, have 
shaped the tumour and NK cell surface phenotype. Future experiments using molecules 
that disrupt receptor-ligand interactions, such as Fc-proteins, should further investigate 
the role of NK cell receptors in MM-induced inhibition of NK cells. In this context, these 
studies should also aim to correlate the inhibitory activity of different MM cell lines with 
their phenotypical characteristics.  
Due to the importance of NKp30, NKG2D and NKp46 on NK-cell induced 
maturation of DC and the killing of immature DCs by NK cells, the downregulation of 
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these receptors is expected to have an impact not only on NK cells, but also on the 
shaping and modulation of the adaptive response. Therefore, future studies should aim 
to evaluate the effect of inhibited NK cells on DC and T cell functions. These data have 
the potential to help define new therapeutic targets and therapeutic guidelines for MM 
patients, according to their immune and tumour phenotypes. 
In view of this immunosuppressive effect, an immunomodulating strategy to 
prevent and/or rescue myeloma-induced suppression of immuno-mediated responses 
was subsequently evaluated (Chapter 3.3). 
The studies described in Chapter 3.2 illustrated that a third-generation lentiviral 
vector is able to successfully and stably modify MM cells to express the 
immunomodulatory molecules CD80 and IL-2. Preliminary results obtained using frozen 
CD138+ plasma cells from one MM patient support the feasibility of this procedure. 
Future studies should validate these results and optimise the cell thawing, culture and 
infection procedures in order to increase viability and expand the primary MM cell. This 
will be crucial with the aim of obtaining sufficient numbers as required for in vivo 
vaccination strategies. 
The results illustrated in Chapter 3.3, finally showed that IL-2/CD80 
genetically-modified U266 cells generated in Chapter 3.2 enhance NK and T cell 
expansion and activation when used to stimulate both healthy donor and patient PBMCs.  
The contribution of CD80 and IL-2 alone on NK and T cell activation should be further 
investigated to determine their stimulatory potential and with the view to explore the 
potential benefit of other cytokine combinations. Furthermore, new experiments using 
purified NK cells as targets of the stimulation should establish whether NK cell activation 
is the result of a direct or indirect stimulation by the genetically-modified cells. In this 
regard, the suggested activation of T cells following stimulation with LV.IL-2/CD80 MM 
cells should be further examined through functional assays such as IFN- and Granzyme 
ELISPOT on pure or sorted T cell populations.  
Due to the limited number of MM patient screened, it is difficult to make any 
conclusion regarding the therapeutic potential of this whole cancer cell vaccine. 
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Therefore, a larger cohort of MM patients (n=30) should be employed. Future studies 
should also consider evaluating the effect of this immunomodulatory strategy using a 
more heterogeneous group of MM patients both in terms of disease status and 
treatment.  
The results from these experiments will help evaluating the potential benefit of 
this strategy for patients in active disease, stable disease and relapse and outline 
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